[go: up one dir, main page]

AU2002365675A1 - Effectors of innate immunity - Google Patents

Effectors of innate immunity Download PDF

Info

Publication number
AU2002365675A1
AU2002365675A1 AU2002365675A AU2002365675A AU2002365675A1 AU 2002365675 A1 AU2002365675 A1 AU 2002365675A1 AU 2002365675 A AU2002365675 A AU 2002365675A AU 2002365675 A AU2002365675 A AU 2002365675A AU 2002365675 A1 AU2002365675 A1 AU 2002365675A1
Authority
AU
Australia
Prior art keywords
seq
peptide
protein
expression
polynucleotide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
AU2002365675A
Other versions
AU2002365675B2 (en
Inventor
Dawn Bowdish
B Brett Finlay
Robert E W Hancock
Jon-Paul Steven Powers
Carrie Melissa Rosenberger
Monisha Gough Scott
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of British Columbia
Original Assignee
University of British Columbia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of British Columbia filed Critical University of British Columbia
Publication of AU2002365675A1 publication Critical patent/AU2002365675A1/en
Assigned to THE UNIVERSITY OF BRITISH COLUMBIA reassignment THE UNIVERSITY OF BRITISH COLUMBIA Amend patent request/document other than specification (104) Assignors: UNIVERSITY OF BRITISH COLUMBIA
Application granted granted Critical
Publication of AU2002365675B2 publication Critical patent/AU2002365675B2/en
Priority to AU2007201885A priority Critical patent/AU2007201885A1/en
Anticipated expiration legal-status Critical
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4723—Cationic antimicrobial peptides, e.g. defensins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7158—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for chemokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)

Description

WO 03/048383 PCT/CA02/01830 EFFECTORS OF INNATE IMMUNITY RELATED APPLICATION DATA This application claims priority under 35 USC 119(e) to US Patent Application Serial No. 60/336,632, filed December 3, 2001, herein incorporated by reference in its entirety. FIELD OF THE INVENTION [0001] The present invention relates generally to peptides and specifically to peptides effective as therapeutics and for drug discovery related to pathologies resulting from microbial infections and for modulating innate immunity or anti-inflammatory activity. BACKGROUND OF THE INVENTION [0002] Infectious diseases are the leading cause of death worldwide. According to a 1999 World Health Organization study, over 13 million people die from infectious diseases each year. Infectious diseases are the third leading cause of death in North America, accounting for 20% of deaths annually and increasing by 50% since 1980. The success of many medical and surgical treatments also hinges on the control of infectious diseases. The discovery and use of antibiotics has been one of the great achievements of modern medicine. Without antibiotics, physicians would be unable to perform complex surgery, chemotherapy or most medical interventions such as catheterization. [0003] Current sales of antibiotics are US$26 billion worldwide. However, the overuse and sometimes unwarranted use of antibiotics have resulted in the evolution of new antibiotic-resistant strains of bacteria. Antibiotic resistance has become part of the medical landscape. Bacteria such as vancomycin-resistant Enterococcus, VRE, and methicillin-resistant Staphylococcus aureus and MRSA, strains cannot be treated with antibiotics and often, patients suffering from infections with such bacteria die.
WO 03/048383 PCT/CA02/01830 Antibiotic discovery has proven to be one of the most difficult areas for new drug development and many large pharmaceutical companies have cut back or completely halted their antibiotic development programs. However, with the dramatic rise of antibiotic resistance, including the emergence of untreatable infections, there is a clear unmet medical need for novel types of anti-microbial therapies, and agents that impact on innate immunity would be one such class of agents. [0004] The innate immune system is a highly effective and evolved general defense system. Elements of innate immunity are always present at low levels and are activated very rapidly when stimulated. Stimulation can include interaction of bacterial signaling molecules with pattern recognition receptors on the surface of the body's cells or other mechanisms of disease. Every day, humans are exposed to tens of thousands of potential pathogenic microorganisms through the food and water we ingest, the air we breathe and the surfaces, pets and people that we touch. The innate immune system acts to prevent these pathogens from causing disease. The innate immune system differs from so-called adaptive immunity (which includes antibodies and antigen-specific B- and T-lymphocytes) because it is always present, effective immediately, and relatively non-specific for any given pathogen. The adaptive immune system requires amplification of specific recognition elements and thus takes days to weeks to respond. Even when adaptive immunity is pre-stimulated by vaccination, it may take three days or more to respond to a pathogen whereas innate immunity is immediately or rapidly (hours) available. Innate immunity involves a variety of effector functions including phagocytic cells, complement, etc, but is generally incompletely understood. Generally speaking many innate immune responses are "triggered" by the binding of microbial signaling molecules with pattern recognition receptors termed Toll-like receptors on the surface of host cells. Many of these effector functions are grouped together in the inflammatory response. However too severe an inflammatory response can result in responses that are harmful to the body, and in an extreme case sepsis and potentially death can occur. [0005] The release of structural components from infectious agents during infection causes an inflammatory response, which when unchecked can lead to the potentially lethal condition, sepsis. Sepsis occurs in approximately 780,000 patients in North 2 WO 03/048383 PCT/CA02/01830 America annually. Sepsis may develop as a result of infections acquired in the community such as pneumonia, or it may be a complication of the treatment of trauma, cancer or major surgery. Severe sepsis occurs when the body is overwhelmed by the inflammatory response and body organs begin to fail. Up to 120,000 deaths occur annually in the United Stated due to sepsis. Sepsis may also involve pathogenic microorganisms or toxins in the blood (e.g., septicemia), which is a leading cause of death among humans. Gram-negative bacteria are the organisms most commonly associated with such diseases. However, gram-positive bacteria are an increasing cause of infections. Gram-negative and Gram-positive bacteria and their components can all cause sepsis. [0006] The presence of microbial components induce the release of pro inflammatory cytokines of which tumor necrosis factor-c (TNF-a) is of extreme importance. TNF-ca and other pro-inflammatory cytokines can then cause the release of other pro-inflammatory mediators and lead to an inflammatory cascade. Gram negative sepsis is usually caused by the release of the bacterial outer membrane component, lipopolysaccharide (LPS; also referred to as endotoxin). Endotoxin in the blood, called endotoxemia comes primarily from a bacterial infection, and may be released during treatment with antibiotics. Gram-positive sepsis can be caused by the release of bacterial cell wall components such as lipoteichoic acid (LTA), peptidoglycan (PG), rhamnose-glucose polymers made by Streptococci, or capsular polysaccharides made by Staphylococci. Bacterial or other non-mammalian DNA that, unlike mammalian DNA, frequently contains unmethyla.ted cytosine-guanosine dimers (CpG DNA) has also been shown to induce septic conditions including the production of TNF-ac. Mammalian DNA contains CpG dinucleotides at a much lower frequency, often in a methylated form. In addition to their natural release during bacterial infections, antibiotic treatment can also cause release of the bacterial cell wall components LPS and LTA and probably also bacterial DNA. This can then hinder recovery from infection or even cause sepsis. [0007] Cationic peptides are being increasingly recognized as a form of defense against infection, although the major effects recognized in the scientific and patent literature are the antimicrobial effects (Hancock, R.E.W., and R. Lehrer. 1998. 3 WO 03/048383 PCT/CA02/01830 Cationic peptides: a new source of antibiotics. Trends in Biotechnology 16: 82-88.). Cationic peptides having antimicrobial activity have been isolated from a wide variety of organisms. In nature, such peptides provide a defense mechanism against microorganisms such as bacteria and yeast. Generally, these cationic peptides are thought to exert their antimicrobial activity on bacteria by interacting with the cytoplasmic membrane, and in most cases, forming channels or lesions. In gram negative bacteria, they interact with LPS to permeabilize the outer membrane, leading to self promoted uptake across the outer membrane and access to the cytoplasmic membrane. Examples of cationic antimicrobial peptides include indolicidin, defensins, cecropins, and magainins. [0008] Recently it has been increasingly recognized that such peptides are effectors in other aspects of innate immunity (Hancock, R.E.W. and G. Diamond. 2000. The role of cationic peptides in innate host defenses. Trends in Microbiology 8:402-410.; Hancock, R.E.W. 2001. Cationic peptides: effectors in innate immunity and novel antimicrobials. Lancet Infectious Diseases 1:156-164) although it was not known if the antimicrobial and effector functions are independent. [0009] Some cationic peptides have an affinity for binding bacterial products such as LPS and LTA. Such cationic peptides can suppress cytokine production in response to LPS, and to varying extents can prevent lethal shock. However it has not been proven as to whether such effects are due to binding of the peptides to LPS and LTA, or due to a direct interaction of the peptides with host cells. Cationic peptides are induced, in response to challenge by microbes or microbial signaling molecules like LPS, by a regulatory pathway similar to that used by the mammalian immune system (involving Toll like receptors and the transcription factor; NFKB). Cationic peptides therefore appear to have a key role in innate immunity. Mutations that affect the induction of antibacterial peptides can reduce survival in response to bacterial challenge. As well, mutations of the Toll pathway of Drosophila that lead to decreased antifungal peptide expression result in increased susceptibility to lethal fungal infections. In humans, patients with specific granule deficiency syndrome, completely lacking in c-defensins, suffer from frequent and severe bacterial infections. Other evidence includes the inducibility of some peptides by infectious 4 WO 03/048383 PCT/CA02/01830 agents, and the very high concentrations that have been recorded at sites of inflammation. Cationic peptides may also regulate cell migration, to promote the ability of leukocytes to combat bacterial infections. For example, two human ot defensin peptides, HNP-1 and HNP-2, have been indicated to have direct chemotactic activity for murine and human T cells and monocytes, and human 3-defensins appear to act as chemoattractants for immature dendritic cells and memory T cells through interaction with CCR6. Similarly, the porcine cationic peptide, PR-39 was found to be chemotactic for neutrophils. It is unclear however as to whether peptides of different structures and compositions share these properties. [00010] The single known cathelicidin from humans, LL-37, is produced by myeloid precursors, testis, human keratinocytes during inflammatory disorders and airway epithelium. The characteristic feature of cathelicidin peptides is a high level of sequence identity at the N-terminus prepro regions termed the cathelin domain. Cathelicidin peptides are stored as inactive propeptide precursors that, upon stimulation, are processed into active peptides. SUMMARY OF THE INVENTION [00011] The present invention is based on the seminal discovery that based on patterns of polynucleotide expression regulated by endotoxic lipopolysaccharide, lipoteichoic acid, CpG DNA, or other cellular components (e.g., microbes or their cellular components), and affected by cationic peptides, one can screen for novel compounds that block or reduce sepsis and/or inflammation in a subject. Further, based on the use of cationic peptides as a tool, one can identify selective enhancers of innate immunity that do not trigger the sepsis reaction and that can block/dampen inflammatory and/or septic responses. [00012] Thus, in one embodiment, a method of identifying a polynucleotide or pattern of polynucleotides regulated by one or more sepsis or inflammatory inducing agents and inhibited by a cationic peptide is provided. The method of the invention includes contacting the polynucleotide or polynucleotides with one or more sepsis or inflammatory inducing agents and contacting the polynucleotide or polynucleotides 5 WO 03/048383 PCT/CA02/01830 with a cationic peptide either simultaneously or immediately thereafter. Differences in expression are detected in the presence and absence of the cationic peptide, and a change in expression, either up- or down-regulation, is indicative of a polynucleotide or pattern of polynucleotides that is regulated by a sepsis or inflammatory inducing agent and inhibited by a cationic peptide. In another aspect the invention provides a polynucleotide or polynucleotides identified by the above method. Examples of sepsis or inflammatory regulatory agents include LPS, LTA or CpG DNA or microbial components (or any combination thereof), or related agents. [0010] In another embodiment, the invention provides a method of identifying an agent that blocks sepsis or inflammation including combining a polynucleotide identified by the method set forth above with an agent wherein expression of the polynucleotide in the presence of the agent is modulated as compared with expression in the absence of the agent and wherein the modulation in expression affects an inflammatory or septic response. [0011] In another embodiment, the invention provides a method of identifying a pattern of polynucleotide expression for inhibition of an inflammatory or septic response by 1) contacting cells with LPS, LTA and/or CpG DNA in the presence or absence of a cationic peptide and 2) detecting a pattern of polynucleotide expression for the cells in the presence and absence of the peptide. The pattern obtained in the presence of the peptide represents inhibition of an inflammatory or septic response. In another aspect the pattern obtained in the presence of the peptide is compared to the pattern of a test compound to identify a compound that provides a similar pattern. In another aspect the invention provides a compound identified by the foregoing method. [00121 In another embodiment, the invention provides a method of identifying an agent that enhances innate immunity by contacting a polynucleotide or polynucleotides that encode a polypeptide involved in innate immunity, with an agent of interest, wherein expression of the polynucleotide in the presence of the agent is modulated as compared with expression of the polynucleotide in the absence of the agent and wherein the modulated expression results in enhancement of innate 6 WO 03/048383 PCT/CA02/01830 immunity. Preferably, the agent does not stimulate a sepsis reaction in a subject. In one aspect, the agent increases the expression of an anti-inflammatory polynucleotide. Exemplary, but non-limiting anti-inflammatory polynucleotides encode proteins such as IL-1 R antagonist homolog 1 (AI167887), IL-10 R beta (AA486393), IL-10 R alpha (U00672) TNF Receptor member lB (AA150416), TNF receptor member 5 (H98636), TNF receptor member 11b (AA194983), IK cytokine down-regulator of HLA II (R39227), TGF-B inducible early growth response 2 (AI473938), CD2 (AA927710), IL-19 (NM_013371) or IL-10 (M57627). In one aspect, the agent decreases the expression of polynucleotides encoding proteasome subunits involved in NF-iB activation such as proteasome subunit 26S (NM 013371). In one aspect, the agent may act as an antagonist of protein kinases. In one aspect, the agent is a peptide selected from SEQ ID NO:4-54. [0013] In another embodiment, the invention provides a method of identifying a pattern of polynucleotide expression for identification of a compound that selectively enhances innate immunity. The invention includes detecting a pattern of polynucleotide expression for cells contacted in the presence and absence of a cationic peptide, wherein the pattern in the presence of the peptide represents stimulation of innate immunity; detecting a pattern of polynucleotide expression for cells contacted in the presence of a test compound, wherein a pattern with the test compound that is similar to the pattern observed in the presence of the cationic peptide, is indicative of a compound that enhances innate immunity. It is preferred that the compound does not stimulate a septic reaction in a subject. [0014] In another embodiment, the invention provides a method for inferring a state of infection in a mammalian subject from a nucleic acid sample of the subject by identifying in the nucleic acid sample a polynucleotide expression pattern exemplified by an increase in polynucleotide expression of at least 2 polynucleotides in Table 50, 51 and or 52, as compared to a non-infected subject. Also included is a polynucleotide expression pattern obtained by any of the methods described above. [00013] In another aspect a cationic peptide that is an antagonist of CXCR-4 is provided. In still another aspect, a method of identifying a cationic peptide that is an 7 WO 03/048383 PCT/CA02/01830 antagonist of CXCR-4 by contacting T cells with SDF-1 in the presence of absence of a test peptide and measuring chemotaxis is provided. A decrease in chemotaxis in the presence of the test peptide is indicative of a peptide that is an antagonist of CXCR-4. Cationic peptide also acts to reduce the expression of the SDF-1 receptor polynucleotide (NM_013371). [0015] In all of the above described methods, the compounds or agents of the invention include but are not limited to peptides, cationic peptides, peptidomimetics, chemical compounds, polypeptides, nucleic acid molecules and the like. [0016] In still another aspect the invention provides an isolated cationic peptide. An isolated cationic peptide of the invention is represented by one of the following general formulas and the single letter amino acid code:
XIX
2
X
3
IX
4
PX
4 IPXsX 2
X
1 (SEQ ID NO: 4), where XI is one or two of R, L or K, X 2 is one of C, S or A, X 3 is one of R or P, X 4 is one of A or V and X 5 is one of V or W; XILX2X 3
KX
4
X
2
X
5
X
3
PX
3 XI (SEQ ID NO: 11), where X 1 is one or two of D, E, S, T or N, X2 is one or two of P, G or D, X 3 is one of G, A, V, L, I or Y, X 4 is one of R, K or H and X 5 is one of S, T, C, M or R;
XIX
2
X
3
X
4
WX
4
WX
4 XsK (SEQ ID NO: 18), where X 1 is one to four chosen from A, P or R, X 2 is one or two aromatic amino acids (F, Y and W), X 3 is one of P or K, X 4 is one, two or none chosen from A, P, Y or W and X 5 is one to three chosen from R or P;
XIX
2
X
3
X
4
XIVX
3
X
4
RGX
4
X
3
X
4
XIX
3 XI (SEQ ID NO: 25) where X 1 is one or two of R or K, X 2 is a polar or charged amino acid (S, T, M, N, Q, D, E, K, R and H),
X
3 is C, S, M, D or A and X 4 is F, I, V, M or R;
XIX
2
X
3
X
4
XIVX
5
X
4
RGX
4
X
5
X
4
XIX
3 Xi (SEQ ID NO: 32), where X 1 is one or two of R or K, X 2 is a polar or charged amino acid (S, T, M, N, Q, D, E, K, R and H),
X
3 is one of C, S, M, D or A, X 4 is one of F, I, V, M or R and X 5 is one of A, I, S, M, D or R; and
KXIKX
2
FX
2
KMLMX
2
ALKKX
3 (SEQ ID NO: 39), where X 1 is a polar amino acid (C, S, T, M, N and Q); X 2 is one of A, L, S or K and X 3 is 1-17 amino acids 8 WO 03/048383 PCT/CA02/01830 chosen from G, A, V, L, I, P, F, S, T, K and H;
KWKX
2
X
1 XIX2X 2
XIX
2
X
2
X
1
XIX
2
X
2 IFHTALKPISS (SEQ ID NO: 46), where
X
1 is a hydrophobic amino acid and X 2 is a hydrophilic amino acid. [0017] Additionally, in another aspect the invention provides isolated cationic peptides KWKSFLRTFKSPVRTVFHTALKPISS (SEQ ID NO: 53) and KWKSYAHTIMSPVRLVFHTALKPISS (SEQ ID NO: 54). [0018] Also provided are nucleic acid sequences encoding the cationic peptides of the invention, vectors including such polynucleotides and host cells containing the vectors. DETAILED DESCRIPTION OF THE INVENTION [0019] The present invention provides novel cationic peptides, characterized by a group of generic formulas, which have ability to modulate (e.g., up- and/or down regulate) polynucleotide expression, thereby regulating sepsis and inflammatory responses and/or innate immunity. [0020] "Innate immunity" as used herein refers to the natural ability of an organism to defend itself against invasions by pathogens. Pathogens or microbes as used herein may include, but are not limited to bacteria, fungi, parasites and viruses. Innate immunity is contrasted with acquired/adaptive immunity in which the organism develops a defensive mechanism based substantially on antibodies and/or immune lymphocytes that is characterized by specificity, amplifiability and self vs. non-self dsicrimination. With innate immunity, broad, nonspecific immunity is provided and there is no immunologic memory of prior exposure. The hallmarks of innate immunity are effectiveness against a broad variety of potential pathogens, independence of prior exposure to a pathogen, and immediate effectiveness (in contrast to the specific immune response which takes days to weeks to be elicited). In addition, innate immunity includes immune responses that affect other diseases, such as cancer, inflammatory diseases, multiple sclerosis, various viral infections, and the like. 9 WO 03/048383 PCT/CA02/01830 [0021] As used herein, the term "cationic peptide" refers to a sequence of amino acids from about 5 to about 50 amino acids in length. In one aspect, the cationic peptide of the invention is from about 10 to about 35 amino acids in length. A peptide is "cationic" if it possesses sufficient positively charged amino acids to have a pKa greater than 9.0. Typically, at least two of the amino acid residues of the cationic peptide will be positively charged, for example, lysine or arginine. "Positively charged" refers to the side chains of the amino acid residues which have a net positive charge at pH 7.0. Examples of naturally occurring cationic antimicrobial peptides which can be recombinantly produced according to the invention include defensins, cathelicidins, magainins, melittin, and cecropins, bactenecins, indolicidins, polyphemusins, tachyplesins, and analogs thereof. A variety of organisms make cationic peptides, molecules used as part of a non-specific defense mechanism against microorganisms. When isolated, these peptides are toxic to a wide variety of microorganisms, including bacteria, fungi, and certain enveloped viruses. While cationic peptides act against many pathogens, notable exceptions and varying degrees of toxicity exist. However this patent reveals additional cationic peptides with no toxicity towards microorganisms but an ability to protect against infections through stimulation of innate immunity, and this invention is not limited to cationic peptides with antimicrobial activity. In fact, many peptides useful in the present invention do not have antimicrobial activity. [00221 Cationic peptides known in the art include for example, the human cathelicidin LL-37, and the bovine neutrophil peptide indolicidin and the bovine variant of bactenecin, Bac2A. LL-37 LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES (SEQ ID NO: 1) Indolicidin ILPWKWPWWPWRR-NH 2 (SEQ ID NO: 2) Bac2A RLARIVVIRVAR-NH 2 (SEQ ID NO: 3) [0023] In innate immunity, the immune response is not dependent upon antigens. The innate immunity process may include the production of secretory molecules and cellular components as set forth above. In innate immunity, the pathogens are recognized by receptors encoded in the germline. These Toll-like receptors have 10 WO 03/048383 PCT/CA02/01830 broad specificity and are capable of recognizing many pathogens. When cationic peptides are present in the immune response, they aid in the host response to pathogens. This change in the immune response induces the release of chemokines, which promote the recruitment of immune cells to the site of infection. [0024] Chemokines, or chemoattractant cytokines, are a subgroup of immune factors that mediate chemotactic and other pro-inflammatory phenomena (See, Schall, 1991, Cytokine 3:165-183). Chemokines are small molecules of approximately 70-80 residues in length and can generally be divided into two subgroups, a which have two N-terminal cysteines separated by a single amino acid (CxC) and 3 which have two adjacent cysteines at the N terminus (CC). RANTES, MIP-la and MIP-113P are members of the 13 subgroup (reviewed by Horuk, R., 1994, Trends Pharmacol. Sci, 15:159-165; Murphy, P. M., 1994, Annu. Rev. Immunol., 12:593-633). The amino terminus of the 3 chemokines RANTES, MCP-1, and MCP-3 have been implicated in the mediation of cell migration and inflammation induced by these chemokines. This involvement is suggested by the observation that the deletion of the amino terminal 8 residues of MCP-1, amino terminal 9 residues of MCP-3, and amino terminal 8 residues of RANTES and the addition of a methionine to the amino terminus of RANTES, antagonize the chemotaxis, calcium mobilization and/or enzyme release stimulated by their native counterparts (Gong et al., 1996 J. Biol. Chem. 271:10521 10527; Proudfoot et al., 1996 J. Biol. Chem. 271:2599-2603). Additionally, a chemokine-like chemotactic activity has been introduced into MCP-1 via a double mutation of Tyr 28 and Arg 30 to leucine and valine, respectively, indicating that internal regions of this protein also play a role in regulating chemotactic activity (Beall et al., 1992, J. Biol. Chem. 267:3455-3459). [0025] The monomeric forms of all chemokines characterized thus far share significant structural homology, although the quaternary structures of a and 1P groups are distinct. While the monomeric structures of the 03 and a chemokines are very similar, the dimeric structures of the two groups are completely different. An additional chemokine, lymphotactin, which has only one N terminal cysteine has also been identified and may represent an additional subgroup (7) of chemokines (Yoshida 11 WO 03/048383 PCT/CA02/01830 et al., 1995, FEBSLett. 360:155-159; and Kelner et al., 1994, Science 266:1395 1399). [0026] Receptors for chemokines belong to the large family of G-protein coupled, 7 transmembrane domain receptors (GCR's) (See, reviews by Horuk, R., 1994, Trends Pharmacol. Sci. 15:159-165; and Murphy, P. M., 1994, Annu. Rev. Immunol. 12:593 633). Competition binding and cross-desensitization studies have shown that chemokine receptors exhibit considerable promiscuity in ligand binding. Examples demonstrating the promiscuity among 3 chemokine receptors include: CC CKR-1, which binds RANTES and MIP-lac (Neote et al., 1993, Cell 72: 415-425), CC CKR-4, which binds RANTES, MIP- la, and MCP-1 (Power et al., 1995, J. Biol. Chem. 270:19495-19500), and CC CKR-5, which binds RANTES, MIP- la, and MIP-1 3 (Alkhatib et al., 1996, Science, in press and Dragic et al., 1996, Nature 381:667-674). Erythrocytes possess a receptor (known as the Duffy antigen) which binds both a and P chemokines (Horuk et al., 1994, J. Biol. Chem. 269:17730-17733; Neote et al., 1994, Blood 84:44-52; and Neote et al., 1993, J. Biol. Chem. 268:12247-12249). Thus the sequence and structural homologies evident among chemokines and their receptors allows some overlap in receptor-ligand interactions. [0027] In one aspect, the present invention provides the use of compounds including cationic peptides of the invention to reduce sepsis and inflammatory responses by acting directly on host cells. In this aspect, a method of identification of a polynucleotide or polynucleotides that are regulated by one or more sepsis or inflammatory inducing agents is provided, where the regulation is altered by a cationic peptide. Such sepsis or inflammatory inducing agents include, but are not limited to endotoxic lipopolysaccharide (LPS), lipoteichoic acid (LTA) and/or CpG DNA or intact bacteria or other bacterial components. The identification is performed by contacting the polynucleotide or polynucleotides with the sepsis or inflammatory inducing agents and further contacting with a cationic peptide either simultaneously or immediately after. The expression of the polynucleotide in the presence and absence of the cationic peptide is observed and a change in expression is indicative of a polynucleotide or pattern of polynucleotides that is regulated by a sepsis or 12 WO 03/048383 PCT/CA02/01830 inflammatory inducing agent and inhibited by a cationic peptide. In another aspect, the invention provides a polynucleotide identified by the method. [0028] Once identified, such polynucleotides will be useful in methods of screening for compounds that can block sepsis or inflammation by affecting the expression of the polynucleotide. Such an effect on expression may be either up regulation or down regulation of expression. By identifying compounds that do not trigger the sepsis reaction and that can block or dampen inflammatory or septic responses, the present invention also presents a method of identifying enhancers of innate immunity. Additionally, the present invention provides compounds that are used or identified in the above methods. [0029] Candidate compounds are obtained from a wide variety of sources including libraries of synthetic or natural compounds. For example, numerous means are available for random and directed synthesis of a wide variety of organic compounds and biomolecules, including expression of randomized oligonucleotides and oligopeptides. Alternatively, libraries of natural compounds in the form of bacterial, fungal, plant and animal extracts are available or readily produced. Additionally, natural or synthetically produced libraries and compounds are readily modified through conventional chemical, physical and biochemical means, and may be used to produce combinatorial libraries. Known pharmacological agents may be subjected to directed or random chemical modifications, such as acylation, alkylation, esterification, amidification, and the like to produce structural analogs. Candidate agents are also found among biomolecules including, but not limited to: peptides, peptidiomimetics, saccharides, fatty acids, steroids, purines, pyrimidines, polypeptides, polynucleotides, chemical compounds, derivatives, structural analogs or combinations thereof. [0030] Incubating components of a screening assay includes conditions which allow contact between the test compound and the polynucleotides of interest. Contacting includes in solution and in solid phase, or in a cell. The test compound may optionally be a combinatorial library for screening a plurality of compounds. Compounds identified in the method of the invention can be further evaluated, 13 WO 03/048383 PCT/CA02/01830 detected, cloned, sequenced, and the like, either in solution or after binding to a solid support, by any method usually applied to the detection of a compound. [0031] Generally, in the methods of the invention, a cationic peptide is utilized to detect and locate a polynucleotide that is essential in the process of sepsis or inflammation. Once identified, a pattern of polynucleotide expression may be obtained by observing the expression in the presence and absence of the cationic peptide. The pattern obtained in the presence of the cationic peptide is then useful in identifying additional compounds that can inhibit expression of the polynucleotide and therefore block sepsis or inflammation. It is well known to one of skill in the art that non-peptidic chemicals and peptidomimetics can mimic the ability of peptides to bind to receptors and enzyme binding sites and thus can be used to block or stimulate biological reactions. Where an additional compound of interest provides a pattern of polynucleotide expression similar to that of the expression in the presence of a cationic peptide, that compound is also useful in the modulation of sepsis or an innate immune response. In this manner, the cationic peptides of the invention, which are known inhibitors of sepsis and inflammation and enhancers of innate immunity are useful as tools in the identification of additional compounds that inhibit sepsis and inflammation and enhance innate immunity. [0032] As can be seen in the Examples below, peptides of the invention have a widespread ability to reduce the expression of polynucleotides regulated by LPS. High levels of endotoxin in the blood are responsible for many of the symptoms seen during a serious infection or inflammation such as fever and an elevated white blood cell count. Endotoxin is a component of the cell wall of Gram-negative bacteria and is a potent trigger of the pathophysiology of sepsis. The basic mechanisms of inflammation and sepsis are related. In Example 1, polynucleotide arrays were utilized to determine the effect of cationic peptides on the transcriptional response of epithelial cells. Specifically, the effects on over 14,000 different specific polynucleotide probes induced by LPS were observed. The tables show the changes seen with cells treated with peptide compared to control cells. The resulting data indicated that the peptides have the ability to reduce the expression of polynucleotides induced by LPS. 14 WO 03/048383 PCT/CA02/01830 [0033] Example 2, similarly, shows that peptides of the invention are capable of neutralizing the stimulation of immune cells by Gram positive and Gram negative bacterial products. Additionally, it is noted that certain pro-inflammatory polynucleotides are down-regulated by cationic peptides, as set forth in table 24 such as TLR1 (AI339155), TLR2 (T57791), TLR5 (N41021), TNF receptor-associated factor 2 (T55353), TNF receptor-associated factor 3 (AA504259), TNF receptor superfamily, member 12 (W71984), TNF receptor superfamily, member 17 (AA987627), small inducible cytokine subfamily B, member 6 (AI889554), IL-12R beta 2 (AA977194), IL-18 receptor 1 (AA482489), while anti-inflammatory polynucleotides are up-regulated by cationic peptides, as seen in table 25 such as IL-1 R antagonist homolog 1 (A1167887), IL-10 R beta (AA486393), TNF Receptor member 1B (AA150416), TNF receptor member 5 (H98636), TNF receptor member 11 b (AA194983), IK cytokine down-regulator of HLA II (R39227), TGF-B inducible early growth response 2 (AI473938), or CD2 (AA927710). The relevance and application of these results are confirmed by an in vivo application to mice. Example 3 demonstrates that such peptides do not generally demponstrate toxicity towards the host cells they contact. [0034] In Example 4 it can be seen that the cationic peptides of the invention alter polynucleotide expression in macrophage and epithelial cells. The results of this example show that pro-inflammatory polynucleotides are down-regulated by cationic peptides (Table 24) whereas anti-inflammatory polynucleotides are up-regulated by cationic peptides (Table 25). [0035] In another aspect, the invention provides a method of identifying an agent that enhances innate immunity. In the method, a host cell polynucleotide or polynucleotides that encode a polypeptide involved in innate immunity is contacted with an agent of interest. Expression of the polynucleotide is determined, both in the presence and absence of the agent. The expression is compared and of the specific modulation of expression was indicative of an enhancement of innate immunity. In another aspect, the agent does not stimulate a septic reaction as revealed by the lack of upregulation of the pro-inflammatory cytokine TNF-ca. In still another aspect the agent reduces or blocks the inflammatory or septic response. In yet another aspect, 15 WO 03/048383 PCT/CA02/01830 the agent reduces the expression of TNF-a and/or interleukins including, but not limited to, IL-103, IL-6, IL-12 p40, IL-12 p70, and IL-8. [0036] In another aspect, the invention provides methods of direct polynucleotide regulation by cationic peptides and the use of compounds including cationic peptides to stimulate elements of innate immunity. In this aspect, the invention provides a method of identification of a pattern of polynucleotide expression for identification of a compound that enhances innate immunity. In the method of the invention, an initial detection of a pattern of polynucleotide expression for cells contacted in the presence and absence of a cationic peptide is made. The pattern resulting from polynucleotide expression in the presence of the peptide represents stimulation of innate immunity. A pattern of polynucleotide expression is then detected in the presence of a test compound, where a resulting pattern with the test compound that is similar to the pattern observed in the presence of the cationic peptide is indicative of a compound that enhances innate immunity. In another aspect, the invention provides compounds that are identified in the above methods. In another aspect, the compound of the invention stimulates chemokine or chemokine receptor expression. Chemokine or chemokine receptors may include, but are not limited to CXCR4, CXCR1, CXCR2, CCR2, CCR4, CCR5, CCR6, MIP-1 alpha, MDC, MIP-3 alpha, MCP-1, MCP-2, MCP-3, MCP-4, MCP-5, and RANTES. In still another aspect, the compound is a peptide, peptidomimetic, chemical compound, or a nucleic acid molecule. [0037] In still another aspect the polynucleotide expression pattern includes expression of pro-inflammatory polynucleotides. Such pro-inflammatory polynucleotides may include, but are not limited to, ring finger protein 10 (D87451), serine/threonine protein kinase MASK (AB040057), KIAAO912 protein (AB020719), KIAA0239 protein (D87076), RAP1, GTPase activating protein 1 (M64788), FEM-1 like death receptor binding protein (AB007856), cathepsin S (M90696), hypothetical protein FLJ20308 (AK000315), pim-1 oncogene (M54915), proteasome subunit beta type 5 (D29011), KIAA0239 protein (D87076), mucin 5 subtype B tracheobronchial (AJ001403), cAMP response element-binding protein CREBPa, integrin alpha M (J03925), Rho-associated kinase 2 (NM_004850), PTD017 protein (AL050361) unknown genes (AK001143, AK034348, AL049250, AL16199, AL031983) and any 16 WO 03/048383 PCT/CA02/01830 combination thereof. In still another aspect the polynucleotide expression pattern includes expression of cell surface receptors that may include but is not limited to retinoic acid receptor (X06614), G protein-coupled receptors (Z94155, X81892, U52219, U22491, AF015257, U66579) chemokine (C-C motif) receptor 7 (L31584), tumor necrosis factor receptor superfamily member 17 (Z29575), interferon gamma receptor 2 (U05875), cytokine receptor-like factor 1 (AF059293), class I cytokine receptor (AF053004), coagulation factor II (thrombin) receptor-like 2 (U92971), leukemia inhibitory factor receptor (NM_002310), interferon gamma receptor 1 (AL050337). [0038] It is shown below, for example, in tables 1-15, that cationic peptides can neutralize the host response to the signaling molecules of infectious agents as well as modify the transcriptional responses of host cells, mainly by down-regulating the pro inflammatory response and/or up-regulating the anti-inflammatory response. Example 5 shows that the cationic peptides can aid in the host response to pathogens by inducing the release of chemokines, which promote the recruitment of immune cells to the site of infection. The results are confirmed by an in vivo application to mice. [0039] It is seen from the examples below that cationic peptides have a substantial influence on the host response to pathogens in that they assist in regulation of the host immune response by inducing selective pro-inflammatory responses that for example promote the recruitment of immune cells to the site of infection but not inducing potentially harmful pro-inflammatory cytokines. Sepsis appears to be caused in part by an overwhelming pro-inflammatory response to infectious agents. Cationic peptides aid the host in a "balanced" response to pathogens by inducing an anti inflammatory response and suppressing certain potentially harmful pro-inflammatory responses. [0040] In Example 7, the activation of selected MAP kinases was examined, to study the basic mechanisms behind the effects of interaction of cationic peptides with cells. Macrophages activate MEK/ERK kinases in response to bacterial infection. MEK is a MAP kinase kinase that when activated, phosphorylates the downstream kinase ERK 17 WO 03/048383 PCT/CA02/01830 (extracellular regulated kinase), which then dimerizes and translocates to the nucleus where it activates transcription factors such as Elk-1 to modify polynucleotide expression. MEK/ERK kinases have been shown to impair replication of Salmonella within macrophages. Signal transduction by MEK kinase and NADPH oxidase may play an important role in innate host defense against intracellular pathogens. By affecting the MAP kinases as shown below the cationic peptides have an effect on bacterial infection. The cationic peptides can directly affect kinases. Table 21 demonstrates but is not limited to MAP kinase polynucleotide expression changes in response to peptide. The kinases include MAP kinase kinase 6 (H070920), MAP kinase kinase 5 (W69649), MAP kinase 7 (H39192), MAP kinase 12 (AI936909) and MAP kinase-activated protein kinase 3 (W68281). [0041] In another method, the methods of the invention may be used in combination, to identify an agent with multiple characteristics, i.e. a peptide with anti inflammatory/anti-sepsis activity, and the ability to enhance innate immunity, in part by inducing chemokines in vivo. [0042] In another aspect, the invention provides a method for inferring a state of infection in a mammalian subject from a nucleic acid sample of the subject by identifying in the nucleic acid sample a polynucleotide expression pattern exemplified by an increase in polynucleotide expression of at least 2 polynucleotides in Table 55 as compared to a non-infected subject. In another aspect the invention provides a method for inferring a state of infection in a mammalian subject from a nucleic acid sample of the subject by identifying in the nucleic acid sample a polynucleotide expression pattern exemplified by a polynucleotide expression of at least 2 polynucleotides in Table 56 or Table 57 as compared to a non-infected subject. In one aspect of the invention, the state of infection is due to infectious agents or signaling molecules derived therefrom, such as, but not limited to, Gram negative bacteria and Gram positive bacteria, viral, fungal or parasitic agents. In still another aspect the invention provides a polynucleotide expression pattern of a subject having a state of infection identified by the above method. Once identified, such polynucleotides will be useful in methods of diagnosis of a condition associated with the activity or presence of such infectious agents or signaling molecules. 18 WO 03/048383 PCT/CA02/01830 [0043] Example 10 below demonstrates this aspect of the invention. Specifically, table 61 demonstrates that both MEK and the NADPH oxidase inhibitors can limit bacterial replication (infection of IFN-y-primed macrophages by S. typhimurium triggers a MEK kinase). This is an example of how bacterial survival can be impacted by changing host cell signaling molecules. [0044] In still another aspect of the invention, compounds are presented that inhibit stromal derived factor-1 (SDF-1) induced chemotaxis of T cells.. Compounds are also presented which decrease expression of SDF-1 receptor. Such compounds also may act as an antagonist or inhibitor of CXCR-4. In one aspect the invention provides a cationic peptide that is an antagonist of CXCR-4. In another aspect the invention provides a method of identifying a cationic peptide that is an antagonist of CXCR-4. The method includes contacting T cells with SDF-1 in the presence of absence of a test peptide and measuring chemotaxis. A decrease in chemotaxis in the presence of the test peptide is then indicative of a peptide that is an antagonist of CXCR-4. Such compounds and methods are useful in therapeutic applications in HIV patients. These types of compounds and the utility thereof is demonstrated, for example, in Example 11 (see also Tables 62, 63). In that example, cationic peptides are shown to inhibit cell migration and therefore antiviral activity. [0045] In one embodiment, the invention provides an isolated cationic peptides having an amino acid sequence of the general formula (Formula A):
X
1
X
2
X
3
IX
4
PX
4 IPXsX 2
X
1 (SEQ ID NO: 4), wherein X 1 is one or two of R, L or K, X 2 is one of C, S or A, X 3 is one of R or P, X 4 is one of A or V and X 5 is one of V or W. Examples of the peptides of the invention include, but are not limited to: LLCRIVPVIPWCK (SEQ ID NO: 5), LRCPIAPVIPVCKK (SEQ ID NO: 6), KSRIVPAIPVSLL (SEQ ID NO: 7), KKSPIAPAIPWSR (SEQ ID NO: 8), RRARIVPAIPVARR (SEQ ID NO: 9) and LSRIAPAIPWAKL (SEQ ID NO: 10). [0046] In another embodiment, the invention provides an isolated linear cationic peptide having an amino acid sequence of the general formula (Formula B): XILX2X 3
KX
4
X
2 XsX 3
PX
3 XI (SEQ ID NO: 11), wherein X 1 is one or two of D, E, S, T or N, X2 is one or two of P, G or D, X 3 is one of G, A, V, L, I or Y, X 4 is one of R, K 19 WO 03/048383 PCT/CA02/01830 or H and Xs is one of S, T, C, M or R. Examples of the peptides of the invention include, but are not limited to: DLPAKRGSAPGST (SEQ ID NO: 12), SELPGLKHPCVPGS (SEQ ID NO: 13), TTLGPVKRDSIPGE (SEQ ID NO: 14), SLPIKHDRLPATS (SEQ ID NO: 15), ELPLKRGRVPVE (SEQ ID NO: 16) and NLPDLKKPRVPATS (SEQ ID NO: 17). [0047] In another embodiment, the invention provides an isolated linear cationic peptide having an amino acid sequence of the general formula (Formula C):
X
1
X
2
X
3
X
4
WX
4
WX
4 XsK (SEQ ID NO: 18) (this formula includes CP12a and CP12d) , wherein X 1 is one to four chosen from A, P or R, X 2 is one or two aromatic amino acids (F, Y and W), X 3 is one of P or K, X 4 is one, two or none chosen from A, P, Y or W and X 5 is one to three chosen from R or P. Examples of the peptides of the invention include, but are not limited to: RPRYPWWPWWPYRPRK (SEQ ID NO: 19), RRAWWKAWWARRK (SEQ ID NO: 20), RAPYWPWAWARPRK (SEQ ID NO: 21), RPAWKYWWPWPWPRRK (SEQ ID NO: 22), RAAFKWAWAWWRRK (SEQ ID NO: 23) and RRRWKWAWPRRK (SEQ ID NO: 24). [0048] In another embodiment, the invention provides an isolated hexadecameric cationic peptide having an amino acid sequence of the general formula (Formula D): X1X 2
X
3
X
4
XIVX
3
X
4
RGX
4
X
3
X
4
XI
1
X
3
X
1 (SEQ ID NO: 25) wherein X 1 is one'or two of R or K, X 2 is a polar or charged amino acid (S, T, M, N, Q, D, E, K, R and H), X 3 is C, S, M, D or A and X 4 is F, I, V, M or R. Examples of the peptides of the invention include, but are not limited to: RRMCIKVCVRGVCRRKCRK (SEQ ID NO: 26), KRSCFKVSMRGVSRRRCK (SEQ ID NO: 27), KKDAIKKVDIRGMDMRRAR (SEQ ID NO: 28), RKMVKVDVRGIMIRKDRR (SEQ ID NO: 29), KQCVKVAMRGMALRRCK (SEQ ID NO: 30) and RREAIRRVAMRGRDMKRMRR (SEQ ID NO: 31). [0049] In still another embodiment, the invention provides an isolated hexadecameric cationic peptide having an amino acid sequence of the general formula (Formula E): X1X 2
X
3
X
4
XIVX
5
X
4
RGX
4
X
5
X
4
X
1
X
3 XI (SEQ ID NO: 32), wherein X 1 is one or two of R or K, X 2 is a polar or charged amino acid (S, T, M, N, Q, D, E, K, R and H), X 3 is one of C, S, M, D or A, X 4 is one of F, I, V, M or R and Xs is one of A, I, S, M, D 20 WO 03/048383 PCT/CA02/01830 or R. Examples of the peptides of the invention include, but are not limited to: RTCVKRVAMRGIIRKRCR (SEQ ID NO: 33), KKQMMKRVDVRGISVKRKR (SEQ ID NO: 34), KESIKVIIRGMMVRMKK (SEQ ID NO: 35), RRDCRRVMVRGIDIKAK (SEQ ID NO: 36), KRTAIKKVSRRGMSVKARR (SEQ ID NO: 37) and RHCIRRVSMRGIIMRRCK (SEQ ID NO: 38). [0050] In another embodiment, the invention provides an isolated longer cationic peptide having an amino acid sequence of the general formula (Formula F):
KXIKX
2
FX
2
KMLMX
2
ALKKX
3 (SEQ ID NO: 39), wherein X 1 is a polar amino acid (C, S, T, M, N and Q); X 2 is one of A, L, S or K and X 3 is 1-17 amino acids chosen from G, A, V, L, I, P, F, S, T, K and H. Examples of the peptides of the invention include, but are not limited to: KCKLFKKMLMLALKKVLTTGLPALKLTK (SEQ ID NO: 40), KSKSFLKMLMKALKKVLTTGLPALIS (SEQ ID NO: 41), KTKKFAKMLMMALKKVVSTAKPLAILS (SEQ ID NO: 42), KMKSFAKMLMLALKKVLKVLTTALTLKAGLPS (SEQ ID NO: 43), KNKAFAKMLMKALKKVTTAAKPLTG (SEQ ID NO: 44) and KQKLFAKMLMSALKKKTLVTTPLAGK (SEQ ID NO: 45). [0051] In yet another embodiment, the invention provides an isolated longer cationic peptide having an amino acid sequence of the general formula (Formula G):
KWKX
2
X
1
X
1
X
2
X
2
XIX
2
X
2
X
1
XIX
2
X
2 IFHTALKPISS (SEQ ID NO: 46), wherein X 1 is a hydrophobic amino acid and X 2 is a hydrophilic amino acid. Examples of the peptides of the invention include, but are not limited to: KWKSFLRTFKSPVRTIFHTALKPISS (SEQ ID NO: 47), KWKSYAHTIMSPVRLIFHTALKPISS (SEQ ID NO: 48), KWKRGAHRFMKFLSTIFHTALKPISS (SEQ ID NO: 49), KWKKWAHSPRKVLTRIFHTALKPISS (SEQ ID NO: 50), KWKSLVMMFKKPARRIFHTALKPISS (SEQ ID NO: 51) and KWKHALMKAHMLWHMIFHTALKPISS (SEQ ID NO: 52). [0052] In still another embodiment, the invention provides an isolated cationic peptide having an amino acid sequence of the formula: 21 WO 03/048383 PCT/CA02/01830 KWKSFLRTFKSPVRTVFHTALKPISS (SEQ ID NO: 53) or KWKSYAHTIMSPVRLVFHTALKPISS (SEQ ID NO: 54). [0053] The term "isolated" as used herein refers to a peptide that is substantially free of other proteins, lipids, and nucleic acids (e.g., cellular components with which an in vivo-produced peptide would naturally be associated). Preferably, the peptide is at least 70%, 80%, or most preferably 90% pure by weight. [0054] The invention also includes analogs, derivatives, conservative variations, and cationic peptide variants of the enumerated polypeptides, provided that the analog, derivative, conservative variation, or variant has a detectable activity in which it enhances innate immunity or has anti-inflammatory activity. It is not necessary that the analog, derivative, variation, or variant have activity identical to the activity of the peptide from which the analog, derivative, conservative variation, or variant is derived. [0055] A cationic peptide "variant" is an peptide that is an altered form of a referenced cationic peptide. For example, the term "variant" includes a cationic peptide in which at least one amino acid. of a reference peptide is substituted in an expression library. The term "reference" peptide means any of the cationic peptides of the invention (e.g., as defined in the above formulas), from which a variant, derivative, analog, or conservative variation is derived. Included within the term "derivative" is a hybrid peptide that includes at least a portion of each of two cationic peptides (e.g., 30-80% of each of two cationic peptides). Also included are peptides in which one or more amino acids are deleted from the sequence of a peptide enumerated herein, provided that the derivative has activity in which it enhances innate immunity or has anti-inflammatory activity. This can lead to the development of a smaller active molecule which would also have utility. For example, amino or carboxy terminal amino acids which may not be required for enhancing innate immunity or anti-inflammatory activity of a peptide can be removed. Likewise, additional derivatives can be produced by adding one or a few (e.g., less than 5) amino acids to a cationic peptide without completely inhibiting the activity of the peptide. In addition, C-terminal derivatives, e.g., C-terminal methyl esters, and N 22 WO 03/048383 PCT/CA02/01830 terminal derivatives can be produced and are encompassed by the invention. Peptides of the invention include any analog, homolog, mutant, isomer or derivative of the peptides disclosed in the present invention, so long as the bioactivity as described herein remains. Also included is the reverse sequence of a peptide encompassed by the general formulas set forth above. Additionally, an amino acid of "D" configuration may be substituted with an amino acid of "L" configuration and vice versa. Alternatively the peptide may be cyclized chemically or by the addition of two or more cysteine residues within the sequence and oxidation to form disulphide bonds. [0056] The invention also includes peptides that are conservative variations of those peptides exemplified herein. The term "conservative variation" as used herein denotes a polypeptide in which at least one amino acid is replaced by another, biologically similar residue. Examples of conservative variations include the substitution of one hydrophobic residue, such as isoleucine, valine, leucine, alanine, cysteine, glycine, phenylalanine, proline, tryptophan, tyrosine, norleucine or methionine for another, or the substitution of one polar residue for another, such as the substitution of arginine for lysine, glutamic for aspartic acid, or glutamine for asparagine, and the like. Neutral hydrophilic amino acids that can be substituted for one another include asparagine, glutamine, serine and threonine. The term "conservative variation" also encompasses a peptide having a substituted amino acid in place of an unsubstituted parent amino acid. Such substituted amino acids may include amino acids that have been methylated or amidated. Other substitutions will be known to those of skill in the art. In one aspect, antibodies raised to a substituted polypeptide will also specifically bind the unsubstituted polypeptide. [0057] Peptides of the invention can be synthesized by commonly used methods such as those that include t-BOC or FMOC protection of alpha-amino groups. Both methods involve stepwise synthesis in which a single amino acid is added at each step starting from the C-terminus of the peptide (See, Coligan, et al., Current Protocols in Immunology, Wiley Interscience, 1991, Unit 9). Peptides of the invention can also be synthesized by the well known solid phase peptide synthesis methods such as those described by Merrifield, J. Am. Chem. Soc., 85:2149, 1962) and Stewart and Young, 23 WO 03/048383 PCT/CA02/01830 Solid Phase Peptides Synthesis, Freeman, San Francisco, 1969, pp.27-62) using a copoly(styrene-divinylbenzene) containing 0.1-1.0 mMol amines/g polymer. On completion of chemical synthesis, the peptides can be deprotected and cleaved from the polymer by treatment with liquid HF-10% anisole for about 1/4-1 hours at O'C. After evaporation of the reagents, the peptides are extracted from the polymer with a 1% acetic acid solution, which is then lyophilized to yield the crude material. The peptides can be purified by such techniques as gel filtration on Sephadex G-15 using 5% acetic acid as a solvent. Lyophilization of appropriate fractions of the column eluate yield homogeneous peptide, which can then be characterized by standard techniques such as amino acid analysis, thin layer chromatography, high performance liquid chromatography, ultraviolet absorption spectroscopy, molar rotation, or measuring solubility. If desired, the peptides can be quantitated by the solid phase Edman degradation. [0058] The invention also includes isolated nucleic acids (e.g., DNA, cDNA, or RNA) encoding the peptides of the invention. Included are nucleic acids that encode analogs, mutants, conservative variations, and variants of the peptides described herein. The term "isolated" as used herein refers to a nucleic acid that is substantially free of proteins, lipids, and other nucleic acids with which an in vivo-produced nucleic acids naturally associated. Preferably, the nucleic acid is at least 70%, 80%, or preferably 90% pure by weight, and conventional methods for synthesizing nucleic acids in vitro can be used in lieu of in vivo methods. As used herein, "nucleic acid" refers toa polymer of deoxyribo-nucleotides or ribonucleotides, in the form of a separate fragment or as a component of a larger genetic construct (e.g., by operably linking a promoter to a nucleic acid encoding a peptide of the invention). Numerous genetic constructs (e.g., plasmids and other expression vectors) are known in the art and can be used to produce the peptides of the invention in cell-free systems or prokaryotic or eukaryotic (e.g., yeast, insect, or mammalian) cells. By taking into account the degeneracy of the genetic code, one of ordinary skill in the art can readily synthesize nucleic acids encoding the polypeptides of the invention. The nucleic acids of the invention can readily be used in conventional molecular biology methods to produce the peptides of the invention. 24 WO 03/048383 PCT/CA02/01830 [0059] DNA encoding the cationic peptides of the invention can be inserted into an "expression vector." The term "expression vector" refers to a genetic construct such as a plasmid, virus or other vehicle known in the art that can be engineered to contain a nucleic acid encoding a polypeptide of the invention. Such expression vectors are preferably plasmids that contain a promoter sequence that facilitates transcription of the inserted genetic sequence in a host cell. The expression vector typically contains an origin of replication, and a promoter, as well as polynucleotides that allow phenotypic selection of the transformed cells (e.g., an antibiotic resistance polynucleotide). Various promoters, including inducible and constitutive promoters, can be utilized in the invention. Typically, the expression vector contains a replicon site and control sequences that are derived from a species compatible with the host cell. [0060] Transformation or transfection of a recipient with a nucleic acid of the invention can be carried out using conventional techniques well known to those skilled in the art. For example, where the host cell is E. coli, competent cells that are capable of DNA uptake can be prepared using the CaCl 2 , MgCl 2 or RbCl methods known in the art. Alternatively, physical means, such as electroporation or microinjection can be used. Electroporation allows transfer of a nucleic acid into a cell by high voltage electric impulse. Additionally, nucleic acids can be introduced into host cells by protoplast fusion, using methods well known in the art. Suitable methods for transforming eukaryotic cells, such as electroporation and lipofection, also are known. [0061] "Host cells" or "Recipient cells" encompassed by of the invention are any cells in which the nucleic acids of the invention can be used to express the polypeptides of the invention. The term also includes any progeny of a recipient or host cell. Preferred recipient or host cells of the invention include E. coli, S. aureus and P. aeruginosa, although other Gram-negative and Gram-positive bacterial, fungal and mammalian cells and organisms known in the art can be utilized as long as the expression vectors contain an origin of replication to permit expression in the host. 25 WO 03/048383 PCT/CA02/01830 [0062] The cationic peptide polynucleotide sequence used according to the method of the invention can be isolated from an organism or synthesized in the laboratory. Specific DNA sequences encoding the cationic peptide of interest can be obtained by: 1) isolation of a double-stranded DNA sequence from the genomic DNA; 2) chemical manufacture of a DNA sequence to provide the necessary codons for the cationic peptide of interest; and 3) in vitro synthesis of a double-stranded DNA sequence by reverse transcription of mRNA isolated from a donor cell. In the latter case, a double stranded DNA complement of mRNA is eventually formed which is generally referred to as cDNA. [0063] The synthesis of DNA sequences is frequently the method of choice when the entire sequence of amino acid residues of the desired peptide product is known. In the present invention, the synthesis of a DNA sequence has the advantage of allowing the incorporation of codons which are more likely to be recognized by a bacterial host, thereby permitting high level expression without difficulties in translation. In addition, virtually any peptide can be synthesized, including those encoding natural cationic peptides, variants of the same, or synthetic peptides. [0064] When the entire sequence of the desired peptide is not known, the direct synthesis of DNA sequences is not possible and the method of choice is the formation of cDNA sequences. Among the standard procedures for isolating cDNA sequences of interest is the formation of plasmid or phage containing cDNA libraries which are derived from reverse transcription of mRNA which is abundant in donor cells that have a high level of genetic expression. When used in combination with polymerase chain reaction technology, even rare expression products can be cloned. In those cases where significant portions of the amino acid sequence of the cationic peptide are known, the production of labeled single or double-stranded DNA or RNA probe sequences duplicating a sequence putatively present in the target cDNA may be employed in DNA/DNA hybridization procedures which are carried out on cloned copies of the cDNA which have been denatured into a single stranded form (Jay, et al., Nuc. AcidRes., 11:2325, 1983). 26 WO 03/048383 PCT/CA02/01830 [0065] The peptide of the invention can be administered parenterally by injection or by gradual infusion over time. The peptide can be administered intravenously, intraperitoneally, intramuscularly, subcutaneously, intracavity, or transdermally. Preferred methods for delivery of the peptide include orally, by encapsulation in microspheres or proteinoids, by aerosol delivery to the lungs, or transdermally by iontophoresis or transdermal electroporation. Other methods of administration will be known to those skilled in the art. [0066] Preparations for parenteral administration of a peptide of the invention include sterile aqueous or non-aqueous solutions, suspensions, and emulsions. Examples of non-aqueous solvents are propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable organic esters such as ethyl oleate. Aqueous carriers include water, alcoholic/aqueous solutions, emulsions or suspensions, including saline and buffered media Parenteral vehicles include sodium chloride solution, Ringer's dextrose, dextrose and sodium chloride, sodium acetate, sodium citrate, lactated Ringer's, or fixed oils. Intravenous vehicles include fluid and nutrient replenishers, electrolyte replenishers (such as those based on Ringer's dextrose), and the like. Preservatives and other additives may also be present such as, for example, antimicrobials, anti-oxidants, chelating agents, and inert gases and the like. [00671 The invention will now be described in greater detail by reference to the following non-limiting examples. While the invention has been described in detail with reference to certain preferred embodiments thereof, it will be understood that modifications and variations are within the spirit and scope of that which is described and claimed. EXAMPLE 1 ANTI-SEPSIS/ANTI-INFLAMMATORY ACTIVITY [0068] Polynucleotide arrays were utilized to determine the effect of cationic peptides on the transcriptional response of epithelial cells. The A549 human epithelial cell line was maintained in DMEM (Gibco) supplemented with 10 % fetal bovine serum (FBS, Medicorp). The A549 cells were plated in 100 mm tissue culture dishes at 2.5 x 106 cells/dish, cultured overnight and then incubated with 100 ng/ml E. coli 0111:B4 LPS 27 WO 03/048383 PCT/CA02/01830 (Sigma), without (control) or with 50 ptg/ml peptide or medium alone for 4 h. After stimulation, the cells were washed once with diethyl pyrocarbonate-treated phosphate buffered saline (PBS), and detached from the dish using a cell scraper. Total RNA was isolated using RNAqueous (Ambion, Austin, TX). The RNA pellet was resuspended in RNase-free water containing Superase-In (RNase inhibitor; Ambion). DNA contamination was removed with DNA-free kit, Ambion). The quality of the RNA was assessed by gel electrophoresis on a 1% agarose gel. [0069] The polynucleotide arrays used were the Human Operon arrays (identification number for the genome is PRHU04-S1), which consist of about 14,000 human oligos spotted in duplicate. Probes were prepared from 10 pg of total RNA and labeled with Cy3 or Cy5 labeled dUTP. The probes were purified and hybridized to printed glass slides overnight at 42-C and washed. After washing, the image was captured using a Perkin Elmer array scanner. The image processing software (Imapolynucleotide 5.0, Marina Del Rey, CA) determines the spot mean intensity, median intensities, and background intensities. A "homemade" program was used to remove background. The program calculates the bottom 10 % intensity for each subgrid and subtracts this for each grid. Analysis was performed with Genespring software (Redwood City, CA). The intensities for each spot were normalized by taking the median spot intensity value from the population of spot values within a slide and comparing this value to the values of all slides in the experiment. The relative changes seen with cells treated with peptide compared to control cells can be found in Tables 1 and 2. These tables 2 reflect only those polynucleotides that demonstrated significant changes in expression of the 14,000 polynucleotides that were tested for altered expression. The data indicate that the peptides have a widespread ability to reduce the expression of polynucleotides that were induced by LPS. [0070] In Table 1, the peptide, SEQ ID NO: 27 is shown to potently reduce the expression of many of the polynucleotides up-regulated by E. coli 0111 :B4 LPS as studied by polynucleotide microarrays. Peptide (50 pg/ml) and LPS (0.1 pg/ml) or LPS alone was incubated with the A549 cells for 4 h and the RNA was isolated. Five pg total RNA was used to make Cy3/Cy5 labeled cDNA probes and hybridized onto Human Operon arrays (PRHU04). The intensity of unstimulated cells is shown in the 28 WO 03/048383 PCT/CA02/01830 third column of Table 1. The "Ratio: LPS/control" column refers to the intensity of polynucleotide expression in LPS simulated cells divided by in the intensity of unstimulated cells. The "Ratio: LPS+ ID 27/control" column refers to the intensity of polynucleotide expression in cells stimulated with LPS and peptide divided by unstimulated cells. Table 1: Reduction, by peptide SEQ ID 27, of A549 human epithelial cell polynucleotide expression up-regulated by E.coli 0111 :B4 LPS Accession Polynucleotide Control: Ratio: Ratio: LPS+ Numbera Gene Function Media only LPS/control ID 27/control Intensity AL031983 Unknown 0.032 302.8 5.1
ADP
ribosylation L04510 factor 0.655 213.6 1.4 ring finger D87451 protein 10 3.896 183.7 2.1 hypothetical AK000869 protein 0.138 120.1 2.3 Ric -like expressed in U78166 neurons 0.051 91.7 0.2 mucin 5 subtype B AJ001403 tracheobronchial 0.203 53.4 15.9 serine/threonine protein kinase AB040057 MASK 0.95 44.3 15.8 Z99756 Unknown 0.141 35.9 14.0 L42243 interferon 0.163 27.6 5.2 29 WO 03/048383 PCT/CA02/01830 Accession Polynucleotide Control: Ratio: Ratio: LPS+ Numbera Gene Function Media only LPS/control ID 27/control Intensity receptor 2 RNA lariat debranching NM_016216 enzyme 6.151 22.3 10.9 hypothetical AK001589 protein 0.646 19.2 1.3 AL137376 Unknown 1.881 17.3 0.6 FEM-1-like death receptor AB007856 binding protein 2.627 15.7 0.6 growth arrest AB007854 specific 7 0.845 14.8 2.2 cytosolic ovarian carcinoma AK000353 antigen 1 0.453 13.5 1.0 myeloid/lymphoi d or mixed lineage leukemia D14539 translocated to 1 2.033 11.6 3.1 integration site for Epstein-Barr X76785 virus 0.728 11.6 1.9 M54915 pim-1 oncogene 1.404 11.4 0.6 caspase recruitment NM 006092 domain 4 0.369 11.0 0.5 integrin_alpha J03925 M 0.272 9.9 4.2 30 WO 03/048383 PCT/CA02/01830 Accession Polynucleotide Control: Ratio: Ratio: LPS+ Numbera Gene Function Media only LPS/control ID 27/control Intensity
ADP
ribosylation NM 001663 factor 6 0.439 9.7 1.7 RAS p21 protein M23379 activator 0.567 9.3 2.8 thymidine kinase K02581 1 soluble 3.099 8.6 3.5 transmembrane 9 superfamily U94831 member 1 3.265 7.1 1.5 zinc finger X70394 protein 146 1.463 6.9 1.7 hypothetical AL137614 protein 0.705 6.8 1.0 guanine nucleotide U43083 binding protein 0.841 6.6 1.6 DKFZp434J181 AL137648 3 protein 1.276 6.5 0.8 ATP-binding cassette sub family C (CFTR/MRP) AF085692 member 3 3.175 6.5 2.4 hypothetical protein AK001239 FLJ10377 2.204 6.4 1.3 ATPase Na+/K+ NM_001679 transporting beta 2.402 6.3 0.9 31 WO 03/048383 PCT/CA02/01830 Accession Polynucleotide Control: Ratio: Ratio: LPS+ Number Gene Function Media only LPS/control ID 27/control Intensity 3 polypeptide unactive progesterone L24804 receptor 3.403 6.1 1.1 dual specificity U15932 phosphatase 5 0.854 6.1 2.1 ligase I DNA_ M36067 ATP-dependent 1.354 6.1 2.2 AL161951 Unknown 0.728 5.8 1.9 colony stimulating M59820 factor 3 receptor 0.38 5.7 2.0 spermidine/ spermine N1 AL050290 acetyltransferase 2.724 5.6 1.4 NM 002291 laminin beta 1 1.278 5.6 1.8 retinoic acid X06614 receptor_ alpha 1.924 5.5 0.8 putative L-type neutral amino AB007896 acid transporter 0.94 5.3 1.8 DKFZP564B 116 AL050333 protein 1.272 5.3 0.6 hypothetical AK001093 protein 1.729 5.3 2.0 hypothetical NM_016406 protein 1.314 5.2 1.2 M86546 pre-B-cell 1.113 5.2 2.2 32 WO 03/048383 PCT/CA02/01830 Accession Polynucleotide Control: Ratio: Ratio: LPS+ Number Gene Function Media only LPS/control ID 27/control Intensity leukemia trans cription factor 1 zona pellucida X56777 glycoprotein 3A 1.414 5.0 1.4 replication initiation region NM_013400 protein 1.241 4.9 2.0 leukemia NM_002309 inhibitory factor 1.286 4.8 1.9 dentatorubral pallidoluysian NM_001940 atrophy 2.034 4.7 1.2 cytosolic acyl coenzyme A thioester U91316 hydrolase 2.043 4.7 1.4 death-associated X76104 protein kinase 1 1.118 4.6 1.8 AF131838 Unknown 1.879 4.6 1.4 AL050348 Unknown 8.502 4.4 1.7 KIAA0095 gene D42085 product 1.323 4.4 1.2 X92896 Unknown 1.675 4.3 1.5 U26648 syntaxin 5A 1.59 4.3 1.4 monocyte to macrophage differentiation X85750 associated 1.01 4.3 1.1 33 WO 03/048383 PCT/CAO2/01830 Accession Polynucleotide Control: Ratio: Ratio: LPS+ Numbera Gene Function Media only LPS/control ID 27/control Intensity CD 164 antigen D14043 sialomucin 1.683 4.2 1.0 fibroblast J04513 growth factor 2 1.281 4.0 0.9 melanoma associated U19796 antigen 1.618 4.0 0.6 hypothetical AK000087 protein 1.459 3.9 1.0 hypothetical AK001569 protein 1.508 3.9 1.2 AF189009 ubiquilin 2 1.448 3.8 1.3 sterol-C4-methyl U60205 oxidase-like 1.569 3.7 0.8 hypothetical AK000562 protein 1.166 3.7 0.6 AL096739 Unknown 3.66 3.7 0.5 hypothetical AK000366 protein 15.192 3.5 1.0 RAN member RAS oncogene NM_006325 family 1.242 3.5 1.4 X51688 cyclin A2 1.772 3.3 1.0 aldehyde U34252 dehydrogenase 9 1.264 3.3 1.2 FH1/FH2 domain NM_013241 containing 1.264 3.3 0.6 34 WO 03/048383 PCT/CA02/01830 Accession Polynucleotide Control: Ratio: Ratio: LPS+ Number Gene Function Media only LPS/control ID 27/control Intensity protein esterase D/formylglutathi AF1 12219 one hydrolase 1.839 3.3 1.1 anaphase promoting complex subunit NM 016237 5 2.71 3.2 0.9 KIAA0669 gene AB014569 product 2.762 3.2 0.2 hypothetical AF151047 protein 3.062 3.1 1.0 protein phosphatase 6 X92972 catalytic subunit 2.615 3.1 1.1 proteasome 26S subunit ATPase AF035309 5 5.628 3.1 1.3 U52960 SRB7 homolog 1.391 3.1 0.8 electron transfer flavoprotein alpha J04058 polypeptide 3.265 3.1 1.2 interleukin 6 M57230 signal transducer 0.793 3.1 1.0 galactosidase_ U78027 alpha 3.519 3.1 1.1 35 WO 03/048383 PCT/CA02/01830 Accession Polynucleotide Control: Ratio: Ratio: LPS+ Number' Gene Function Media only LPS/control ID 27/control Intensity AK000264 Unknown 2.533 3.0 0.6 mitogen activated protein X80692 kinase 6 2.463 2.9 1.3 L25931 lamin B receptor 2.186 2.7 0.7 X13334 CD14 antigen 0.393 2.5 1.1 tumor necrosis factor receptor superfamily M32315 member 1B 0.639 2.4 0.4 LPS-induced TNF-alpha NM 004862 factor 6.077 2.3 1.1 interferon gamma receptor AL050337 1 2.064 2.1 1.0 'All Accession Numbers in Table 1 through Table 64 refer to GenBank Accession Numbers. [0071] In Table 2, the cationic peptides at a concentration of 50 pg/ml were shown to potently reduce the expression of many of the polynucleotides up-regulated by 100 ng/ml E. coli 0111:B4 LPS as studied by polynucleotide microarrays. Peptide and LPS or LPS alone was incubated with the A549 cells for 4 h and the RNA was isolated. 5 [tg total RNA was used to make Cy3/Cy5 labeled cDNA probes and hybridized onto Human Operon arrays (PRHU04). The intensity of unstimulated cells is shown in the third column of Table 2. The "Ratio: LPS/control" column refers to the intensity of polynucleotide expression in LPS-simulated cells divided by in the intensity of unstimulated cells. The other columns refer to the intensity of 36 WO 03/048383 PCT/CA02/01830 polynucleotide expression in cells stimulated with LPS and peptide divided by unstimulated cells. [0072] Table 2: Human A549 Epithelial Cell Polynucleotide Expression up-regulated by E.coli 0111:B4 LPS and reduced by Cationic Peptides Accession Gene Control: Ratio: Ratio: Ratio: Ratio: Number Media LPS/ LPS+ LPS+ID LPS+ID only control ID 27/ 16/ 22/ Intensity control control control AL031983 Unknown 0.03 302.8 5.06 6.91 0.31
ADP
ribosylation L04510 factor 0.66 213.6 1.4 2.44 3.79 ring finger D87451 protein 3.90 183.7 2.1 3.68 4.28 hypothetical AK000869 protein 0.14 120.1 2.34 2.57 2.58 U78166 Ric like 0.05 91.7 0.20 16.88 21.37 MHC class II X03066 DO beta 0.06 36.5 4.90 12.13 0.98 hypothetical AK001904 protein 0.03 32.8 5.93 0.37 0.37 AB037722 Unknown 0.03 21.4 0.30 0.30 2.36 hypothetical AK001589 protein 0.65 19.2 1.26 0.02 0.43 AL137376 Unknown 1.88 17.3 0.64 1.30 1.35 thioredoxin dependent peroxide L19185 reductase 1 0.06 16.3 0.18 2.15 0.18 Transcobalamin J05068 I 0.04 15.9 1.78 4.34 0.83 FEM-1-like death AB007856 receptor binding 2.63 15.7 0.62 3.38 0.96 37 WO 03/048383 PCT/CA02/01830 Accession Gene Control: Ratio: Ratio: Ratio: Ratio: Number Media LPS/ LPS+ LPS+ID LPS+ID only control ID 27/ 16/ 22/ Intensity control control control protein cytosolic ovarian AK000353 carcinoma ag 1 0.45 13.5 1.02 1.73 2.33 smooth muscle X16940 enteric actin y2 0.21 11.8 3.24 0.05 2.26 M54915 pim-1 oncogene 1.40 11.4 0.63 1.25 1.83 hypothetical AL122111 protein 0.37 10.9 0.21 1.35 0.03 phospholipase C M95678 beta 2 0.22 7.2 2.38 0.05 1.33 hypothetical AK001239 protein 2.20 6.4 1.27 1.89 2.25 AC004849 Unknown 0.14 6.3 0.07 2.70 0.07 retinoic acid X06614 receptor alpha 1.92 5.5 0.77 1.43 1.03 putative L-type neutral amino AB007896 acid transporter 0.94 5.3 1.82 2.15 2.41 BAll-associated AB010894 protein 0.69 5.0 1.38 1.03 1.80 U52522 partner of RAC1 1.98 2.9 1.35 0.48 1.38 hypothetical AK001440 protein 1.02 2.7 0.43 1.20 0.01 ankyrin 2 NM 001148 neuronal 0.26 2.5 0.82 0.04 0.66 inter-alpha X07173 inhibitor H2 0.33 2.2 0.44 0.03 0.51 brain and nasopharyngeal carcinoma susceptibility AF095687 protein 0.39 2.1 0.48 0.03 0.98 38 WO 03/048383 PCT/CA02/01830 Accession Gene Control: Ratio: Ratio: Ratio: Ratio: Number Media LPS/ LPS+ LPS+ID LPS+ID only control ID 27/ 16/ 22/ Intensity control control control NK cell activation inducing ligand NM 016382 NAIL 0.27 2.1 0.81 0.59 0.04 KIAAO981 AB023198 protein 0.39 2.0 0.43 0.81 0.92 EXAMPLE 2 NEUTRALIZATION OF THE STIMULATION OF IMMUNE CELLS [0073] The ability of compounds to neutralize the stimulation of immune cells by both Gram-negative and Gram-positive bacterial products was tested. Bacterial products stimulate cells of the immune system to produce inflammatory cytokines and when unchecked this can lead to sepsis. Initial experiments utilized the murine macrophage cell line RAW 264.7, which was obtained from the American Type Culture Collection, (Manassas, VA), the human epithelial cell line, A549, and primary macrophages derived from the bone marrow of BALB/c mice (Charles River Laboratories, Wilmington, MA). The cells from mouse bone marrow were cultured in 150-mm plates in Dulbecco's modified Eagle medium (DMEM; Life Technologies, Burlington, ON) supplemented with 20 % FBS (Sigma Chemical Co,St. Louis, MO) and 20 % L cell-conditioned medium as a source of M-CSF. Once macrophages were 60-80 % confluent, they were deprived of L cell-conditioned medium for 14-16 h to render the cells quiescent and then were subjected to treatments with 100 ng/ml LPS or 100 ng/ml LPS + 20 ptg/ml peptide for 24 hours. The release of cytokines into the culture supernatant was determined by ELISA (R&D Systems, Minneapolis, MN). The cell lines, RAW 264.7 and A549, were maintained in DMEM supplemented with 10 % fetal calf serum. RAW 264.7 cells were seeded in 24 well plates at a density of 106 cells per well in DMEM and A549 cells were seeded in 24 well plates at a density of 10 5 cells per well in DMEM and both were incubated at 37 0 C in 5 % CO 2 overnight. DMEM was aspirated from cells grown overnight and replaced with fresh 39 WO 03/048383 PCT/CA02/01830 medium. In some experiments, blood from volunteer human donors was collected (according to procedures accepted by UBC Clinical Research Ethics Board, certificate COO-0537) by venipuncture into tubes (Becton Dickinson, Franklin Lakes, NJ) containing 14.3 USP units heparin/ml blood. The blood was mixed with LPS with or without peptide in polypropylene tubes at 37 0 C for 6 h. The samples were centrifuged for 5 min at 2000 x g, the plasma was collected and then stored at -20 0 C until being analyzed for IL-8 by ELISA (R&D Systems). In the experiments with cells, LPS or other bacterial products were incubated with the cells for 6-24 hr at 37 0 C in 5 % C0 2 . S. typhimurium LPS andE. coli 0111:B4 LPS were purchased from Sigma. Lipoteichoic acid (LTA) from S. aureus (Sigma) was resuspended in endotoxin free water (Sigma). The Limulus amoebocyte lysate assay (Sigma) was performed on LTA preparations to confirm that lots were not significantly contaminated by endotoxin. Endotoxin contamination was less than 1 ng/ml, a concentration that did not cause significant cytokine production in the RAW 264.7 cells. Non-capped lipoarabinomannan (AraLAM) was a gift from Dr. John T. Belisle of Colorado State University. The AraLAM from Mycobacterium was filter sterilized and the endotoxin contamination was found to be 3.75 ng per 1.0 mg of LAM as determined by Limulus Amebocyte assay. At the same time as LPS addition (or later where specifically described), cationic peptides were added at a range of concentrations. The supernatants were removed and tested for cytokine production by ELISA (R&D Systems). All assays were performed at least three times with similar results. To confirm the anti-sepsis activity in vivo, sepsis was induced by intraperitoneal injection of 2 or 3 Rg of E. coli O111:B4 LPS in phosphate-buffered saline (PBS; pH 7.2) into galactosamine-sensitized 8- to 10- week-old female CD-1 or BALB/c mice. In experiments involving peptides, 200 lag in 100pl of sterile water was injected at separate intraperitoneal sites within 10 min of LPS injection. In other experiments, CD-1 mice were injected with 400 pig E. coli Ol 1:B4 LPS and 10 min later peptide (200 [tg) was introduced by intraperitoneal injection. Survival was monitored for 48 hours post injection. [0074] Hyperproduction of TNF-cc has been classically linked to development of sepsis. The three types of LPS, LTA or AraLAM used in this example represented 40 WO 03/048383 PCT/CA02/01830 products released by both Gram-negative and Gram-positive bacteria. Peptide, SEQ ID NO: 1, was able to significantly reduce TNF-c production stimulated by S. typhimurium, B. cepacia, and E. coli 0111 :B4 LPS, with the former being affected to a somewhat lesser extent (Table 3). At concentrations as low as 1 pg/ml of peptide (0.25 nM) substantial reduction of TNF-a production was observed in the latter two cases. A different peptide, SEQ ID NO: 3 did not reduce LPS-induced production of TNF-ac in RAW macrophage cells, demonstrating that this is not a uniform and predictable property of cationic peptides. Representative peptides from each Formula were also tested for their ability to affect TNF-a production stimulated by E. coli O111:B4 LPS (Table 4). The peptides had a varied ability to reduce TNF-a production although many of them lowered TNF-c by at least 60%. [0075] At certain concentrations peptides SEQ ID NO: 1 and SEQ ID NO: 2, could also reduce the ability of bacterial products to stimulate the production of IL-8 by an epithelial cell line. LPS is a known potent stimulus of IL-8 production by epithelial cells. Peptides, at low concentrations (1-20 gg/ml), neutralized the IL-8 induction responses of epithelial cells to LPS (Table 5-7). Peptide SEQ ID 2 also inhibited LPS-induced production of IL-8 in whole human blood (Table 4). Conversely, high concentrations of peptide SEQ ID NO: 1 (50 to 100 pg/ml) actually resulted in increased levels of IL-8 (Table 5). This suggests that the peptides have different effects at different concentrations. [0076] The effect of peptides on inflammatory stimuli was also demonstrated in primary murine cells, in that peptide SEQ ID NO: 1 significantly reduced TNF-c production (>90 %) by bone marrow-derived macrophages from BALB/c mice that had been stimulated with 100 ng/ml E. coli 0111:B4 LPS (Table 8). These experiments were performed in the presence of serum, which contains LPS-binding protein (LBP), a protein that can mediate the rapid binding of LPS to CD14. Delayed addition of SEQ ID NO: 1 to the supernatants of macrophages one hour after stimulation with 100 ng/ml E. coli LPS still resulted in substantial reduction (70 %) of TNF-a production (Table 9). 41 WO 03/048383 PCT/CA02/01830 [0077] Consistent with the ability of SEQ ID NO: 1 to prevent LPS-induced production of TNF-c in vitro, certain peptides also protected mice against lethal shock induced by high concentrations of LPS. In some experiments, CD-1 mice were sensitized to LPS with a prior injection of galactosamine. Galactosamine-sensitized mice that were injected with 3 pig of E. coli 0111:B4 LPS were all killed within 4-6 hours. When 200 pg of SEQ ID NO: 1 was injected 15 min after the LPS, 50 % of the mice survived (Table 10). In other experiments when a higher concentration of LPS was injected into BALB/c mice with no D-galactosamine, peptide protected 100 % compared to the control group in which there was no survival (Table 13). Selected other peptides were also found to be protective in these models (Tables 11,12). [0078] Cationic peptides were also able to lower the stimulation of macrophages by Gram-positive bacterial products such as Mycobacterium non-capped lipoarabinomannan (AraLAM) and S. aureus LTA. For example, SEQ ID NO: 1 inhibited induction of TNF- in RAW 264.7 cells by the Gram-positive bacterial products, LTA (Table 14) and to a lesser extent AraLAM (Table 15). Another peptide, SEQ ID NO: 2, was also found to reduce LTA-induced TNF-a production by RAW 264.7 cells. At a concentration of 1 [ig/ml SEQ ID NO: 1 was able to substantially reduce (>75 %) the induction of TNF-a production by 1 gg/ml S. aureus LTA. At 20 pg/ml SEQ ID NO: 1, there was >60 % inhibition of AraLAM induced TNF-a. Polymyxin B (PMB) was included as a control to demonstrate that contaminating endotoxin was not a significant factor in the inhibition by SEQ ID NO: 1 of AraLAM induced TNF-a. These results demonstrate that cationic peptides can reduce the pro-inflammatory cytokine response of the immune system to bacterial products. [0079] Table 3: Reduction by SEQ ID 1 of LPS induced TNF-c production in RAW 264.7 cells. RAW 264.7 mouse macrophage cells were stimulated with 100 ng/ml S. typhimurium LPS, 100 ng/ml B. cepacia LPS and 100 ng/ml E. coli 0111:B4 LPS in the presence of the indicated concentrations of SEQ ID 1 for 6 hr. The concentrations of TNF-ac released into the culture supernatants were determined by ELISA. 100 % represents the amount of TNF-a resulting from RAW 264.7 cells 42 WO 03/048383 PCT/CA02/01830 incubated with LPS alone for 6 hours (S. typhimurium LPS = 34.5 ± 3.2 ng/ml, B. cepacia LPS = 11.6 + 2.9 ng/ml, and E. coli 0111:B4 LPS = 30.8 + 2.4 ng/ml). Background levels of TNF-a production by the RAW 264.7 cells cultured with no stimuli for 6 hours resulted in TNF-a levels ranging from 0.037 - 0.192 ng/ml. The data is from duplicate samples and presented as the mean of three experiments + standard error. Amount of Inhibition of TNF-ct (%)* SEQ ID 1 (pg/ml) B. cepacia LPS E. coli LPS S. typhimurium LPS 0.1 8.5 + 2.9 0.0 + 0.6 0.0 + 0 1 23.0 + 11.4 36.6 + 7.5 9.8 + 6.6 5 55.4 + 8 65.0 + 3.6 31.1 + 7.0 10 63.1 + 8 75.0 + 3.4 37.4 + 7.5 20 71.7 + 5.8 81.0 + 3.5 58.5 + 10.5 50 86.7 + 4.3 92.6 + 2.5 73.1 + 9.1 [0080] Table 4: Reduction by Cationic Peptides of E. coli LPS induced TNF-ca production in RAW 264.7 cells. RAW 264.7 mouse macrophage cells were stimulated with 100 ng/ml E. coli 0111 :B4 LPS in the presence of the indicated concentrations of cationic peptides for 6 h. The concentrations of TNF-a released into the culture supernatants were determined by ELISA. Background levels of TNF-aX production by the RAW 264.7 cells cultured with no stimuli for 6 hours resulted in TNF-a levels ranging from 0.037 - 0.192 ng/ml. The data is from duplicate samples and presented as the mean of three experiments + standard deviation. Peptide (20 pg/ml) Inhibition of TNF-ac (%) SEQ ID 5 65.6 ± 1.6 SEQ ID 6 59.8 ± 1.2 SEQ ID 7 50.6 ± 0.6 SEQ ID 8 39.3 ± 1.9 43 WO 03/048383 PCT/CA02/01830 Peptide (20 pg/ml) Inhibition of TNF-ca (%) SEQ ID 9 58.7 ± 0.8 SEQ ID 10 55.5 + 0.52 SEQ ID 12 52.1 + 0.38 SEQ ID 13 62.4 ± 0.85 SEQ ID 14 50.8 ± 1.67 SEQ ID 15 69.4 ± 0.84 SEQ ID 16 37.5 ± 0.66 SEQ ID 17 28.3 ± 3.71 SEQ ID 19 69.9 ± 0.09 SEQ ID 20 66.1 ± 0.78 SEQ ID 21 67.8 ± 0.6 SEQ ID 22 73.3 ± 0.36 SEQ ID 23 83.6 ± 0.32 SEQ ID 24 60.5 ± 0.17 SEQ ID 26 54.9 1.6 SEQ ID 27 51.1 ± 2.8 SEQ ID 28 56 ± 1.1 SEQ ID 29 58.9 ± 0.005 SEQ ID 31 60.3 ± 0.6 SEQ ID 33 62.1 ± 0.08 SEQ ID 34 53.3 ± 0.9 SEQ ID 35 60.7 ± 0.76 SEQ ID 36 63 ± 0.24 SEQ ID 37 58.9 + 0.67 SEQ ID 38 54 1 SEQ ID 40 75 ± 0.45 SEQ ID 41 86 ± 0.37 SEQ ID 42 80.5 ± 0.76 SEQ ID 43 88.2 ± 0.65 SEQ ID 44 44.9 ± 1.5 44 WO 03/048383 PCT/CA02/01830 Peptide (20 pg/ml) Inhibition of TNF-ot (%) SEQ ID 45 44.7 ± 0.39 SEQ ID 47 36.9 ± 2.2 SEQ ID 48 64 ± 0.67 SEQ ID 49 86.9 ± 0.69 SEQ ID 53 46.5 ± 1.3 SEQ ID 54 64 ± 0.73 [0081] Table 5: Reduction by SEQ ID 1 of LPS induced IL-8 production in A549 cells. A549 cells were stimulated with increasing concentrations of SEQ ID 1 in the presence of LPS (100 ng/ml E. coli O111:B4) for 24 hours. The concentration of IL-8 in the culture supernatants was determined by ELISA. The background levels of IL-8 from cells alone was 0.172 + 0.029 ng/ml. The data is presented as the mean of three experiments + standard error. SEQ ID 1 (pg/ml) Inhibition of IL-8 (%) 0.1 1+0.3 1 32+10 10 60+9 20 47+12 50 40+13 100 0 [0082] Table 6: Reduction by SEQ ID 2 of E. coli LPS induced IL-8 production in A549 cells. Human A549 epithelial cells were stimulated with increasing concentrations of SEQ ID 2 in the presence of LPS (100 ng/ml E. coli 0111:B4) for 24 hours. The concentration of IL-8 in the culture supernatants was determined by ELISA. The data is presented as the mean of three experiments + standard error. 45 WO 03/048383 PCT/CA02/01830 Concentration of SEQ ID 2 (pg/ml) Inhibition of IL-8 (%) 0.1 6.8 + 9.6 1 12.8 + 24.5 10 29.0 + 26.0 50 39.8 + 1.6 100 45.0 + 3.5 [0083] Table 7: Reduction by SEQ ID 2 of E. coli LPS induced IL-8 in human blood. Whole human blood was stimulated with increasing concentrations of peptide and E.coli 0111:B4 LPS for 4 hr. The human blood samples were centrifuged and the serum was removed and tested for IL-8 by ELISA. The data is presented as the average of 2 donors. SEQ ID 2 (pg/ml) IL-8 (pg/ml) 0 3205 10 1912 50 1458 [0084] Table 8: Reduction by SEQ ID 1 of E. coli LPS induced TNF-a production in murine bone marrow macrophages. BALB/c Mouse bone marrow derived macrophages were cultured for either 6 h or 24 h with 100 ng/ml E. coli 0111 :B4 LPS in the presence or absence of 20 pg/ml of peptide. The supernatant was collected and tested for levels of TNF-a by ELISA. The data represents the amount of TNF-a resulting from duplicate wells of bone marrow-derived macrophages incubated with LPS alone for 6 h (1.1 ± 0.09 ng/ml) or 24 h (1.7 ± 0.2 ng/ml). Background levels of TNF-a were 0.038 ± 0.008 ng/ml for 6 h and 0.06 + 0.012 ng/ml for 24h. 46 WO 03/048383 PCT/CA02/01830 SEQ ID 1 (jig/ml) Production of TNF-a (ng/ml) 6 hours 24 hours LPS alone 1.1 1.7 1 0.02 0.048 10 0.036 0.08 100 0.033 0.044 No LPS control 0.038 0.06 [0085] Table 9: Inhibition of E. coli LPS-induced TNF-a production by delayed addition of SEQ ID 1 to A549 cells. Peptide (20 tg/ml) was added at increasing time points to wells already containing A549 human epithelial cells and 100 ng/ml E. coli 0111 :B4 LPS. The supernatant was collected after 6 hours and tested for levels of TNF-c by ELISA. The data is presented as the mean of three experiments + standard error. Time of addition of SEQ ID 1 Inhibition of TNF-a (%) after LPS (min) 0 98.3 + 0.3 15 89.3 + 3.8 30 83 + 4.6 60 68+8 90 53 + 8 [0086] Table 10: Protection against lethal endotoxaemia in galactosamine sensitized CD-1 mice by SEQ ID 1. CD-1 mice (9 weeks-old) were sensitized to endotoxin by three intraperitoneal injections of galactosamine (20 mg in 0.1 ml sterile PBS). Then endotoxic shock was induced by intraperitoneal injection of E. coli 0111:B4 LPS (3 ig in 0.1 ml PBS). Peptide, SEQ ID 1, (200 jig/mouse = 8mg/kg) 47 WO 03/048383 PCT/CA02/01830 was injected at a separate intraperitoneal site 15 min after injection of LPS. The mice were monitored for 48 hours and the results were recorded. D-Galactosamine E. coli Peptide or Total Survival post treatment 0111 :B4 LPS buffer mice endotoxin shock 0 3 Vtg PBS 5 5 (100%) 20 mg 3 pg PBS 12 0(0%) 20 mg 3 pg SEQ ID 1 12 6(50%) [0087] Table 11: Protection against lethal endotoxaemia in galactosamine sensitized CD-1 mice by Cationic Peptides. CD-1 mice (9 weeks-old) were sensitized to endotoxin by intraperitoneal injection of galactosamine (20 mg in 0.1 ml sterile PBS). Then endotoxic shock was induced by intraperitoneal injection of E. coli 0111:B4 LPS (2 pg in 0.1 ml PBS). Peptide (200 pg/mouse = 8mg/kg) was injected at a separate intraperitoneal site 15 min after injection of LPS. The mice were monitored for 48 hours and the results were recorded. Peptide Treatment E. coli 0111:B4 Number Survival (%) LPS added of Mice Control (no peptide) 2 pg 5 0 SEQ ID 6 2 gg 5 40 SEQ ID 13 2 pg 5 20 SEQ ID 17 2 Vg 5 40 SEQ ID 24 2 pg 5 0 SEQ ID 27 2 pg 5 20 48 WO 03/048383 PCT/CA02/01830 [0088] Table 12: Protection against lethal endotoxaemia in galactosamine sensitized BALB/c mice by Cationic Peptides. BALB/c mice (8 weeks-old) were sensitized to endotoxin by intraperitoneal injection of galactosamine (20 mg in 0.1 ml sterile PBS). Then endotoxic shock was induced by intraperitoneal injection of E. coli 0111:B4 LPS (2 ag in 0.1 ml PBS). Peptide (200 ag/mouse = 8mg/kg) was injected at a separate intraperitoneal site 15 min after injection of LPS. The mice were monitored for 48 hours and the results were recorded. Peptide Treatment E. coli Number of Mice Survival (%) 0111:B4 LPS added No peptide 2 pg 10 10 SEQ ID 1 2 pg 6 17 SEQ ID 3 2 pg 6 0 SEQ ID 5 2 pg 6 17 SEQ ID 6 2 [g 6 17 SEQ ID 12 2 tg 6 17 SEQ ID 13 2 pg 6 33 SEQ ID 15 2 Vg 6 0 SEQ ID 16 2 Vg 6 0 SEQ ID 17 2 pg 6 17 SEQ ID 23 2 [g 6 0 SEQ ID 24 2 [g 6 17 SEQID26 2 ig 6 0 SEQ ID 27 2 gg 6 50 SEQ ID 29 2 Vg 6 0 SEQID37 2 ig 6 0 SEQ ID 38 2 [g 6 0 SEQ ID41 2 gg 6 0 . SEQ ID 44 2 lg 6 0 SEQ ID 45 2 gg 6 0 49 WO 03/048383 PCT/CA02/01830 [0089] Table 13: Protection against lethal endotoxaemia in BALB/c mice by SEQ ID 1. BALB/c mice were injected intraperitoneal with 400 pg E. coli 0111 :B4 LPS. Peptide (200 ag/mouse = 8mg/kg) was injected at a separate intraperitoneal site and the mice were monitored for 48 hours and the results were recorded. Peptide E. coli Number of Mice Survival (%) Treatment 0111 :B4 LPS No peptide 400 pg 5 0 SEQ ID 1 400 pg 5 100 [0090] Table 14: Peptide inhibition of TNF-a production induced by S. aureus LTA. RAW 264.7 mouse macrophage cells were stimulated with 1 pg/ml S. aureus LTA in the absence and presence of increasing concentrations of peptide. The supernatant was collected and tested for levels of TNF-a by ELISA. Background levels of TNF-a production by the RAW 264.7 cells cultured with no stimuli for 6 hours resulted in TNF-a levels ranging from 0.037 - 0.192 ng/ml. The data is presented as the mean of three or more experiments + standard error. SEQ ID 1 added (pg/ml) Inhibition of TNF-cc (%) 0.1 44.5 + 12.5 1 76.7 + 6.4 5 91+1 10 94.5 + 1.5 20 96 + 1 [0091] Table 15: Peptide inhibition of TNF-a production induced by Mycobacterium non-capped lipoarabinomannan. RAW 264.7 mouse macrophage cells were stimulated with 1 pg/ml AraLAM in the absence and presence of 20 pg/ml peptide or Polymyxin B. The supernatant was collected and tested for levels of TNF a by ELISA. Background levels of TNF-a production by the RAW 264.7 cells 50 WO 03/048383 PCT/CA02/01830 cultured with no stimuli for 6 hours resulted in TNF-c levels ranging from 0.037 0.192 ng/ml. The data is presented as the mean inhibition of three or more experiments + standard error. Peptide (20 jtg/ml) Inhibition of TNF-a (%) No peptide 0 SEQ ID 1 64 + 5.9 Polymyxin B 15 + 2 EXAMPLE 3 ASSESSMENT OF TOXICITY OF THE CATIONIC PEPTIDES [0092] The potential toxicity of the peptides was measured in two ways. First, the Cytotoxicity Detection Kit (Roche) (Lactate dehydrogenase -LDH) Assay was used. It is a colorimetric assay for the quantification of cell death and cell lysis, based on the measurement of LDH activity released from the cytosol of damaged cells into the supernatant. LDH is a stable cytoplasmic enzyme present in all cells and it is released into the cell culture supernatant upon damage of the plasma membrane. An increase in the amount of dead or plasma membrane-damaged cells results in an increase of the LDH enzyme activity in the culture supernatant as measured with an ELISA plate reader, OD 490 nm (the amount of color formed in the assay is proportional to the number of lysed cells). In this assay, human bronchial epithelial cells (16HBEol4, HBE) cells were incubated with 100 Vg of peptide for 24 hours, the supernatant removed and tested for LDH. The other assay used to measure toxicity of the cationic peptides was the WST-1 assay (Roche). This assay is a colorimetric assay for the quantification of cell proliferation and cell viability, based on the cleavage of the tetrazolium salt WST-1 by mitochondrial dehydrogenases in viable cells (a non radioactive alternative to the [ 3 H]-thymidine incorporation assay). In this assay, HBE cells were incubated with 100 ptg of peptide for 24 hours, and then 10 gl/well Cell Proliferation Reagent WST-1 was added. The cells are incubated with the reagent and the plate is then measured with an ELISA plate reader, OD 490 nm. 51 WO 03/048383 PCT/CA02/01830 [00931 The results shown below in Tables 16 and 17 demonstrate that most of the peptides are not toxic to the cells tested. However, four of the peptides from Formula F (SEQ ID NOS: 40, 41, 42 and 43) did induce membrane damage as measured by both assays. [0094] Table 16: Toxicity of the Cationic Peptides as Measured by the LDH Release Assay. Human HBE bronchial epithelial cells were incubated with 100 pg/ml peptide or Polymyxin B for 24 hours. LDH activity was assayed in the supematant of the cell cultures. As a control for 100% LDH release, Triton X-100 was added. The data is presented as the mean ± standard deviation. Only peptides SEQ ID 40,41,42 and 43 showed any significant toxicity. Treatment LDH Release (OD 4 90 nrm) No cells Control 0.6 ± 0.1 Triton X-100 Control 4.6 ± 0.1 No peptide control 1.0 ± 0.05 SEQ ID 1 1.18 0.05 SEQ ID 3 1.05 ± 0.04 SEQ ID 6 . 0.97 0.02 SEQ ID 7 1.01 ± 0.04 SEQ ID 9 1.6 0.03 SEQ ID 10 1.04 ± 0.04 SEQ ID 13 0.93 + 0.06 SEQ ID 14 0.99 ± 0.05 SEQ ID 16 0.91 0.04 SEQ ID 17 0.94 ± 0.04 SEQ ID 19 1.08 ± 0.02 SEQ ID 20 1.05 ± 0.03 SEQ ID 21 1.06 0.04 SEQ ID 22 1.29 ± 0.12 SEQ ID 23 1.26 ± 0.46 SEQ ID 24 1.05 + 0.01 52 WO 03/048383 PCT/CA02/01830 Treatment LDH Release (OD 49 o nm) SEQ ID 26 0.93 ± 0.04 SEQ ID 27 0.91 ± 0.04 SEQ ID 28 0.96 ± 0.06 SEQ ID 29 0.99 ± 0.02 SEQ ID 31 0.98 ± 0.03 SEQ ID 33 1.03 ± 0.05 SEQ ID 34 1.02 ± 0.03 SEQ ID 35 0.88 ± 0.03 SEQ ID 36 0.85 ± 0.04 SEQ ID 37 0.96± 0.04 SEQ ID 38 0.95± 0.02 SEQ ID 40 2.8 ± 0.5 SEQ ID 41 3.3 ± 0.2 SEQ ID 42 3.4 ± 0.2 SEQ ID 43 4.3 ± 0.2 SEQ ID 44 0.97 ± 0.03 SEQ ID 45 0.98 ± 0.04 SEQ ID 47 1.05 ± 0.05 SEQ ID 48 0.95 ± 0.05 SEQ ID 53 1.03 ± 0.06 Polymyxin B 1.21 + 0.03 [0095] Table 17: Toxicity of the Cationic Peptides as Measured by the WST-1 Assay. HBE cells were incubated with 100 [tg/ml peptide or Polymyxin B for 24 hours and cell viability was tested. The data is presented as the mean ± standard deviation. As a control for 100% LDH release, Triton X-100 was added. Only peptides SEQ ID 40,41,42 and 43 showed any significant toxicity. 53 WO 03/048383 PCT/CA02/01830 Treatment OD 490 nm No cells Control 0.24 ± 0.01 Triton X-100 Control 0.26 ± 0.01 No peptide control 1.63 ± 0.16 SEQ ID 1 1.62 ±+ 0.34 SEQ ID 3 1.35 ± 0.12 SEQ ID 10 1.22 ± 0.05 SEQ ID 6 1.81 ± 0.05 SEQ ID 7 1.78 ± 0.10 SEQ ID 9 1.69 ± 0.29 SEQ ID 13 1.23 ± 0.11 SEQ ID 14 1.25 ± 0.02 SEQ ID 16 1.39 ± 0.26 SEQ ID 17 1.60 ± 0.46 SEQ ID 19 1.42 ± 0.15 SEQ ID 20 1.61 ± 0.21 SEQ ID 21 1.28 ± 0.07 SEQ ID 22 1.33 ± 0.07 SEQ ID 23 1.14 ± 0.24 SEQ ID 24 1.27 ± 0.16 SEQ ID 26 1.42 ± 0.11 SEQ ID 27 1.63 ± 0.03 SEQ ID 28 1.69 ± 0.03 SEQ ID 29 1.75 ± 0.09 SEQ ID 31 1.84 ± 0.06 SEQ ID 33 1.75 ± 0.21 SEQ ID 34 0.96 ± 0.05 SEQ ID 35 1.00 + 0.08 SEQ ID 36 1.58 ± 0.05 SEQ ID 37 1.67 ± 0.02 SEQ ID 38 1.83 ± 0.03 54 WO 03/048383 PCT/CA02/01830 Treatment OD 490 nm SEQ ID 40 0.46 ± 0.06 SEQ ID 41 0.40 ± 0.01 SEQ ID 42 0.39 ± 0.08 SEQ ID 43 0.46 ± 0.10 SEQ ID 44 1.49 ± 0.39 SEQ ID 45 1.54 ± 0.35 SEQ ID 47 1.14 ± 0.23 SEQ ID 48 0.93 ± 0.08 SEQ ID 53 1.51 ± 0.37 Polymyxin B 1.30 + 0.13 EXAMPLE 4 POLYNUCLEOTIDE REGULATION BY CATIONIC PEPTIDES [0096] Polynucleotide arrays were utilized to determine the effect of cationic peptides by themselves on the transcriptional response of macrophages and epithelial cells. Mouse macrophage RAW 264.7, Human Bronchial cells (HBE), or A549 human epithelial cells were plated in 150 mm tissue culture dishes at 5.6 x 10 6 cells/dish, cultured overnight and then incubated with 50 ptg/ml peptide or medium alone for 4 h. After stimulation, the cells were washed once with diethyl pyrocarbonate-treated PBS, and detached from the dish using a cell scraper. Total RNA was isolated using Trizol (Gibco Life Technologies). The RNA pellet was resuspended in RNase-free water containing RNase inhibitor (Ambion, Austin, TX). The RNA was treated with DNaseI (Clontech, Palo Alto, CA) for 1 h at 37 0 C. After adding termination mix (0.1 M EDTA [pH 8.0], 1 mg/ml glycogen), the samples were extracted once with phenol: chloroform: isoamyl alcohol (25:24:1), and once with chloroform. The RNA was then precipitated by adding 2.5 volumes of 100% ethanol and 1
/
1 0
'
h volume sodium acetate, pH 5.2. The RNA was resuspended in RNase-free water with RNase inhibitor (Ambion) and stored at -70 0 C. The quality of the RNA was assessed by gel electrophoresis on a 1% agarose gel. Lack of genomic DNA contamination was assessed by using the isolated RNA as a template for PCR amplification with P-actin 55 WO 03/048383 PCT/CA02/01830 specific primers (5'-GTCCCTGTATGCCTCTGGTC-3' (SEQ ID NO: 55) and 5' GATGTCACGCACGATTTCC-3' (SEQ ID NO: 56)). Agarose gel electrophoresis and ethidium bromide staining confirmed the absence of an amplicon after 35 cycles. [0097] Atlas cDNA Expression Arrays (Clontech, Palo Alto, CA), which consist of 588 selected mouse cDNAs spotted in duplicate on positively charged membranes were used for early polynucleotide array studies (Tables 18,19) _ 32 P-radiolabeled cDNA probes prepared from 5 ptg total RNA were incubated with the arrays overnight at 71'C. The filters were washed extensively and then exposed to a phosphoimager screen (Molecular Dynamics, Sunnyvale, CA) for 3 days at 4 0 C. The image was captured using a Molecular Dynamics PSI phosphoimager. The hybridization signals were analyzed using Atlaslmage 1.0 Image Analysis software (Clontech) and Excel (Microsoft, Redmond, WA). The intensities for each spot were corrected for background levels and normalized for differences in probe labeling using the average values for 5 polynucleotides observed to vary little between the stimulation conditions: 3-actin, ubiquitin, ribosomal protein S29, glyceraldehyde-3-phosphate dehydrogenase (GAPDH), and Ca 2 + binding protein. When the normalized hybridization intensity for a given cDNA was less than 20, it was assigned a value of 20 to calculate the ratios and relative expression. [0098] The next polynucleotide arrays used (Tables 21-26) were the Resgen Human cDNA arrays (identification number for the genome is PRHU03-S3), which consist of 7,458 human cDNAs spotted in duplicate. Probes were prepared from 15-20 ltg of total RNA and labeled with Cy3 labeled dUTP. The probes were purified and hybridized to printed glass slides overnight at 42'C and washed. After washing, the image was captured using a Virtek slide reader.- The image processing software (Imagene 4.1, Marina Del Rey, CA) determines the spot mean intensity, median intensities, and background intensities. Normalization and analysis was performed with Genespring software (Redwood City, CA). Intensity values were calculated by subtracting the mean background intensity from the mean intensity value determined by Imagene. The intensities for each spot were normalized by taking the median spot intensity value from the population of spot values within a slide and comparing this 56 WO 03/048383 PCT/CA02/01830 value to the values of all slides in the experiment. The relative changes seen with cells treated with peptide compared to control cells can be found in the Tables below. [0099] The other polynucleotide arrays used (Tables 27-35) were the Human Operon arrays (identification number for the genome is PRHU04-S1), which consist of about 14,000 human oligos spotted in duplicate. Probes were prepared from 10 pIg of total RNA and labeled with Cy3 or Cy5 labeled dUTP. In these experiments, A549 epithelial cells were plated in 100 mm tissue culture dishes at 2.5 x 106 cells/dish. Total RNA was isolated using RNAqueous (Ambion). DNA contamination was removed with DNA-free kit (Ambion). The probes prepared from total RNA were purified and hybridized to printed glass slides overnight at 42°C and washed. After washing, the image was captured using a Perkin Elmer array scanner. The image processing software (Imagene 5.0, Marina Del Rey, CA) determines the spot mean intensity, median intensities, and background intensities. An "in house" program was used to remove background. The program calculates the bottom 10% intensity for each subgrid and subtracts this for each grid. Analysis was performed with Genespring software (Redwood City, CA). The intensities for each spot were normalized by taking the median spot intensity value from the population of spot values within a slide and comparing this value to the values of all slides in the experiment. The relative changes seen with cells treated with peptide compared to control cells can be found in the Tables below. [001001 Semi-quantitative RT-PCR was performed to confirm polynucleotide array results. 1 tg RNA samples were incubated with 1 pl oligodT (500 pg/ml) and 1 p1 mixed dNTP stock at 1 mM, in a 12 pl1 volume with DEPC treated water at 65'C for 5 min in a thermocycler. 4 pl 5X First Strand buffer, 2 p1 0.1M DTT, and 1 pl RNaseOUT recombinant ribonuclease inhibitor (40 units/pl) were added and incubated at 42 oC for 2 min, followed by the addition of 1 pl ( 2 00 units) of Superscript II (Invitrogen, Burlington, ON). Negative controls for each RNA source were generated using parallel reactions in the absence of Superscript II. cDNAs were amplified in the presence of 5' and 3' primers (1.0 pM), 0.2 mM dNTP mixture, 1.5 mM MgCI, 1 U of Taq DNA polymerase (New England Biolabs, Missisauga, ON), and 1X PCR buffer. Each PCR was performed with a thermal cycler by using 30-40 57 WO 03/048383 PCT/CA02/01830 cycles consisting of 30s of denaturation at 94 °C, 30s of annealing at either 52 oC or 55 'C and 40s of extension at 72 0 C. The number of cycles of PCR was optimized to lie in the linear phase of the reaction for each primer and set of RNA samples. A housekeeping polynucleotide P3-actin was amplified in each experiment to evaluate extraction procedure and to estimate the amount of RNA. The reaction product was visualized by electrophoresis and analyzed by densitometry, with relative starting RNA concentrations calculated with reference to P-actin amplification. [00101] Table 18 demonstrates that SEQ ID NO: 1 treatment of RAW 264.7 cells up-regulated the expression of more than 30 different polynucleotides on small Atlas microarrays with selected known polynucleotides. The polynucleotides up-regulated by peptide, SEQ ID NO: 1, were mainly from two categories: one that includes receptors (growth, chemokine, interleukin, interferon, hormone, neurotransmitter), cell surface antigens and cell adhesion and another one that includes cell-cell communication (growth factors, cytokines, chemokines, interleukin, interferons, hormones), cytoskeleton, motility, and protein turnover. The specific polynucleotides up-regulated included those encoding chemokine MCP-3, the anti-inflammatory cytokine IL-10, macrophage colony stimulating factor, and receptors such as IL-1R-2 (a putative antagonist of productive IL-1 binding to IL-1R1), PDGF receptor B, NOTCH4, LIF receptor, LFA-1, TGF3 receptor 1, G-CSF receptor, and IFNy receptor. The peptide also up-regulated polynucleotides encoding several metalloproteinases, and inhibitors thereof, including the bone morphogenetic proteins BMP-1, BMP-2, BMP-8a, TIMP2 and TIMP3. As well, the peptide up-regulated specific transcription factors, including JunD, and the YY and LIM-1 transcription factors, and kinases such as Etkl and Csk demonstrating its widespread effects. It was also discovered from the polynucleotide array studies that SEQ ID NO: 1 down regulated at least 20 polynucleotides in RAW 264.7 macrophage cells (Table 19). The polynucleotides down-regulated by peptide included DNA repair proteins and several inflammatory mediators such as MIP-lc, oncostatin M and IL-12. A number of the effects of peptide on polynucleotide expression were confirmed by RT-PCR (Table 20). The peptides, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 19, and SEQ ID NO: 1, and representative peptides from each of the formulas also altered the 58 WO 03/048383 PCT/CA02/01830 transcriptional responses in a human epithelial cell line using mid-sized microarrays (7835 polynucleotides). The effect of SEQ ID NO: 1 on polynucleotide expression was compared in 2 human epithelial cell lines, A549 and HBE. Polynucleotides related to the host immune response that were up-regulated by 2 peptides or more by a ratio of 2-fold more than unstimulated cells are described in Table 21. Polynucleotides that were down-regulated by 2 peptides or more by a ratio of 2-fold more than unstimulated cells are described in Table 22. In Table 23 and Table 24, the human epithelial pro-inflammatory polynucleotides that are up- and down-regulated respectively are shown. In Table 25 and Table 26 the anti-inflammatory polynucleotides affected by cationic peptides are shown. The trend becomes clear that the cationic peptides up-regulate the anti-inflammatory response and down-regulate the pro-inflammatory response. It was very difficult to find a polynucleotide related to the anti-inflammatory response that was down-regulated (Table 26). The pro inflammatory polynucleotides upregulated by cationic peptides were mainly polynucleotides related to migration and adhesion. Of the down-regulated pro inflammatory polynucleotides, it should be noted that all the cationic peptides affected several toll-like receptor (TLR) polynucleotides, which are very important in signaling the host response to infectious agents. An important anti-inflammatory polynucleotide that was up-regulated by all the peptides is the IL-10 receptor. IL-10 is an important cytokine involved in regulating the pro-inflammatory cytokines. These polynucleotide expression effects were also observed using primary human macrophages as observed for peptide SEQ ID NO: 6 in Tables 27 and 28. The effect of representative peptides from each of the formulas on human epithelial cell expression of selected polynucleotides (out of 14,000 examined) is shown in Tables 31-37 below. At least 6 peptides from each formula were tested for their ability to alter human epithelial polynucleotide expression and indeed they had a wide range of stimulatory effects. In each of the formulas there were at least 50 polynucleotides commonly up-regulated by each of the peptides in the group. [00102] Table 18: Polynucleotides up-regulated by peptide, SEQ ID NO: 1, treatment of RAW macrophage cellsa. The cationic peptides at a concentration of 50 [tg/ml were shown to potently induce the expression of several polynucleotides. Peptide was incubated with the RAW cells for 4 h and the RNA was isolated, 59 WO 03/048383 PCT/CA02/01830 converted into labeled cDNA probes and hybridized to Atlas arrays. The intensity of unstimulated cells is shown in the third column. The "Ratio Peptide: Unstimulated" column refers to the intensity of polynucleotide expression in peptide-simulated cells divided by the intensity of unstimulated cells. [00103] The changes in the normalized intensities of the housekeeping polynucleotides ranged from 0.8-1.2 fold, validating the use of these polynucleotides for normalization. When the normalized hybridization intensity for a given cDNA was less than 20, it was assigned a value of 20 to calculate the ratios and relative expression. The array experiments were repeated 3 times with different RNA preparations and the average fold change is shown above. Polynucleotides with a two fold or greater change in relative expression levels are presented. Polynucleotide Polynucleotide Unstimulated Ratio Accession / Protein Function Intensity peptide: Number Unstimulatedb Etkl Tyrosine-protein 20 43 M68513 kinase receptor PDGFRB Growth factor receptor 24 25 X04367 Corticotropin releasing 20 23 X72305 factor receptor NOTCH4 proto- 48 18 M80456 oncopolynucleotide IL-1R2 Interleukin receptor 20 16 X59769 MCP-3 Chemokine 56 14 S71251 BMP-1 Bone morpho- 20 14 L24755 polynucleotidetic protein Endothelin b Receptor 20 14 U32329 receptor c-ret Oncopolynucleotide 20 13 X67812 precursor LIFR Cytokine receptor 20 12 D26177 60 WO 03/048383 PCT/CA02/01830 Polynucleotide Polynucleotide Unstimulated Ratio Accession / Protein Function Intensity peptide: Number Unstimulatedb BMP-8a Bone morpho- 20 12 M97017 polynucleotidetic protein Zfp92 Zinc finger protein 92 87 11 U47104 MCSF Macrophage colony 85 11 X05010 stimulating factor 1 GCSFR Granulocyte colony- 20 11 M58288 stimulating factor receptor IL-8RB Chemokine receptor 112 10 D17630 IL-9R Interleukin receptor 112 6 M84746 Cas Crk-associated 31 6 U48853 substrate p58/GTA Kinase 254 5 M58633 CASP2 Caspase precursor 129 5 D28492 IL-113 Interleukin precursor 91 5 M15131 precursor SPI2-2 Serine protease 62 5 M64086 inhibitor C5AR Chemokine receptor 300 4 S46665 L-myc Oncopolynucleotide 208 4 X13945 IL-10 Interleukin 168 4 M37897 pl9ink4 cdk4 and cdk6 147 4 U19597 inhibitor ATOH2 Atonal homolog 2 113 4 U29086 DNAsel DNase 87 4 U00478 CXCR-4 Chemokine receptor 36 4 D87747 Cyclin D3 Cyclin 327 3 U43844 IL-7Rcx Interleukin receptor 317 3 M29697 POLA DNA polymerase, 241 3 D17384 Tie-2 Oncopolynucleotide 193 3 S67051 61 WO 03/048383 PCT/CA02/01830 Polynucleotide Polynucleotide Unstimulated Ratio Accession / Protein Function Intensity peptide: Number Unstimulatedb DNL1 DNA ligase I 140 3 U04674 BAD Apoptosis protein 122 3 L37296 GADD45 DNA-damage- 88 3 L28177 inducible protein Sik Src-related kinase 82 3 U16805 integrin,4 Integrin 2324 2 X53176 TGF3R1 Growth factor receptor 1038 2 D25540 LAMR1 Receptor 1001 2 J02870 Crk Crk adaptor protein 853 2 S72408 ZFX Chromosomal protein 679 2 M32309 Cyclin El Cylcin 671 2 X75888 POLD1 DNA polymerase 649 2 Z21848 subunit Vav proto- 613 2 X64361 oncopolynucleotide YY (NF-E1) Transcription factor 593 2 L13968 JunD Transcription factor 534 2 J050205 Csk c-src kinase 489 2 U05247 Cdk7 Cyclin-dependent 475 2 U11822 kinase MLC1A Myosin light subunit 453 2 M19436 isoform ERBB-3 Receptor 435 2 L47240 UBF Transcription factor 405 2 X60831 TRAIL Apoptosis ligand 364 2 U37522 LFA-1 Cell adhesion receptor 340 2 X14951 SLAP Src-like adaptor protein 315 2 U29056 IFNGR Interferon gamma 308 2 M28233 receptor LIM-1 Transcription factor 295 2 Z27410 ATF2 Transcription factor 287 2 S76657 62 WO 03/048383 PCT/CA02/01830 Polynucleotide Polynucleotide Unstimulated Ratio Accession / Protein Function Intensity peptide: Number Unstimulatedb FST Follistatin precursor 275 2 Z29532 TIMP3 Protease inhibitor 259 2 L19622 RU49 Transcription factor 253 2 U41671 IGF-1R a Insulin-like growth 218 2 U00182 factor receptor Cyclin G2 Cyclin 214 2 U95826 fyn Tyrosine-protein 191 2 U70324 kinase BMP-2 Bone morpho- 186 2 L25602 polynucleotidetic protein Brn-3.2 POU Transcription factor 174 2 S68377 KIF1A Kinesin family protein 169 2 D29951 MRC1 Mannose receptor 167 2 Z11974 PAI2 Protease inhibitor 154 2 X19622 BKLF CACCC Box- binding 138 2 U36340 protein .TIMP2 Protease inhibitor 136 2 X62622 Mas Proto- 131 2 X67735 oncopolynucleotide NURR-1 Transcription factor 129 2 S53744 [00104] Table 19: Polynucleotides down-regulated by SEQ ID NO: 1 treatment of RAW macrophage cellsa. The cationic peptides at a concentration of 50 pg/ml were shown to reduce the expression of several polynucleotides. Peptide was incubated with the RAW cells for 4 h and the RNA was isolated, converted into labeled cDNA probes and hybridized to Atlas arrays. The intensity of unstimulated cells is shown in the third column. The "Ratio Peptide: Unstimulated" column refers to the intensity of polynucleotide expression in peptide-simulated cells divided by the intensity of unstimulated cells. The array experiments were repeated 3 times with 63 WO 03/048383 PCT/CA02/01830 different cells and the average fold change is shown below. Polynucleotides with an approximately two fold or greater change in relative expression levels are presented. Unstimulated Ratio Accession Polynucleotide Polynucleotide Intensity peptide: Number /Protein Function Unstimulated sodium channel Voltage-gated ion 257 0.08 L36179 channel XRCC1 DNA repair protein 227 0.09 U02887 ets-2 Oncopolynucleotide 189 0.11 J04103 XPAC DNA repair protein 485 0.12 X74351 EPOR Receptor precursor 160 0.13 J04843 PEA 3 Ets-related protein 158 0.13 X63190 orphan receptor Nuclear receptor 224 0.2 U11688 N-cadherin Cell adhesion receptor 238 0.23 M31131 OCT3 Transcription factor 583 0.24 M34381 PLCI3 phospholipase 194 0.26 U43144 KRT18 Intermediate filament 318 0.28 M11686 proteins THAM Enzyme 342 0.32 X58384 CD40L CD40 ligand 66 0.32 X65453 CD86 T-lymphocyte antigen 195 0.36 L25606 oncostatin M Cytokine 1127 0.39 D31942 PMS2 DNA DNA repair protein 200 0.4 U28724 IGFBP6 Growth factor 1291 0.41 X81584 MIP-13 Cytokine 327 0.42 M23503 ATBF1 AT motif-binding factor 83 0.43 D26046 nucleobindin Golgi resident protein 367 0.43 M96823 bcl-x Apoptosis protein 142 0.43 L35049 uromodulin glycoprotein 363 0.47 L33406 IL-12 p 4 0 Interleukin 601 0.48 M86671 MmRad52 DNA repair protein 371 0.54 Z32767 64 WO 03/048383 PCT/CA02/01830 Unstimulated Ratio Accession Polynucleotide Polynucleotide Intensity peptide: Number /Protein Function Unstimulated Tobl Antiproliferative factor 956 0.5 D78382 Ungl DNA repair protein 535 0.51 X99018 KRT19 Intermediate filament 622 0.52 M28698 proteins PLCy phospholipase 251 0.52 X95346 Integrin 6 Cell adhesion receptor 287 0.54 X69902 GLUT1 Glucose transporter 524 0.56 M23384 CTLA4 immunoglobin 468 0.57 X05719 superfamily FRA2 Fos-related antigen 446 0.57 X83971 MTRP Lysosome-associated 498 0.58 U34259 protein [00105] Table 20: Polynucleotide Expression changes in response to peptide, SEQ ID NO: 1, could be confirmed by RT-PCR. RAW 264.7 macrophage cells were incubated with 50 pg/ml of peptide or media only for 4 hours and total RNA isolated and subjected to semi-quantitative RT-PCR. Specific primer pairs for each polynucleotide were used for amplification of RNA. Amplification of P-actin was used as a positive control and for standardization. Densitometric analysis of RT-PCR products was used. The results refer to the relative fold change in polynucleotide expression of peptide treated cells compared to cells incubated with media alone. The data is presented as the mean ± standard error of three experiments. Polynucleotide Array Ratio-* RT-PCR Ratio -* CXCR-4 4.0 ± 1.7 4.1 ± 0.9 IL-8RB 9.5 ± 7.6 7.1 ± 1.4 MCP-3 13.5 _ 4.4 4.8 ± 0.88 IL-10 4.2 _ 2.1 16.6 ± 6.1 65 WO 03/048383 PCT/CA02/01830 Polynucleotide Array Ratio-* RT-PCR Ratio -* CD14 0.9 ± 0.1 0.8 ± 0.3 MIP-1B 0.42 ± 0.09 0.11 ± 0.04 XRCC1 0.12 ± 0.01 0.25 0.093 MCP-1 Not on array 3.5 ± 1.4 [00106] Table 21: Polynucleotides up-regulated by peptide treatment of A549 epithelial cellsa. The cationic peptides at concentrations of 50 pg/ml were shown to increase the expression of several polynucleotides. Peptide was incubated with the human A549 epithelial cells for 4 h and the RNA was isolated, converted into labeled cDNA probes and hybridized to Human cDNA arrays ID#PRHU03-S3. The intensity of polynucleotides in unstimulated cells is shown in the second column. The "Ratio Peptide: Unstimulated" columns refers to the intensity of polynucleotide expression in peptide-simulated cells divided by the intensity of unstimulated cells. Accession Unstimulated Ratio Peptide: Unstimulated Number Polynucleotide/Protein Intensity ID 2 ID 3 ID 19 ID 1 IL-1 R antagonist homolog 1 0.00 3086 1856 870 A1167887 IL-10 R beta 0.53 2.5 1.6 1.9 3.1 AA486393 IL-11 R alpha 0.55 2.4 1.0 4.9 1.8 AA454657 IL-17 R 0.54 2.1 2.0 1.5 1.9 AW029299 TNF R superfamily, member 1B 0.28 18 3.0 15 3.6 AA150416 I'NF R superfamily, member 5 (CD40LR) 33.71 3.0 0.02 H98636 TNF R superfamily, member 11b 1.00 5.3 4.50 0.8 AA194983 IL-8 0.55 3.6 17 1.8 1.1 AA102526 interleukin enhancer binding factor 2 0.75 1.3 2.3 0.8 4.6 AA894687 interleukin enhancer binding 0.41 2.7 5.3 2.5 R56553 66 WO 03/048383 PCT/CA02/01830 Accession Unstimulated Ratio Peptide: Unstimulated Number Polynucleotide/Protein Intensity ID 2 ID 3 ID 19 ID 1 factor 1 cytokine inducible SH2 containing protein 0.03 33 44 39 46 AA427521 IK cytokine, down-regulator of HLA II 0.50 3.1 2.0 1.7 3.3 R39227 cytokine inducible SH2 containing protein 0.03 33 44 39 46 AA427521 IK cytokine, down-regulator of HLA II 0.50 3.1 2.0 1.7 3.3 R39227 small inducible cytokine subfamily A (Cys-Cys), member 21 1.00 3.9 2.4 AI922341 TGFB inducible early growth response 2 0.90 2.4 2.1 0.9 1.1 AI473938 NK cell R 1.02 2.5 0.7 0.3 1.0 AA463248 CCR6 0.14 4.5 7.8 6.9 7.8 N57964 cell adhesion molecule 0.25 4.0 3.9 3.9 5.1 R40400 melanoma adhesion molecule 0.05 7.9 20 43 29.1 AA497002 CD31 0.59 2.7 3.1 1.0 1.7 R22412 integrin, alpha 2 (CD49B, alpha 2 subunit of VLA-2. receptor 1.00 0.9 2.4 3.6 0.9 AA463257 integrin, alpha 3 (antigen CD49C, alpha 3 subunit of VLA-3 receptor) 0.94 0.8 2.5 1.9 1.1 AA424695 integrin, alpha E 0.01 180 120 28 81 AA425451 integrin, beta 1 0.47 2.1 2.1 7.0 2.6 W67174 integrin, beta 3 0.55 2.7 2.8 1.8 1.0 AA037229 integrin, beta 3 0.57 2.6 1.4 1.8 2.0 AA666269 integrin, beta 4 0.65 0.8 2.2 4.9 1.5 AA485668 integrin beta 4 binding protein 0.20 1.7 5.0 6.6 5.3 A1017019 67 WO 03/048383 PCT/CA02/01830 Accession Unstimulated Ratio Peptide: Unstimulated Number Polynucleotide/Protein Intensity ID 2 ID 3 ID 19 ID 1 calcium and integrin binding protein 0.21 2.8 4.7 9.7 6.7 AA487575 disintegrin and metalloproteinase domain 8 0.46 3.1 2.2 3.8 AA279188 disintegrin and metalloproteinase domain 9 0.94 1.1 2.3 3.6 0.5 H59231 disintegrin and metalloproteinase domain 10 0.49 1.5 2.1 3.3 2.2 AA043347 disintegrin and metalloproteinase domain 23 0.44 1.9 2.3 2.5 4.6 H11006 cadherin 1, type 1, E-cadherin (epithelial) 0.42 8.1 2.2 2.4 7.3 H97778 cadherin 12, type 2 (N cadherin 2) 0.11 13 26 9.5 AI740827 protocadherin 12 0.09 14.8 11.5 2.6 12.4 A1652584 protocadherin gamma subfamily C, 3 0.34 3.0 2.5 4.5 9.9 R89615 catenin (cadherin-associated protein), delta 1 0.86 1.2 2.2 2.4 AA025276 laminin R 1 (67kD, ribosomal protein SA) 0.50 0.4 2.0 4.4 3.0 AA629897 killer cell lectin-like receptor subfamily C, member 2 0.11 9.7 9.0 4.1 13.4 AA190627 killer cell lectin-like receptor subfamily C, member 3 1.00 3.2 1.0 0.9 1.3 W93370 killer cell lectin-like receptor subfamily G, member 1 0.95 2.3 1.7 0.7 1.1 AI433079 C-type lectin-like receptor-2 0.45 2.1 8.0 2.2 5.3 H70491 CSF 3 R 0.40 1.9 2.5 3.5 4.0 AA458507 macrophage stimulating 1 R 1.00 1.7 2.3 0.4 0.7 AA173454 BMP R type IA 0.72 1.9 2.8 0.3 1.4 W15390 68 WO 03/048383 PCT/CA02/01830 Accession Unstimulated Ratio Peptide: Unstimulated Number Polynucleotide/Protein Intensity ID 2 ID 3 ID 19 ID 1 formyl peptide receptor 1 1.00 3.1 1.4 0.4 AA425767 CD2 1.00 2.6 0.9 1.2 0.9 AA927710 CD36 0.18 8.2 5.5 6.2 2.5 N39161 vitamin DR 0.78 2.5 1.3 1.1 1.4 AA485226 Human proteinase activated R-2 0.54 6.1 1.9 2.2 AA454652 prostaglandin E receptor 3 (subtype EP3) 0.25 4.1 4.9 3.8 4.9 AA406362 PDGF R beta polypeptide 1.03 2.5 1.0 0.5 0.8 R56211 VIP R 2 1.00 3.1 2.0 A1057229 growth factor receptor-bound protein 2 0.51 2.2 2.0 2.4 0.3 AA449831 Mouse Mammary Turmor Virus Receptor homolog 1.00 6.9 16 W93891 adenosine A2a R 0.41 3.1 1.8 4.0 2.5 N57553 adenosine A3 R 0.83 2.0 2.3 1.0 1.2 AA863086 T cell R delta locus 0.77 2.7 1.3 1.8 AA670107 prostaglandin E receptor 1 (subtype EP1) 0.65 7.2 6.0 1.5 AA972293 growth factor receptor-bound protein 14 0.34 3.0 6.3 2.9 R24266 Epstein-Barr virus induced polynucleotide 2 0.61 1.6 2.4 8.3 AA037376 complement component receptor 2 0.22 26 4.5 2.6 18.1 AA521362 endothelin receptor type A 0.07 12 14 14 16 AA450009 v-SNARE R 0.56 11 12 1.8 AA704511 tyrosine kinase, non-receptor, 1 0.12 7.8 8.5 10 8.7 A1936324 receptor tyrosine kinase-like orphan receptor 2 0.40 7.3 5.0 1.6 2.5 N94921 69 WO 03/048383 PCT/CAO2/01830 Accession Unstimulated Ratio Peptide: Unstimulated Number Polynucleotide/Protein Intensity ID 2 ID 3 ID 19 ID I protein tyrosine phosphatase, non-receptor type 3 1.02 1.0 13.2 0.5 0.8 AA682684 protein tyrosine phosphatase, non-receptor type 9 0.28 3.5 4.0 0.9 5.3 AA434420 protein tyrosine phosphatase, non-receptor type 11 0.42 2.9 2.4 2.2 3.0 AA995560 protein tyrosine phosphatase, non-receptor type 12 1.00 2.3 2.2 0.8 0.5 AA446259 protein tyrosine phosphatase, non-receptor type 13 0.58 1.7 2.4 3.6 1.7 AA679180 protein tyrosine phosphatase, non-receptor type 18 0.52 3.2 0.9 1.9 6.5 AI668897 protein tyrosine phosphatase, receptor type, A 0.25 4.0 2.4 16.8 12.8 H82419 protein tyrosine phosphatase, receptor type, J 0.60 3.6 3.2 1.6 1.0 AA045326 protein tyrosine phosphatase, receptor type, T 0.73 1.2 2.8 3.0 1.4 R52794 protein tyrosine phosphatase, receptor type, U 0.20 6.1 1.2 5.6 5.0 AA644448 protein tyrosine phosphatase, receptor type, C-associated protein 1.00 5.1 2.4 AA481547 phospholipase A2 receptor 1 0.45 2.8 2.2 1.9 2.2 AA086038 MAP kinase-activated protein kinase 3 0.52 2.1 2.7 1.1 1.9 W68281 MAP kinase kinase 6 0.10 18 9.6 32 H07920 MAP kinase kinase 5 1.00 3.0 5.2 0.8 0.2 W69649 MAP kinase 7 0.09 11.5 12 33 H39192 MAP kinase 12 0.49 2.1 1.7 2.2 2.0 AI936909 G protein-coupled receptor 4 0.40 3.7 3.0 2.4 2.5 A1719098 70 WO 03/048383 PCT/CA02/01830 Accession Unstimulated Ratio Peptide: Unstimulated Number Polynucleotide/Protein Intensity ID 2 ID 3 ID 19 ID I G protein-coupled receptor 49 0.05 19 19 27 AA460530 G protein-coupled receptor 55 0.08 19 15 12 N58443 G protein-coupled receptor 75 0.26 5.2 3.1 7.1 3.9 H84878 G protein-coupled receptor 85 0.20 '6.8 5.4 4.9 5.0 N62306 regulator of G-protein signalling 20 0.02 48 137 82 AI264190 regulator of G-protein signalling 6 0.27 3.7 8.9 10.6 R39932 BCL2-interacting killer (apoptosis-inducing) 1.00 1.9 5.2 AA291323 apoptosis inhibitor 5 0.56 2.8 1.6 2.4 1.8 A1972925 caspase 6, apoptosis-related cysteine protease 0.79 0.7 2.6 1.3 2.8 W45688 apoptosis-related protein PNAS-1 0.46 2.2 1.4 2.3 2.9 AA521316 caspase 8, apoptosis-related cysteine protease 0.95 2.2 1.0 0.6 2.0 AA448468 [00107] Table 22: Polynucleotides down-regulated by peptide treatment of A549 epithelial cellsa. The cationic peptides at concentrations of 50 Vg/ml were shown to decrease the expression of several polynucleotides. Peptide was incubated with the human A549 epithelial cells for 4 h and the RNA was isolated, converted into labeled cDNA probes and hybridized to Human cDNA arrays ID#PRHU03-S3. The intensity of polynucleotides in unstimulated cells is shown in the second column. The "Ratio Peptide: Unstimulated" columns refers to the intensity of polynucleotide expression in peptide-simulated cells divided by the intensity of unstimulated cells. 71 WO 03/048383 PCT/CA02/01830 Accession Unstimulated Ratio Peptide: Unstimulated Number Polynucleotide/Protein Intensity ID 2 ID 3 ID 19 ID 1 TLR 1 3.22 0.35 0.31 0.14 0.19 AI339155 TLR 2 2.09 0.52 0.31 0.48 0.24 T57791 TLR 5 8.01 0.12 0.39 N41021 TLR 7 5.03 0.13 0.11 0.20 0.40 N30597 TNF receptor-associated factor 2 0.82 1.22 0.45 2.50 2.64 T55353 TNF receptor-associated factor 3 3.15 0.15 0.72 0.32 AA504259 TNF receptor superfamily, member 12 4.17 0.59 0.24 0.02 W71984 TNF R superfamily, member 17 2.62 0.38 0.55 0.34 AA987627 TRAF and TNF receptor associated protein 1.33 0.75 0.22 0.67 0.80 AA488650 IL-1 receptor, type I 1.39 0.34 0.72 1.19 0.34 AA464526 IL-2 receptor, alpha 2.46 0.41 0.33 0.58 AA903183 IL-2 receptor, gamma (severe combined immunodeficiency) 3.34 0.30 0.24 0.48 N54821 IL-12 receptor, beta 2 4.58 0.67 0.22 AA977194 IL-18 receptor 1 1.78 0.50 0.42 0.92 0.56 AA482489 TGF beta receptor III 2.42 0.91 0.24 0.41 0.41 H62473 leukotriene b4 receptor (chemokine receptor-like 1) 1.00 1.38 4.13 0.88 AI982606 small inducible cytokine subfamily A (Cys-Cys), member 18 2.26 0.32 0.44 1.26 AA495985 small inducible cytokine subfamily A (Cys-Cys), member 20 2.22 0.19 0.38 0.45 0.90 AI285199 small inducible cytokine subfamily A (Cys-Cys), 2.64 0.38 0.31 1.53 AA916836 72 WO 03/048383 PCT/CA02/01830 Accession Unstimulated Ratio Peptide: Unstimulated Number Polynucleotide/Protein Intensity ID 2 ID 3 ID 19 ID 1 member 23 small inducible cytokine subfamily B (Cys-X-Cys), member 6 (granulocyte chemotactic protein 2) 3.57 0.11 0.06 0.28 0.38 AI889554 small inducible cytokine subfamily B (Cys-X-Cys), member 10 2.02 0.50 1.07 0.29 0.40 AA878880 small inducible cytokine A3 (homologous to mouse Mip la) 2.84 1.79 0.32 0.35 AA677522 cytokine-inducible kinase 2.70 0.41 0.37 0.37 0.34 AA489234 complement component Clq receptor 1.94 0.46 0.58 0.51 0.13 AI761788 cadherin 11, type 2, OB cadherin (osteoblast) 2.00 0.23 0.57 0.30 0.50 AA136983 cadherin 3, type 1, P-cadherin (placental) 2.11 0.43 0.53 0.10 0.47 AA425217 cadherin, EGF LAG seven pass G-type receptor 2, flamingo (Drosophila) homolog 1.67 0.42 0.41 1.21 0.60 H39187 cadherin 13, H-cadherin (heart) 1.78 0.37 0.40 0.56 0.68 R41787 selectin L (lymphocyte adhesion molecule 1) 4.43 0.03 0.23 0.61 H00662 vascular cell adhesion molecule 1 1.40 0.20 0.72 0.77 0.40 H16591 intercellular adhesion molecule 3 1.00 0.12 0.31 2.04 1.57 AA479188 integrin, alpha 1 2.42 0.41 0.26 0.56 AA450324 73 WO 03/048383 PCT/CA02/01830 Accession Unstimulated Ratio Peptide: Unstimulated Number Polynucleotide/Protein Intensity ID 2 ID 3 ID 19 ID 1 integrin, alpha 7 2.53 0.57 0.39 0.22 0.31 AA055979 integrin, alpha 9 1.16 0.86 0.05 0.01 2.55 AA865557 integrin, alpha 10 1.00 0.33 0.18 1.33 2.25 AA460959 integrin, beta 5 1.00 0.32 1.52 1.90 0.06 AA434397 integrin, beta 8 3.27 0.10 1.14 0.31 0.24 W56754 disintegrin and metalloproteinase domain 18 2.50 0.40 0.29 0.57 0.17 AI205675 disintegrin-like and metalloprotease with thrombospondin type 1 motif, 3 2.11 0.32 0.63 0.47 0.35 AA398492 disintegrin-like and metalloprotease with thrombospondin type 1 motif, 5 1.62 0.39 0.42 1.02 0.62 AI375048 T-cell receptor interacting molecule 1.00 0.41 1.24 1.41 0.45 AI453185 diphtheria toxin receptor (heparin-binding epidermal growth factor-like growth factor) 1.62 0.49 0.85 0.62 0.15 R45640 vasoactive intestinal peptide receptor 1 2.31 0.43 0.31 0.23 0.54 H73241 Fc fragment of IgG, low affinity IIIb, receptor for (CD16) 3.85 -0.20 0.26 0.76 0.02 H20822 Fc fragment of IgG, low affinity IIb, receptor for (CD32) 1.63 0.27 0.06 1.21 0.62 R68106 Fc fragment of IgE, high affinity I, receptor for; alpha 1.78 0.43 0.00 0.56 0.84 AI676097 74 WO 03/048383 PCT/CA02/01830 Accession Unstimulated Ratio Peptide: Unstimulated Number Polynucleotide/Protein Intensity ID 2 ID 3 ID 19 ID 1 polypeptide leukocyte immunoglobulin like receptor, subfamily A 2.25 0.44 0.05 0.38 0.99 N63398 leukocyte immunoglobulin like receptor, subfamily B (with TM and ITIM domains), member 3 14.21 1.10 0.07 AI815229 leukocyte immunoglobulin like receptor, subfamily B (with TM and ITIM domains), member 4 2.31 0.75 0.43 0.19 0.40 AA076350 leukocyte immunoglobulin like receptor, subfamily B 1.67 0.35 0.60 0.18 0.90 H54023 peroxisome proliferative activated receptor, alpha 1.18 0.38 0.85 0.87 0.26 AI739498 protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), cl 2.19 0.43 1.06 0.46 N49751 protein tyrosine phosphatase, receptor type, C 1.55 0.44 0.64 0.30 0.81 H74265 protein tyrosine phosphatase, receptor type, E 2.08 0.23 0.37 0.56 0.48 AA464542 protein tyrosine phosphatase, receptor type, N polypeptide 2 2.27 0.02 0.44 0.64 AA464590 protein tyrosine phosphatase, receptor type, H 2.34 0.11 0.43 0.24 0.89 AI924306 protein tyrosine phosphatase, receptor-type, Z polypeptide 1 1.59 0.63 0.34 0.72 0.35 AA476461 protein tyrosine phosphatase, non-receptor type 21 1.07 0.94 0.43 0.25 1.13 . H03504 75 WO 03/048383 PCT/CA02/01830 Accession Unstimulated Ratio Peptide: Unstimulated Number Polynucleotide/Protein Intensity ID 2 ID 3 ID 19 ID 1 MAP kinase 8 interacting protein 2 1.70 0.07 0.85 0.47 0.59 AA418293 MAP kinase kinase kinase 4 1.27 0.37 0.79 1.59 -5.28 AA402447 MAP kinase kinase kinase 14 1.00 0.34 0.66 2.10 1.49 W61116 MAP kinase 8 interacting protein 2 2.90 0.16 0.35 0.24 0.55 AI202738 MAP kinase kinase kinase 12 1.48 0.20 0.91 0.58 0.68 AA053674 MAP kinase kinase kinase kinase 3 2.21 0.45 0.20 1.03 0.41 AA043537 MAP kinase kinase kinase 6 2.62 0.37 0.38 0.70 AW084649 MAP kinase kinase kinase kinase 4 1.04 0.96 0.09 0.29 2.79 AA417711 MAP kinase kinase kinase 11 1.53 0.65 0.41 0.99 0.44 R80779 MAP kinase kinase kinase 10 1.32 1.23 0.27 0.50 0.76 H01340 MAP kinase 9 2.54 0.57 0.39 0.16 0.38 AA157286 MAP kinase kinase kinase 1 1.23 0.61 0.42 0.81 1.07 AI538525 MAP kinase kinase kinase 8 0.66 1.52 1.82 9.50 0.59 W56266 MAP kinase-activated protein kinase 3 0.52 2.13 2.68 1.13 1.93 W68281 MAP kinase kinase 2 0.84 1.20 3.35 0.02 1.31 AA425826 MAP kinase kinase kinase 7 1.00 0.97 1.62 7.46 AA460969 MAPkinase 7 0.09 11.45 11.80 33.43 H39192 MAP kinase kinase 6 0.10 17.83 9.61 32.30 H07920 regulator of G-protein signalling 5 3.7397 0.27 0.06 0.68 0.18 AA668470 regulator of G-protein signalling 13 1.8564 0.54 0.45 0.07 1.09 H70047 G protein-coupled receptor 1.04 1.84 0.16 0.09 0.96 R91916 G protein-coupled receptor 17 1.78 0.32 0.56 0.39 0.77 AI953187 G protein-coupled receptor kinase 7 2.62 0.34 0.91 0.38 AA488413 76 WO 03/048383 PCT/CA02/01830 Accession Unstimulated Ratio Peptide: Unstimulated Number Polynucleotide/Protein Intensity ID 2 ID 3 ID 19 ID I orphan seven-transmembrane receptor, chemokine related 7.16 1.06 0.10 0.11 0.14 A1131555 apoptosis antagonizing transcription factor 1.00 0.28 2.50 1.28 0.19 AI439571 caspase 1, apoptosis-related cysteine protease (intcrleukin 1, beta, convertase) 2.83 0.44 0.33 0.35 T95052 programmed cell death 8 (apoptosis-inducing factor) 1.00 1.07 0.35 1.94 0.08 AA496348 [00108] Table 23: Pro-inflammatory polynucleotides up-regulated by peptide treatment of A549 cells. The cationic peptides at concentrations of 50 tg/ml were shown to increase the expression of certain pro-inflammatory polynucleotides (data is a subset of Table 21). Peptide was incubated with the human A549 epithelial cells for 4 h and the RNA was isolated, converted into labeled cDNA probes and hybridized to Human cDNA arrays ID#PRHU03-S3. The intensity of polynucleotides in unstimulated cells is shown in the second column. The "Ratio Peptide: Unstimulated" columns refers to the intensity of polynucleotide expression in peptide-simulated cells divided by the intensity of unstimulated cells. Accession Polynucleotide/Protein and Unstim. Ratio Peptide: Unstimulated Number function Intensity ID 2 ID 3 ID 19 ID 1 IL-11 Ra; Receptor for pro inflammatory cytokine, inflammation 0.55 2.39 0.98 4.85 1.82 AA454657 IL-17 R; Receptor for IL-17, an inducer of cytokine production in epithelial cells 0.54 2.05 1.97 1.52 1.86 AW029299 77 WO 03/048383 PCT/CA02/01830 Accession Polynucleotide/Protein and Unstim. Ratio Peptide: Unstimulated Number function Intensity ID 2 ID 3 ID 19 ID 1 small inducible cytokine subfamily A, member 21; a chemokine 1.00 3.88 2.41 AI922341 CD31; Leukocyte and cell to cell adhesion (PECAM) 0.59 2.71 3.13 1.01 1.68 R22412 CCR6; Receptor for chemokine MIP-30 0.14 4.51 7.75 6.92 7.79 N57964 integrin, alpha 2 (CD49B, alpha 2 subunit of VLA-2 receptor; Adhesion to leukocytes 1.00 0.89 2.44 3.62 0.88 AA463257 integrin, alpha 3 (antigen CD49C, alpha 3 subunit of VLA-3 receptor); Leukocyte Adhesion 0.94 0.79 2.51 1.88 1.07 AA424695 integrin, alpha E; Adhesion 0.01 179.33 120.12 28.48 81.37 AA425451 integrin, beta 4; Leukocyte adhesion 0.65 0.79 2.17 4.94 1.55 AA485668 C-type lectin-like receptor 2;Leukocyte adhesion 0.45 2.09 7.92 2.24 5.29 H70491 [00109] Table 24: Pro-inflammatory polynucleotides down-regulated by peptide treatment of A549 cells. The cationic peptides at concentrations of 50 Pg/ml were shown to decrease the expression of certain pro-inflammatory polynucleotides (data is a subset of Table 22). Peptide was incubated with the human A549 epithelial cells for 4 h and the RNA was isolated, converted into labeled cDNA probes and hybridized to Human cDNA arrays ID#PRHU03-S3. The intensity of polynucleotides in unstimulated cells is shown in the second column. The "Ratio Peptide: Unstimulated" columns refers to the intensity of polynucleotide expression in peptide simulated cells divided by the intensity of unstimulated cells. 78 WO 03/048383 PCT/CA02/01830 Unstim Ratio Peptide:Unstimulated Accession Polynucleotide/Protein; Function Intensity ID 2 ID 3 ID 19 ID 1 Number Toll-like receptor (TLR) 1; Response to gram positive bacteria 3.22 0.35 0.31 0.14 0.19 A1339155 TLR 2; Response to gram positive bacteria and yeast 2.09 0.52 0.31 0.48 0.24 T57791 TLR 5; May augment other TLR responses, Responsive to flagellin 8.01 0.12 0.39 N41021 TLR 7: Putative host defence mechanism 5.03 0.13 0.11 0.20 0.40 N30597 TNF receptor-associated factor 2; Inflammation 0.82 1.22 0.45 2.50 2.64 T55353 TNF receptor-associated factor 3; Inflammation 3.15 0.15 0.72 0.32 AA504259 TNF receptor superfamily, member 12; Inflammation 4.17 0.59 0.24 0.02 W71984 TNF R superfamily, member 17; Inflammation 2.62 0.38 0.55 0.34 AA987627 TRAF and TNF receptor associated protein; TNF signalling 1.33 0.75 0.22 0.67 0.80 AA488650 small inducible cytokine subfamily A, member 18; Chemokine 2.26 0.32 0.44 1.26 AA495985 small inducible cytokine subfamily A, member 20; Chemokine 2.22 0.19 0.38 0.45 0.90 AI285199 small inducible cytokine subfamily A, member 23; Chemokine 2.64 0.38 0.31 1.53 AA916836 small inducible cytokine subfamily B, member 6 (granulocyte chemotactic protein); Chemokinc 3.57 0.11 0.06 0.28 0.38 AI889554 small inducible cytokine subfamily B, member 10; Chemokine 2.02 0.50 1.07 0.29 0.40 AA878880 small inducible cytokine A3 (homologous to mouse Mip-lac); 2.84 1.79 0.32 0.35 AA677522 79 WO 03/048383 PCT/CA02/01830 Unstim Ratio Peptide:Unstimulated Accession Polynucleotide/Protein; Function Intensity ID 2 ID 3 ID 19 ID 1 Number Chemokine IL-12 receptor, beta 2; Interleukin and Interferon receptor 4.58 0.67 0.22 AA977194 IL-18 receptor 1; Induces IFN-y 1.78 0.50 0.42 0.92 0.56 AA482489 selectin L (lymphocyte adhesion molecule 1); Leukocyte adhesion 4.43 0.03 0.23 0.61 H00662 vascular cell adhesion molecule 1; Leukocyte adhesion 1.40 0.20 0.72 0.77 0.40 H16591 intercellular adhesion molecule 3; Leukocyte adhesion 1.00 0.12 0.31 2.04 1.57 AA479188 integrin, alpha 1; Leukocyte adhesion 2.42 0.41 0.26 0.56 AA450324 [00110] Table 25: Anti-inflammatory polynucleotides up-regulated by peptide treatment of A549 cells. The cationic peptides at concentrations of 50 [tg/ml were shown to increase the expression of certain anti-inflammatory polynucleotides (data is a subset of Table 21). Peptide was incubated with the human A549 epithelial cells for 4 h and the RNA was isolated, converted into labeled cDNA probes and hybridized to Human cDNA arrays ID#PRHU03-S3. The intensity of polynucleotides in unstimulated cells is shown in the second column. The "Ratio Peptide: Unstimulated" columns refers to the intensity of polynucleotide expression in peptide-simulated cells divided by the intensity of unstimulated cells. Polynucleotide/Protein; Unstim Ratio Peptide: Unstimulated Accession Function Intensity ID 2 ID 3 ID 19 ID 1 Number IL-1 R antagonist homolog 1; Inhibitor of septic shock 0.00 3085.96 1855.90 869.57 A1167887 IL-10 R beta; Receptor for cytokine synthesis inhibitor 0.53 2.51 1.56 1.88 3.10 AA486393 TNF R, member IB; Apoptosis 0.28 17.09 3.01 14.93 3.60 AA150416 80 WO 03/048383 PCT/CA02/01830 Polynucleotide/Protein; Unstim Ratio Peptide: Unstimulated Accession Function Intensity ID 2 ID 3 ID 19 ID 1 Number TNF R, member 5; Apoptosis (CD40L) 33.71 2.98 0.02 H98636 TNF R, member 1 b; Apoptosis 1.00 5.29 4.50 0.78 AA194983 IK cytokine, down-regulator of HLA II; Inhibits antigen presentation 0.50 3.11 2.01 1.74 3.29 R39227 TGFB inducible early growth response 2; anti-inflammatory cytokine 0.90 2.38 2.08 0.87 1.11 AI473938 CD2; Adhesion molecule, binds LFAp3 1.00 2.62 0.87 1.15 0.88 AA927710 [00111] Table 26: Anti-inflammatory polynucleotides down-regulated by peptide treatment of A549 cells. The cationic peptides at concentrations of 50 Vg/ml were shown to increase the expression of certain anti-inflammatory polynucleotides (data is a subset of Table 21). Peptide was incubated with the human A549 epithelial cells for 4 h and the RNA was isolated, converted into labeled cDNA probes and hybridized to Human cDNA arrays ID#PRHU03-S3. The intensity of polynucleotides in unstimulated cells is shown in the second column. The "Ratio Peptide: Unstimulated" columns refers to the intensity of polynucleotide expression in peptide simulated cells divided by the intensity of unstimulated cells. Polynucleotide/Protein; Unstim Ratio Peptide: Unstimulated Accession Function Intensity ID 2 ID 3 ID 19 ID 1 Number MAP kinase9 2.54 0.57 0.39 0.16 0.38 AA157286 81 WO 03/048383 PCT/CA02/01830 [00112] Table 27: Polynucleotides up-regulated by SEQ ID NO: 6, in primary human macrophages. The peptide SEQ ID NO: 6 at a concentration of 50 pg/ml was shown to increase the expression of many polynucleotides. Peptide was incubated with the human macrophages for 4 h and the RNA was isolated, converted into labeled cDNA probes and hybridized to Human Operon arrays (PRHU04). The intensity of polynucleotides in unstimulated cells is shown in the second column. The "Ratio peptide treated : Control" columns refer to the intensity of polynucleotide expression in peptide-simulated cells divided by the intensity of unstimulated cells. Gene (Accession Number) Control: Ratio peptide Unstimulated treated:control cells proteoglycan 2 (Z26248) 0.69 9.3 Unknown (AK001843) 26.3 8.2 phosphorylase kinase alpha 1 (X73874) 0.65 7.1 actinin, alpha 3 (M86407) 0.93 6.9 DKFZP586B2420 protein (AL050143) 0.84 5.9 Unknown (AL109678) 0.55 5.6 transcription factor 21 (AF047419) 0.55 5.4 Unknown (A433612) 0.62 5.0 chromosome condensation 1-like (AF060219) 0.69 4.8 Unknown (AL137715) 0.66 4.4 apoptosis inhibitor 4 (U75285) 0.55 4.2 TERF1 (TRF1)-interacting nuclear factor 2 (NM_012461) 0.73 4.2 LINE retrotransposable element 1 (M22333) 6.21 4.0 1-acylglycerol-3-phosphate O acyltransferase 1 (U56417) 0.89 4.0 Vacuolar proton-ATPase, subunit D; V ATPase, subunit D (X71490) 1.74 4.0 82 WO 03/048383 PCT/CA02/01830 KIAA0592 protein (AB011164) 0.70 4.0 potassium voltage-gated channel KQT like subfamily member 4 (AF105202) 0.59 3.9 CDC14 homolog A (AF000367) 0.87 3.8 histone fold proteinCHRAC17 (AF070640) 0.63 3.8 Cryptochrome 1 (D83702) 0.69 3.8 pancreatic zymogen granule membrane associated protein (AB035541) 0.71 3.7 Sp3 transcription factor (X68560) 0.67 3.6 hypothetical protein FLJ20495 (AK000502) 0.67 3.5 E2F transcription factor 5, p130-binding (U31556) 0.56 3.5 hypothetical protein FLJ20070 (AK000077) 1.35 3.4 glycoprotein IX (X52997) 0.68 3.4 KIAA1013 protein (AB023230) 0.80 3.4 eukaryotic translation initiation factor 4A, isoforrn 2 (AL137681) 2.02 3.4 FYN-binding protein (AF198052) 1.04 3.3 guanine nucleotide binding protein, gamma transducing activity polypeptide 1 (U41492) 0.80 3.3 glypican 1 (X54232) 0.74 3.2 mucosal vascular addressin cell adhesion molecule 1 (U43628) 0.65 3.2 lymphocyte antigen (M38056) 0.70 3.2 H1 histone family, member 4 (M60748) 0.81 3.0 translational inhibitor protein p14.5 (X95384) 0.78 3.0 83 WO 03/048383 PCT/CA02/01830 hypothetical protein FLJ20689 (AB032978) 1.03 2.9 KIAA1278 protein (AB03104) 0.80 2.9 unknown (AL031864) 0.95 2.9 chymotrypsin-like protease (X71877) 3.39 2.9 calumenin (NM_001219) 2.08 2.9 protein kinase, cAMP-dependent, regulatory, type I, beta (M65066) 7.16 2.9 POU domain, class 4, transcription factor 2 (U06233) 0.79 2.8 POU domain, class 2, associating factor 1 (Z49194) 1.09 2.8 KIAA0532 protein (ABO11104) 0.84 2.8 unknown (AF068289) 1.01 2.8 unknown (AL117643) 0.86 2.7 cathepsin E (M84424) 15.33 2.7 matrix metalloproteinase 23A (AF056200) 0.73 2.7 interferon receptor 2 (L42243) 0.70 2.5 MAP kinase kinase 1 (L11284) 0.61 2.4 protein kinase C, alpha (X52479) 0.76 2.4 c-Cbl-interacting protein (AF230904) 0.95 2.4 c-fos induced growth factor (Y12864) 0.67 2.3 cyclin-dependent kinase inhibitor 1B (S76988) 0.89 2.2 zinc finger protein 266 (X78924) 1.67 2.2 MAP kinase 14 (L35263) 1.21 2.2 KIAA0922 protein (AB023139) 0.96 2.1 bone morphogenetic protein 1 (NM_006129) 1.10 2.1 NADH dehydrogenase 1 alpha 1.47 2.1 84 WO 03/048383 PCT/CA02/01830 subcomplex, 10 (AF087661) bone morphogenetic protein receptor, type IB (U89326) 0.50 2.1 interferon regulatory factor 2 (NM 002199) 1.46 2.0 protease, serine, 21 (AB031331) 0.89 2.0 [00113] Table 28: Polynucleotides down-regulated by SEQ ID NO: 6, in primary human macrophages. The peptide SEQ ID NO: 6 at a concentration of 50 ig/ml was shown to increase the expression of many polynucleotides. Peptide was incubated with the human macrophages for 4 h and the RNA was isolated, converted into labeled cDNA probes and hybridized to Human Operon arrays (PRHU04). The intensity of polynucleotides in unstimulated cells is shown in the second column. The "Ratio of Peptide: Control" columns refer to the intensity of polynucleotide expression in peptide-simulated cells divided by the intensity of unstimulated cells. Gene (Accession Number) Control: Ratio peptide Unstimulated treated:control cells Unknown (AL049263) 17 0.06 integrin-linked kinase (U40282) 2.0 0.13 KIAA0842 protein (AB020649) 1.1 0.13 Unknown (AB037838) 13 0.14 Granulin (AF055008) 8.6 0.14 glutathione peroxidase 3 (NM_002084) 1.2 0.15 KIAA0152 gene product (D63486) 0.9 0.17 TGFB1-induced anti-apoptotic factor 1 (D86970) 0.9 0.19 disintegrin protease (Y13323) 1.5 0.21 proteasome subunit beta type 7 (D38048) 0.7 0.22 cofactor required for Spl transcriptional activation subunit 3 (AB033042) 0.9 0.23 TNF receptor superfamily, member 14 (U81232) 0.8 0.26 proteasome 26S subunit non-ATPase 8 (D38047) 1.1 0.28 proteasome subunit beta type, 4 (D26600) 0.7 0.29 TNF receptor superfamily member IB (M32315) 1.7 0.29 85 WO 03/048383 PCT/CA02/01830 cytochrome c oxidase subunit Vic (X13238) 3.3 0.30 S100.calcium-binding protein A4 (M80563) 3.8 0.31 proteasome subunit alpha type, 6 (X59417) 2.9 0.31 proteasome 26S subunit non-ATPase, 10 (AL031177) 1.0 0.32 MAP kinase kinase kinase 2 (NM_006609) 0.8 0.32 ribosomal protein L11 (X79234) 5.5 0.32 matrix metalloproteinase 14 (Z48481) 1.0 0.32 proteasome subunit beta type, 5 (D29011) 1.5 0.33 MAP kinase-activated protein kinase 2 (U12779) 1.5 0.34 caspase 3 (U13737) 0.5 0.35 jun D proto-oncogene (X56681) 3.0 0.35 proteasome 26S subunit, ATPase, 3 (M34079) 1.3 0.35 IL-1 receptor-like 1 (AB012701) 0.7 0.35 interferon alpha-inducible protein (AB019565) 13 0.35 SDF receptor 1 (NM_012428) 1.6 0.35 Cathepsin D (M63138) 46 0.36 MAP kinase kinase 3 (D87116) 7.4 0.37 TGF, beta-induced, (M77349) 1.8 0.37 TNF receptor superfamily, member 10b (AF016266) 1.1 0.37 proteasome subunit beta type, 6 (M34079) 1.3 0.38 nuclear receptor binding protein (NM_013392) 5.2 0.38 Unknown (AL050370) 1.3 0.38 protease inhibitor 1 alpha-1 -antitrypsin (X01683) 0.7 0.40 proteasome subunit alpha type, 7 (AF054185) 5.6 0.40 LPS-induced TNF-alpha factor (NM_004862) 5.3 0.41 transferrin receptor (X01060) 14 0.42 proteasome 26S subunit non-ATPase 13 (AB009398) 1.8 0.44 MAP kinase kinase 5 (U25265) 1.3 0.44 Cathepsin L (X12451) 15 0.44 IL-1 receptor-associated kinase 1 (L76191) 1.7 0.45 MAP kinase kinase kinase kinase 2 (U07349) 1.1 0.46 peroxisome proliferative activated receptor delta (AL022721) 2.2 0.46 TNF superfamily, member 15 (AF039390) 16 0.46 86 WO 03/048383 PCT/CA02/01830 defender against cell death 1 (D15057) 3.9 0.46 TNF superfamily member 10 (U37518) 287 0.46 cathepsin H (X16832) 14 0.47 protease inhibitor 12 (Z81326) 0.6 0.48 proteasome subunit alpha type, 4 (D00763) 2.6 0.49 proteasome 26S subunit ATPase, 1 (L02426) 1.8 0.49 proteasome 26S subunit ATPase, 2 (D11094) 2.1 0.49 caspase 7 (U67319) 2.4 0.49 matrix metalloproteinase 7 (Z11887) 2.5 0.49 [00114] Table 29: Polynucleotides up-regulated by SEQ ID NO: 1, in HBE cells. The peptide SEQ ID NO: 1 at a concentration of 50 pg/ml was shown to increase the expression of many polynucleotides. Peptide was incubated with the human HBE epithelial cells for 4 h and the RNA was isolated, converted into labeled cDNA probes and hybridized to Human Operon arrays (PRHU04). The intensity of polynucleotides in unstimulated cells is shown in the second column. The "Ratio Peptide: Control" columns refer to the intensity of polynucleotide expression in peptide-simulated cells divided by the intensity of unstimulated cells. Accession Gene Control: Ratio peptide Number Unstimulated treated:control cells AL110161 Unknown 0.22 5218.3 AF131842 Unknown 0.01 573.1 AJ000730 solute carrier family 0.01 282.0 Z25884 chloride channel 1 0.01 256.2 protein tyrosine phosphatase M93426 receptor-type,zeta 0.01 248.7 olfactory receptor, family 1, X65857 subfamily D,member 2 0.01 228.7 M55654 TATA box binding protein 0.21 81.9 AK001411 hypothetical protein 0.19 56.1 D29643 dolichyl- 1.56 55.4 87 WO 03/048383 PCT/CA02/01830 Accession Gene Control: Ratio peptide Number Unstimulated treated:control cells diphosphooligosaccharide-protein glycosyltransferase AF006822 myelin transcription factor 2 0.07 55.3 AL117601 Unknown 0.05 53.8 AL117629 DKFZP434C245 protein 0.38 45.8 tumor necrosis factor,alpha M59465 induced protein 3 0.50 45.1 AB013456 aquaporin 8 0.06 41.3 SEC24 related gene family, AJ131244 member A 0.56 25.1 AL110179 Unknown 0.87 24.8 AB037844 Unknwon 1.47 20.6 Z47727 polymerase II polypeptide K 0.11 20.5 AL035694 Unknown 0.81 20.4 X68994 H.sapiens CREB gene 0.13 19.3 AJ238379 hypothetical protein 1.39 18.5 NM_003519 H2B histone family member 0.13 18.3 glutamate receptor, ionotropic U16126 kainate 2 0.13 17.9 adenosine monophosphate U29926 deaminase 0.16 16.3. AK001160 hypothetical protein 0.39 14.4 U18018 ets variant gene 4 0.21 12.9 D80006 KIAA0184 protein 0.21 12.6 AK000768 hypothetical protein 0.30 12.3 X99894 insulin promoter factor 1, 0.26 12.0 AL031177 Unknown 1.09 11.2 AF052091 unknown 0.28 10.9 88 WO 03/048383 PCT/CA02/01830 Accession Gene Control: Ratio peptide Number Unstimulated treated:control cells 5,10-methenyltetrahydrofolate L38928 synthetase 0.22 10.6 AL117421 unknown 0.89 10.1 AL133606 hypothetical protein 0.89 9.8 NM_016227 membrane protein CH1 0.28 9.6 NM_006594 adaptor-related protein complex 4 0.39 9.3 U54996 ZW10 homolog,protein 0.59 9.3 AJ007557 potassium channel, 0.28 9.0 AF043938 muscle RAS oncogene 1.24 8.8 AK001607 unknown 2.74 8.7 ALO31320 peroxisomal biogenesis factor 3 0.31 8.4 D38024 unknown 0.31 8.3 AF059575 LIM homeobox TF 2.08 8.2 hepatitis A virus cellular receptor AF043724 1 0.39 8.1 AK002062 hypothetical protein 2.03 8.0 L13436 natriuretic peptide receptor 0.53 7.8 U33749 thyroid transcription factor 1 0.36 7.6 AF011792 cell cycle progression 2 protein 0.31 7.6 AK000193 hypothetical protein 1.18 6.8 AF039022 exportin, tRNA 0.35 6.8 M17017 interleukin 8 0.50 6.7 AF044958 NADH dehydrogenase 0.97 6.5 U35246 vacuolar protein sorting 0.48 6.5 AK001326 tetraspan 3 1.59 6.5 Krueppel-related zinc finger M55422 protein 0.34 6.4 U44772 palmitoyl-protein thioesterase 1.17 6.3 89 WO 03/048383 PCT/CA02/01830 Accession Gene Control: Ratio peptide Number Unstimulated treated:control cells AL1 17485 hypothetical protein 0.67 5.9 AB037776 unknown 0.75 5.7 AF131827 unknown 0.69 5.6 AL137560 unknown 0.48 5.2 X05908 annexin Al 0.81 5.1 X68264 melanoma adhesion molecule 0.64 5.0 AL161995 neurturin 0.86 4.9 AF037372 cytochrome c oxidase 0.48 4.8 NM_016187 bridging integrator 2 0.65 4.8 AL137758 unknown 0.57 4.8 TRAF family member-associated U59863 NFKB activator 0.46 4.7 Z30643 chloride channel Ka 0.70 4.7 acetyl-Coenzyme A D16294 acyltransferase 2 1.07 4.6 AJ132592 zinc finger protein 281 0.55 4.6 X82324 POU domain TF 1.73 4.5 NM_016047 CGI-110 protein 1.95 4.5 AK001371 hypothetical protein 0.49 4.5 M60746 H3 histone family member D 3.05 4.5 AB033071 hypothetical protein 4.47 4.4 AB002305 KIAAO307 gene product 1.37 4.4 UDP-N-acetyl-alpha-D galactosamine:polypeptide N X92689 acetylgalactosaminyltransferase 3 0.99 4.4 AL049543 glutathione peroxidase 5 1.62 4.3 U43148 patched homolog 0.96 4.3 M67439 dopamine receptor D5 2.61 4.2 90 WO 03/048383 PCT/CA02/01830 Accession Gene Control: Ratio peptide Number Unstimulated treated:control cells U09850 zinc finger protein 143 0.56 4.2 L20316 glucagon receptor 0.75 4.2 a disintegrin-like and AB037767 metalloprotease 0.69 4.2 NM_017433 myosin IIIA 99.20 4.2 a disintegrin and metalloprotease D26579 domain 8 0.59 4.1 L10333 reticulon 1 1.81 4.1 AK000761 unknown 1.87 4.1 U91540 NK homeobox family 3, A 0.80 4.1 Z17227 interleukin 10 receptor, beta 0.75 4.0 [00115] Table 30: Polynucleotides down-regulated by Peptide (50 jig/ml), SEQ ID NO: 1, in HBE cells. The peptide SEQ ID NO: 1 at a concentration of 50 gg/ml was shown to decrease the expression of many polynucleotides. Peptide was incubated with the human A549 epithelial cells for 4 h and the RNA was isolated, converted into labeled cDNA probes and hybridized to Human Operon arrays (PRHU04). The intensity of polynucleotides in unstimulated cells is shown in the third column. The "Ratio Peptide: Control" columns refer to the intensity of polynucleotide expression in peptide-simulated cells divided by the intensity of unstimulated cells. Accession Gene Control: Ratio SEQ ID Number Unstimulated NO:1- treated: Cells control AC004908 Unknown 32.4 0.09 S70622 G1 phase-specific gene 43.1 0.10 91 WO 03/048383 PCT/CA02/01830 Accession Gene Control: Ratio SEQ ID Number Unstimulated NO:1- treated: Cells control Z97056 DEAD/H box polypeptide 12.8 0.11 AK002056 hypothetical protein 11.4 0.12 L33930 CD24 antigen 28.7 0.13 X77584 thioredoxin 11.7 0.13 NM_014106 PRO 1914 protein 25.0 0.14 M37583 H2A histone family member 22.2 0.14 polymerase (RNA) II U89387 polypeptide D 10.2 0.14 ras-related C3 botulinum toxin D25274 substrate 1 10.3 0.15 J04173 phosphoglycerate mutase 1 11.4 0.15 U19765 zinc finger protein 9 8.9 0.16 X67951 proliferation-associated gene A 14.1 0.16 AL096719 profilin 2 20.0 0.16 AF165217 tropomodulin 4 14.6 0.16 NM_014341 mitochondrial carrier homolog 1 11.1 0.16 AL022068 Unknown 73.6 0.17 X69150 ribosomal protein S18 42.8 0.17 AL031577 Unknown 35.0 0.17 AL031281 Unknown 8.9 0.17 Human mRNA for ornithine AF090094 decarboxylase antizyme, 10.3 0.17 HLA-G histocompatibility antigen, AL022723 class I, G 20.6 0.18 ATP synthase, H+ transporting U09813 mitochondrial FO complex 9.8 0.18 Homo sapiens TTF-I interacting AF000560 peptide 20 20.2 0.19 92 WO 03/048383 PCT/CA02/01830 Accession Gene Control: Ratio SEQ ID Number Unstimulated NO:1- treated: Cells control NM_016094 HSPCO42 protein 67.2 0.19 AF047183 NADH dehydrogenase 7.5 0.19 anti-oxidant protein 2 (non selenium glutathione peroxidase, acidic calcium-independent D14662 phospholipas 8.1 0.19 X16662 annexin A8 8.5 0.19 U14588 paxillin 11.3 0.19 AL1 17654 DKFZP586D0624 protein 12.6 0.20 AK001962 hypothetical protein 7.7 0.20 6-pyruvoyl-tetrahydropterin synthase/dimerization cofactor of L41559 hepatocyte nuclear factor 1 alpha 9.1 0.20 NM_016139 16.7Kd protein 21.0 0.21 NM_016080 CGI-150 protein 10.7 0.21 26S proteasome-associated padl U86782 homolog 6.7 0.21 tumor protein, translationally AJ400717 controlled 1 9.8 0.21 X07495 homeo box C4 31.0 0.21 AL034410 Unknown 7.3 0.22 X14787 thrombospondin 1 26.2 0.22 purine-rich element binding AF081192 protein B 6.8 0.22 protein disulfide isomerase-related D49489 protein 11.0 0.22 NM_014051 PTD011 protein 9.3 0.22 AK001536 Unknown 98.0 0.22 93 WO 03/048383 PCT/CA02/01830 Accession Gene Control: Ratio SEQ ID Number Unstimulated NO:1- treated: Cells control X62534 high-mobility group protein 2 9.5 0.22 endothelial differentiation-related AJ005259 factor 1 6.7 0.22 NM_000120 epoxide hydrolase 1, microsomal 10.0 0.22 M38591 S100 calcium-binding protein A10 23.9 0.23 AF071596 immediate early response 3 11.5 0.23 methylene tetrahydrofolate X16396 dehydrogenase 8.3 0.23 AK000934 ATPase inhibitor precursor 7.6 0.23 AL1 17612 Unknown 10.7 0.23 transcriptional intermediary factor AF119043 1 gamma 7.3 0.23 solute carrier family 22 member 1 AF037066 like antisense 7.6 0.23 AF134406 cytochrome c oxidase subunit 13.3 0.23 AE000661 Unknown 9.2 0.24 AL157424 synaptojanin 2 7.2 0.24 tyrosine 3 monooxygenase/tryptophan 5 X56468 monooxygenase activation protein, 7.2 0.24 ubiquitin-conjugating enzyme U39318 E2D 3 10.7 0.24 AL034348 Unknown 24.4 0.24 D26600 proteasome subunit beta type 4 11.4 0.24 AB032987 Unknown 16.7 0.24 lysosomal-associated membrane J04182 protein 1 7.4 0.24 X78925 zinc finger protein 267 16.1 0.25 94 WO 03/048383 PCT/CA02/01830 Accession Gene Control: Ratio SEQ ID Number Unstimulated NO:1- treated: Cells control NM_000805 gastrin 38.1 0.25 anti-Mullerian hormone receptor, U29700 type II 12.0 0.25 Z98200 Unknown 13.4 0.25 U07857 signal recognition particle 10.3 0.25 Homo sapiens ribosomal protein L05096 L39 25.3 0.25 AK001443 hypothetical protein 7.5 0.25 K03515 glucose phosphate isomerase 6.2 0.25 interferon induced transmembrane X57352 protein 3 7.5 0.26 J02883 colipase pancreatic 5.7 0.26 M24069 cold shock domain protein 6.3 0.26 AJ269537 chondroitin-4-sulfotransferase 60.5 0.26 ALl 37555 Unknown 8.5 0.26 U89505 RNA binding motif protein 4 5.5 0.26 U82938 CD27-binding protein 7.5 0.26 X99584 SMT3 homolog 1 12.8 0.26 AK000847 Unknown 35.8 0.27 NM_014463 Lsm3 protein 7.8 0.27 AL133645 Unknown 50.8 0.27 X78924 zinc finger protein 266 13.6 0.27 NM_004304 anaplastic lymphoma kinase 15.0 0.27 X57958 ribosomal protein L7 27.9 0.27 U63542 Unknown 12.3 0.27 AK000086 hypothetical protein 8.3 0.27 X57138 H2A histone family member N 32.0 0.27 AB023206 KIAA0989 protein 6.5 0.27 95 WO 03/048383 PCT/CA02/01830 Accession Gene Control: Ratio SEQ ID Number Unstimulated NO:1- treated: Cells control gonadotropin inducible transcriptn AB021641 repressor-1 5.5 0.28 AF050639 NADH dehydrogenase 5.5 0.28 complement component 5 receptor M62505 1 7.5 0.28 X64364 basigin 5.8 0.28 AJ224082 Unknown 22.5 0.28 AF042165 cytochrome c oxidase 20.4 0.28 AK001472 anillin 10.9 0.28 X86428 protein phosphatase 2A subunit 12.7 0.28 AF227132 candidate taste receptor T2R5 5.1 0.28 Z98751 Unknown 5.3 0.28 D21260 clathrin heavy polypeptide 8.3 0.28 AF041474 actin-like 6 15.1 0.28 NM_005258 GTP cyclohydrolase I protein 7.6 0.28 L20859 solute carrier family 20 9.6 0.29 Z80783 H2B histone family member 9.0 0.29 AB011105 laminin alpha 5 7.1 0.29 protective protein for beta AL008726 galactosidase 5.2 0.29 D29012 proteasome subunit 12.6 0.29 X63629 cadherin 3 P-cadherin 6.8 0.29 X02419 plasminogen activator urokinase 12.9 0.29 X13238 cytochrome c oxidase 8.0 0.29 X59798 cyclin D1 12.7 0.30 D78151 proteasome 26S subunit 7.6 0.31 AF054185 proteasome subunit 18.8 0.31 J03890 surfactant pulmonary-associated 5.5 0.32 96 WO 03/048383 PCT/CA02/01830 Accession Gene Control: Ratio SEQ ID Number Unstimulated NO: 1- treated: Cells control protein C M34079 proteasome 26S subunit, 5.2 0.33 [00116] Table 31: Up-regulation of Polynucleotide expression in A549 cells induced by Formula A Peptides. The peptides at a concentration of 50 Vg/ml were shown to increase the expression of many polynucleotides. Peptide was incubated with the human A549 epithelial cells for 4 h and the RNA was isolated, converted into labeled cDNA probes and hybridized to Human Operon arrays (PRHU04). The intensity of polynucleotides in control, unstimulated cells are shown in the second and third columns for labeling of cDNA with the dyes Cy3 and Cy5 respectively. The "ID#: Control" columns refer to the intensity of polynucleotide expression in peptide simulated cells divided by the intensity of unstimulated cells. 97 WO 03/048383 PCT/CA02101830 In N, -n NOq rn) (D 00 00 00 n t- -c \ 1f) 00 O -l L 0 1NO0 D -n In -, 0 CZ 0 Zn L. NO NO N: N m a) 0- =s - - NO IC)C) O~ I" r- ONLOc-l O rq C) 6 0 0 0 CD 0CD 0n"=U 0 X~~ X I ~) 0 ~ 98 WO 03/048383 PCT/CA02101830 c ~~ ~ r rr -4 \ nt~O m t0N 0 M-~ " N 0N O\ "00 0 - 0i -2 0 0 ) 7f Q. "a "! '- - ON ) b N CCoz r. ClCC L ( - 03 IC)~~0 ON NT l N l 0 -. C ,l .C C) 0)C q 0l c6 6r 0q 0 0 0 0n ct 0n tn Cl - l CL) r I CD CDC w~~c Ln l 0 ~ ~ ' ) 99 ~ 0~- ~ - WO 03/048383 PCT/CA02101830 -n L. L - n in) zr) Lr)zt C in 00 ini r- Ln ONO n o - N" -- 0q r \C t-o L) C3 00 0l N-l Nr U C3 - 0 -) 0 N r n N ON 0 in 0000 If 00 in -n Ln -0 - :)0 in CL) N 0 -4 LN N: NN 100 WO 03/048383 PCT/CA02/01830 00 ~ N O 00 C0 N0 N 0N re) 66 i U- ON i 0l N, Nn 0n00N00 -n 000 nr m> tn NT 00 - 0 N I N - 00 - 03 -- 0 0 4) ND Na t n ~ I c S- 00 : 6 6 00 DO 6 0 0 0f 0 1010 WO 031048383 PCTCA02IOI830 00 -6 06C \ C Ln0c ON 00 -n 0 00 (N)~CI N-() N-:T 1~ U -) 0 . = N.O0 - 0 (q cq- CD -4 0 0 \0 tn 10 WO 03/048383 PCT/CA02101830 o S. 0C0 00 00 Cfl Q o6 00 %-nr r - C= 06 fIt (N) (J 00 N 10 -0) N I- 0 N -5 0n t -6 06 0d -l 03 -,n Lr ure o e 00 4o en 0 0)C' ~ < n rn 0) -D 00-D r LC en ND ONN - .". C)n in 00 103 WO 03/048383 PCT/CA02101830 000 00 Oo6 -n -n ri 'n 00 CN (Ln rC) 00 N I) 00L U M00 00) IC n C -0 00L 10 WO 03/048383 PCT/CA02101830 W0 _n 00 r- NN O 00 6. re) Lr 00 N '00 0 cc r- 00 -c 6 0 0 a) O 0lr 0 L 00 r-n 00 \0 N 0 N n C- 0 q r -o M 00 ON 00 in "07 -) 0 N - -0 0 CD t- Nn 0"0 00 ~ O iC:) 0. 0 0105 WO 03/048383 PCT/CA02101830 in 0.C r-) C) (N] N (Nj - -~ .0 ~ ~ ~Z5 0.Lq. fn 00 . C:) \0 0 S C) -~ S C) tn mn0 0 u0 Z - E u CD C, o 0 C r- Ln w u C) o) m Lt' r - n 0 n C)\ C) ____ C\ - C) C)u C ~ N -0 '0 in ~-106 WO 03/048383 PCT/CA02101830 - - NO -~NO e ) O ON C 00 C O N N N 6 060n)q L 0o '0 N - 0 O r-~- Lfn - Ln \ ~6 '0 Lr L o6 r iLr \6 o6 Ln '0) \0 -l -0 0 t ~ C: L N Lfl L,: NOC N N - ., N O 00 C00 r- 00 CI r X0 r- CD -) x x-0 I -n 0)n ~o6~ei in \r 0 I- N l ON CON N C) 00 ON 00 m irn 00 >,6 66 C) C66 66 0) 6 O 0 m n ON C\ NO NO\ 00 T - O - N C N 0)0 a. C -O 00 0 E ~ c..0 ON o- 0. 0r -. u ~ 000t 0 >' < .- 0' (m ~ ~ ~ ~ ( 0 . r~ 0 n 00 0q " \0o --- ) 0 C o~L C\ NOC\ N Q In r C C M C L Q C C N NO C C C C C 107 WO 03/048383 PCT/CA02101830 In) 00 n C C) N 00 ~ N ' n
-.
\0C,00 \ -' '0 ~~ N '0 00 \90 In O 0 O 0 1-CI I in C7\ cc r- t ,* I 'IT Ir n in N0 N 00 M~ 00 C N , - I- 't r~~- -4r 4 - n q C ONr N0 i 0'00 C 'C r?) 0 '0 0O - 0 N ND b4 ~ .0 CON O N I 00 N C> O 0 00 ON 0 O 0 r ? NN- 00 6~0 00Lnoo ~ 6 7 CD r U) \0 \ 0 0 CD -n 0 n 0nM C Q 0 C0 X z I L*n H 0 0 ' 0 CO N 0 n r q E ~ - ~ *~H ~0 N < ~ -108~ WO 03/048383 PCT/CA02101830 u- al 1- in 0 00 cn 0 00 rn in fn~ mn On e) C- q~ Lr rn oq 00 00 (NI rNJ ' (n] V) -i 00 e) m0 fn in re) - 0 (NJ an N ON -4 mC] 0.C -D 0 ZZ 0 0( 0C o ~ N t '] N N O -4 00 I ~~- W* \0 e n (N C j M 66 C= C CC C 10 WO 03/048383 PCT/CA02101830 m CN IC tN Nq N - 0i -6 N 6 >.. \O ttn C~ N 0.- 00 o" 0.0 IC) 00 00 \_ Ln n LT -I ON Ne N 0 - _i - n 0Ut - 0 rl C- r.. N O I) IC) Ln CC) N U C 0 (I L-) a. cu C .) 0- a.) 0.0 UO E0 0 O -= = : a ;11 a 0 b-D 0 H C.) m. . - DG)~ C ~~ -n CK) 00 E~0 cu Eo CD00 CJ m) CZD C) 0DC) 0 100 WO 03/048383 PCT/CA02101830 IC n I n I M Ln I) NI. = 0 0 -0 -j !T c.n CO 0\ 11) 0C Q 0 m N n C" 0 N t N Nq \0 QO 71 0 cu C) 0. '0 00 ) CD Ln C) CC I) N - CD', CN 'IT C\ 'IT CC) N \ - 7 -) a)) 7 C.) 7t) -d 0) ' o ~ ~ ~ ~ ~ ~ O Ir 00>]I1~I) t 0 o a) C) 0. 0 Q) 0r 0) F > 2 0 X1 0 0) 0 ) WO 03/048383 PCT/CA02101830 -,r O. N C O c c _n c. t- N~ Nq 0 0 N ~ .. -F .4 oN 0q ON C\C t) N C 00 r o6 6 r 6p P- 0 " -i .- ( N C.. ~f O ON Nr NOL)N m ~ ri r- i) n 06 C~ \ ONN Lr c, 00 C 0 1 0N 0N 0 \6 0 UCONONr 0_ C\CO O 00 If) Nq ON 00 CC) C0 00 0000 5 n V C) ) N - - - -0 \0 - 0 0> r60 0 re LN U 0j Na) C t N C - 0 0 C 4) r- a) U. u 00 0D as a -- w. 0 o5: .0~~" Cj a ) 0 ~ 00 0 ~0 ~ 000 0-0- 0 a NrN Q ~ (= "T oo tn m zC IT) ON) : 000 c1~ X0 -- 0 - N N 0 O O 0 112 N WO 031048383 PCTCA02IOI830 0- c: 00 00 6 O\ 00 00 O .- 2- fn N r 00 Lfq r- N 1) C: N\ _n \0 NN 0n \ o6 o6 o6 o \ r- 00 00 f~ 'n - N Nn (qON \ 0- N q \O L L' N C 00 0z Q) "a V) 7; -; 0, E ~ -C c: 8AC) L. o ~ -. ~ o ~ n V) 0l a) -~~~ 0~I~ C - - * ~ ~ c < Q) ) ) Q 0 C) . 0l ClL)~ ) 0 0 0 ~ n NC ON'0O r' n 0\ 0e '0 U- C U C) rn '0C - 0' 0e fn CDLI 113 WO 03/048383 PCT/CA02101830 :i ~\6 06 0n 0 In o O Oq N Nq Qt rq CON 00 N 0 t I-r I n re 000ol 0 I n N~ rN en CN 'IT C\ 00 \0 N 6 6 C; 66 6 6 66C O0 co IO ONV)N N 0 '0 0 a -c a -0 U 0 tjo -d :Q \0 E S - .- - 0 CL a.). cof cu0 0 u 0 0~\ C ) 00 C) \C CI 0 N c Ln~0 Ln0 C\ 5 4 Q 1 \C 0 Q .. ND C0 C)N o ~ NON IX)'114 WO 03/048383 PCT/CA02101830 rL n t- " re r- Nl in ~ ~Ln 00 00\ Ln I n0 m 00 \0 t 6~ NO - l 0- ONi L6 cNO C~ o- 06 0 00 rn inri n ON-r 6 O 0: -n0 0 )L m mO Nn N ) 600 C\ m- 00 N mN IT 0 n 4 ;-1 -4C oc M- u 00 o t n 00 N i n N 0 .' N C .0C II w = D r \'T - O 0= QZ zl cq o -o t- fq 0 _ 0 - ,C .C~ C\ 0c \ 0~ ~ 1) ~ ~ C 0 0 i)>. - 115- - WO 03/048383 PCT/CA02101830 (l4 N0 C'J CK 1-1 (\ 00 \O 0-4 Nn 00 rn rn M \' C 0 tLn ' cN C) C mt 0 tn x N 7 \ \ 0 00 C: n 00 ' Clu l C C; C; l C C l~ mn -= L00 ,o Ln 00 n O\ \00 N n -n 0 t4-Cl NC 0 I0 0 CIO C)f () \ '0 C a w n0 TC 00 00() " 0N C wq I- C)M C) CD M~o J 0- 14C C> C)ZO z m 00 L. .0 C~)0\N- n N ' 116 WO 03/048383 PCT/CA02101830 \0 oN ) \ Cfq Cl 'or 'r:j O - CC) C L 0 -i C.)li-1y ~ ; 0 NC5 00) CD~ C:. ~ CDCD -0 0 r \C.)n o r n Ln m r 06 - C.O -n 0 Ql S. 'C N) [- ~ 0 ~ N 00~ ON ~ 0l0fC CD m C:) - 00 a ~ I) - q 'C Cl 'C 'C O I-q I.) C) C r C) C r luf 66 6 66 6 0.0 C117 WO 03/048383 PCT/CA02101830 VD r- - to 0 0 CU C 0= -C o= -~ . - 0 C)Z C0 \0 o. -n t- r c CD 0 -~ CC)C C)C tn~ 00 C) ) Q n1 0 co e C)) U=<- C -~~ - u - C CO0 m 0 00 a) a D>, > 60 (U C c- 0 = COO -- C) Ln enC)0 t "N 'I U) . S Q In (n cO D = C) tn CD = c CO .~? .8 118O ~ WO 03/048383 PCT/CA02101830 en Ni 11; Nq C -'l Nn -n r- 00 N~ N -n \. NO 00 O - 0 Nn Nn N 0 C a) Ln ON 0 - .2'9E;"r "-d v -o c (D 6 - C) E C) C- N C = C) 6- C 6 0 0 C)z o r~ N NN C -119 WO 03/048383 PCT/CA02101830 -- 0 -~~ 000 So~ _L N \ r 00 y - "a t- 00 t Cl C C)C 12 WO 031048383 PCTCA02OI830 -L0 \C "0 '.0 C.) en 00C 0l Lr ON 0 cq Lt) C) 'Lt I In ~ ~ r fn I N _ 0 It C. r 00 C)r.cn\ - - *- L- -C 0 a CL CL _ C\ \ 00 0* 2 in 0n r- \ .2 In In C:)'. ej .0j 0I 121 WO 03/048383 PCT/CA02101830 1 4 - o 0 N _ O NO 0 ON tCo rn C: 100 u 0 C .0NON 00 N 0 E Cl. CD 000 CO N- CD C) -i C)C)r > C): o~0 r -N 00 0 NO10 -NO 1 6Li o2 WO 03/048383 PCT/CA02101830 0 ON 00 00 In Ltn In Lfn I) In 7T'~ re Nn C" n ON r eqI e n 00 N C\3 'T\-- t 00 I-i 00 'IT 0 in o - ). - 00 C:) N 00 0 ON-r) nC 0n \ 0 m00 n : - C)) Nn Ln 0 I N '~O 1N I on u 00n0 In Ml ON Inc GoC I Nn \0 CC' 1.) ON' I\ InM~ \C - 0 o ~~ In N ON In (I '0 . 0 I 123 0'CC WO 03/048383 PCT/CA02101830 C~ L oo -- N uN \C) .
.
CO C In N- tn O C) '. .rD.0~ c_ z~ ON 0 f ~ Q 6 oo c124 WO 031048383 PCTCA02IOI830 _ 00 r- rO rO '0 Nn 0 \ 00 N Lfn 00 00 0000 N 0 10 O t- \0 rq -0 Nl r CD) \6 N M' -n ON-i c C N 7 00 00 C 0'0 P- L) 00 C) U0 CA CL CL a u0 0. 0 N 66 z_ 60-0 0n\C U 125) WO 03/048383 PCT/CA02101830 a 0n 00r L N n 6 0N -r Ur 6(i f r ~ l ON CO \N C)O Ni V- i 0 C\tf r q 4 r 0n c 0 0 0alr -n CDUD ci - 80 on rL) C 0 00 \0 _0 .r tfl - 4 0fl Q ~ CD C) ON L!l) C L e. ~ N - \ ON126f WO 03/048383 PCT/CA02101830 Z:~ enN - C. 00 Lr 0 0 00 00 -m r- N0U Q0 re) 0 SQ 0 C 0z C127 WO 03/048383 PCT/CA02101830 ON 00 00 00N N N eq S. CO ON 00 In fn C) CN 00 NCDr~ \O - n 0 C: Ud - 0) E 00 0 0N N O In 00 n 0n ON 6 6 626 WO 03/048383 PCT/CA02/01830 _~ '0L \ n In In _ (N 00 (N] 00 00 -. ; -r 00 NN 00 00 - 00 oN r 0 I.. In I- r-. NO rn 0\ 0 \- V _t .C000I 0 0 I (nI \ C) CON L t fl N C- C o No r_ .
In MN .- N)0 C), r-] cz L 00 In NO O 0 ~ In 0.) C) (:7 CD0 U ~ m 00 0 a ~ ~12I WO 03/048383 PCT/CA02101830 CO CD CL co C) E or w~ -6 ~0 0.0. C.. ) 00 \0 E00 t m 00 fC 06 0 CL . -a uO u C)O 74- fq CO 0 \0 CD \ C:, C 00 XC o CA Q 0'. Q. P.4 ~~~~c wC~~. C 130O~ -.
WO 03/048383 PCT/CA02101830 L) N 00 o6 co6 \6 r_ C-r rn~~N ONONCNO n -4 U) 0n N - t- ND \f) rO\
E
0 A a)) 0 0 Q) = : 0 Z~ Z3 o oK 631 WO 03/048383 PCT/CA02101830 _ * *ON 00 CC0 in 7t 1- 0f LrO in inN in Lq 0 ": -0 0~ -r e rnn en CD N r 00 NO) n 00 N NT00 - r C\ \C 0 \ i ON N \0 N 11 C w iU to CLO r N 0 toN 00 _R 0 E n O ~ ~ L 00~ 00 O t N N N 0 0 00 N 00 0I 0 f 7 Ql 0 n 0 n C0 00 \0 0 0 -T W Qn 6 6 6 \ 0 re 0- 0 0 Ci) \0C Ofn I C) C)) C M Ci) 0 0130 132 WO 03/048383 PCT/CA02101830 _N Nn r N N C-) 06 CN 00 00 c- Q in) 00 0D c' N0 Q00 0r 66 66 0n
U
00 00 \ - 0 1303O WO 03/048383 PCT/CA02101830 -- I'0oL r n L a r ON m N Ln ON f )n - Un 0~ 0 Cr) 00 r- Ln n r C N CD) cq Oe) ON N \- UUC 00 N N N0O - z a -l u ICI c_ -- N\ N N - -n '- o C) C) C) ON ND OC C)) ON IC z -4 u QQ N1 N 0 C) N co6 66 6166 WO 03/048383 PCT/CA02101830 00 N 0 rn -L I:~ -N , -n ON 00 CI \,c C) 0 00 00I I N if)ON 0 0 .- 0 00 C) N~~~r N C=NN NC . ) 66 6 D o 0 : Uz - ifl 0 00 ON~135 WO 03/048383 PCT/CA02101830 _0 rN tLn n I) Ln 'I- CCD O 00 en in CD n re) -n ON \0 a ~ 1 (Ni N~ r 6 ln0 in t rriin N 7r O 0 t ON n C0 \00 _ q N n cqO rn 000 N N n N N cu a L n in - N z N 4 '->1 Z.. . M 0 O ONC) N O 0 N w 0: 6 6 6 6 \0 \6x C l 0 w~j in rnI- r) C Q 0. 0n C) z~ 0 -~ - 136 WO 03/048383 PCTICAO2/01830 00 1- \Oq ir Lq ON- s.- 00 en ON C: \O 00 en . m Nn m n 000T \i00 fn -: N O O 0 n Nn N M 0) r) M f \ r U 00 0 a C '5 a) ' N n ON rn z C7\ -C ) CO I- 0) 00 C) C - ND 0 6 ~ ~ 66 6 66 13 WO 031048383 PCTCA02IOI830 ON2 C) c .r EliS 0 o 0 4 V) C- Q 00 -~7 U __ 6 -oj rqb N IT .. : re C)Ln Sa4 i W C.) 1384- WO 03/048383 PCT/CA02101830 o6 Ln \ 4~ 0 - 0 00 -" ~1 ~ \0 00 rrn N N LI-; 0f6 N N 1f; (J 7i Nn M rfn -CON rn I'- - 0 7 -< 0 C) 0 Q. o > NO Ln CD- 00 C-) 00 ~ C -C) N .. <C 139 WO 03/048383 PCT/CA02101830 r- C7- 00 m~ ON fn C0 > 00 0 Nq 10 N I- m Un f r6 ~lj rl rli o6 ci 4 r -. j .re N LA ON N- 'I tn 10 CC 4 fl rl; 06 -~ N L0 N i -J 00U 7 I q c III r C ) Ne \0 N '. q0 N A N N L 0 0 C) C0 0D UU 0 o - 0r .E M 0 n 02 -2. -' 2S N 0 a; 0 nM 7 0 00 7 ON LA O OYN =T r Cq r- Nn N 00 \ 0 LA 0 0 C 00 N~ ON ) 0\O LA - 00 r Q = LA) N- - 0 0 0 0: 00 N- :2 z. C\ ~ 14d\-1r 140 WO 03/048383 PCT/CA02101830 i o6 6 f 6 \O rn re) r~ 00 Cl m F rn 00c - N "I UN f ON _ O C6l \ m C) C\ 0 C:) c -- Nq r N 0 0 N 0 ON000 X~ a) 0 CL E ad ) .0 M 0~ ) .
- CK n C 7 0 0- Nn 0 0 0 N O rq IC) M ,-) 0Q 0 N D C'\) CD 0Ore CN 0 0 0 ~ C) 141 WO 03/048383 PCT/CA02101830 r- \1 -n rO N rn in i in Nn ON n 00 C1 N\0 ~ . ~m 00 C) CNN -)dn 0 C0 00 -- NN ON N: NO N - CD- 00 D D CD C (U rn u0 -c -o u ~in n ~1 (0 - N l CIS 0 N N CL m N qO 7. ( ( N ( all 0 0n kn fn 00t') (U mU 0 ( (n rn 0 = 0 0Z CD u -<Z2 -~~( C~ ~ C- C. -142 WO 03/048383 PCT/CA02101830 _ _ r- i 00 r-. C> - n cc . _ ON if) Im O- C uN ) CD C) (] rCD CD) w Uz Cl 0 0 ej C\ C:) Cr 0 r 0n 0 0 0 o~ Uf a-n z.)-C - N C) c 143l~tC WO 03/048383 PCT/CA02101830 t w00 N- \ f a N 00 00 fitl - -"N \0 00 'IT~ 00 00 M t- 00 -T 00 UON' N I) 00 C\O \O 00 C Nq ON o ~ ON N O CD 00 \O C 00 'C C' 00 06 C'j 0 o L- . .aa M0 ZC nN I Nn cn -C o 0 L C 'c', 0 ' as C'C' >~ 0 OI. CL o U? acz ~) o ~ ~ CC r- CJ cj 1 .C CqC ) re) Q 00 C) - n C C z re) 00 \.C re 00 (9 \C 144 WO 03/048383 PCT/CA02101830 '. 00 *n 0N 00 tn 7t MNr I.'IT -r ttr) o6 C -' ~ 00 m001-' 10 -CC) 0 m 0 0 0 r O 0 N 0 CDC) C C) = L c zC.) N - CC CO. EQ -~~ 0-C 0 0 ~) >- ~ *~ 0. 0 C..) Ln 0, 0 C= 0\ N1 -A 0 Q CD \O Ct) N 00 0 z~0 O N\ 145 WO 03/048383 PCT/CA02101830 _ - 00 LCn " " 01 C\O 0\ r- 00 CD 0-Ln oo- C\I 000 C- C)1, 0 4= t-C)0 O q -M \6g .- \ 11 Nf LP O N N 00 L. rnLn 1 n - u ) :)C a bo U-bi C .) a) 0 Q C) tn cc6 0\ 0n C0 0 0 0 z C: I-fl > n N - - N N146 WO 03/048383 PCT/CA02101830 C)C V~ ) U 4 rn 0-4 0 O Nc~~ $ . \0 Go0
T
. 2 ( 000 0- N ON r- C: -) C) 0 -C C NO0 re) 0 CD C) -: C:O CDC 0 . 0)) -o - U I.- a N Na *-e) 2 co co Cd C r) 0 C a- ~ a C)) C) C) z_ _ _ .(n< -o < C1 ON cz - 0 o *0) ~E 0. A~-C N - j .~ EN ~ 147 WO 03/048383 PCT/CA02101830 00 20 CD cu 0~l C) CU Ln . Q o6 Nr 4- ,1 IC) a) S. I. 0 cz ;-- : n c 'r s- 6 \L) CO "o p C~ \ cu 0.C0 - -t U) Z C 0.0 Et -C 0N ~ N ~~a 0 . O 0- S 0 : cu C: o r- m o ~ O N E < < 0 00~ o~C C\ C - C) 0n _' n C V) C) CL M)_ >, r- N -a rn C) .ri CCO E; r, o * N 5-0 0.ON c N 0 0 t-o N n o U) XL C: C)C 0 tN -u C C) < N >~0 u L 0 rq \ T 0 m m -O CZ -q U)C) 5- C) "o co~ COO Q0 C> 0 rn~C ) .0* -n 0 a) NO to -L< ~~~~r 0 0co - 0 O ;)0 CU): .0 00__ 148 WO 03/048383 PCT/CA02101830 \C rt \O 'ri 00 Lr -4 4 -i N4 CO r O - 0n r-~ n~ - 'z n O n ON I- ' t- Mn t- ON N ,i ~ ~ ~ ~ ~ - -i-i c 4 4 \ 6 , 00 C00 0' r - r n C\ \ .0 W . \C - rfl Mf ON \ ~0 r M . N N U 0 .0 00 00 ON r - Ln n ON c: in C U 0 c nN z U - - < 14 WO 03/048383 PCT/CA02101830 in m' 00 r- tn in tn tt Nq Nq c .j SN ' 00 N 00 o 00 - 00 00 in 0y 0 \6 vi -6-;Li 4 Ci U ~ - kn LN Nl 0nC)0 \ 0 fn rL i 0 q 'I \0 r- I- X 0t CD C) 0 N _n CC i- n N N N m, m~ -'T N tn 0 0 CD N ~ N N m~ m N) CDN 0 -- I O n 0000 C:) ONT N N ON NX0 ~ m Ln L - O ' n N C',~ O 0 - ON in ~~" "T I- "T ~ ~ N rn N S6 6 6 6 0 0 0 6 6 0 0 00 0 w0 N O 00 \ 0 \N C > q- O N w2 rn m 00 C\ 'IT \0 r m m~ m ON m m N N ,r 00 in o" ON CD 0\ CD N N 00 N~ - 44 00 00 150 WO 03/048383 PCT/CA02/01830 EXAMPLE 5 INDUCTION OF CHEMOKINES IN CELL LINES, WHOLE HUMAN BLOOD, AND IN MICE BY PEPTIDES [00123] The murine macrophage cell line RAW 264.7, THP-1 cells (human monocytes), a human epithelial cell line (A549), human bronchial epithelial cells (16HBEo14), and whole human blood were used. HBE cells were grown in MEM with Earle's. THP-1 cells were grown and maintained in RPMI 1640 medium. The RAW and A549 cell lines were maintained in DMEM supplemented with 10% fetal calf serum. The cells were seeded in 24 well plates at a density of 106 cells per well in DMEM (see above) and A549 cells were seeded in 24 well plates at a density of 105 cells per well in DMEM (see above) and both were incubated at 37 0 C in 5 % CO 2 overnight. DMEM was aspirated from cells grown overnight and replaced with fresh medium. After incubation of the cells with peptide, the release of chemokines into the culture supernatant was determined by ELISA (R&D Systems, Minneapolis, MN). [00124] Animal studies were approved by the UBC Animal Care Committee (UBC ACC # A01-0008). BALB/c mice were purchased from Charles River Laboratories and housed in standard animal facilities. Age, sex and weight matched adult mice were anaesthetized with an intraperitoneal injection of Avertin (4.4 mM 2-2-2 tribromoethanol, 2.5% 2-methyl-2-butanol, in distilled water), using 200 p1 per 10 g body weight. The instillation was performed using a non-surgical, intratracheal instillation method adapted from Ho and Furst 1973. Briefly, the anaesthetized mouse was placed with its upper teeth hooked over a wire at the top of a support frame with its jaw held open and a spring pushing the thorax forward to position the pharynx, larynx and trachea in a vertical straight line. The airway was illuminated externally and an intubation catheter was inserted into the clearly illuminated tracheal lumen. Twenty-pl of peptide suspension or sterile water was placed in a well at the proximal end of the catheter and gently instilled into the trachea with 200 pl of air. The animals were maintained in an upright position for 2 minutes after instillation to allow the 151 WO 03/048383 PCT/CA02/01830 fluid to drain into the respiratory tree. After 4 hours the mice were euthanaised by intraperitoneal injection of 300 mg/kg of pentobarbital. The trachea was exposed; an intravenous catheter was passed into the proximal trachea and tied in place with suture thread. Lavage was performed by introducing 0.75 ml sterile PBS into the lungs via the tracheal cannula and then after a few seconds, withdrawing the fluid. This was repeated 3 times with the same sample of PBS. The lavage fluid was placed in a tube on ice and the total recovery volume per mouse was approximately 0.5 ml. The bronchoalveolar lavage (BAL) fluid was centrifuged at 1200 rpm for 10 min, the clear supematant removed and tested for TNF-a and MCP-1 by ELISA. [00125] The up-regulation of chemokines by cationic peptides was confirmed in several different systems. The murine MCP-1, a homologue of the human MCP-1, is a member of the P3(C-C) chemokine family. MCP-1 has been demonstrated to recruit monocytes, NK cells and some T lymphocytes. When RAW 264.7 macrophage cells and whole human blood from 3 donors were stimulated with increasing concentrations of peptide, SEQ ID NO: 1, they produced significant levels of MCP-1 in their supernatant, as judged by ELISA (Table 36). RAW 264.7 cells stimulated with peptide concentrations ranging from 20-50 tg/ml for 24 hr produced significant levels of MCP-1 (200-400 pg/ml above background). When the cells (24h) and whole blood (4h) were stimulated with 100 pg/ml of LL-37, high levels of MCP-1 were produced. [00126] The effect of cationic peptides on chemokine induction was also examined in a completely different cell system, A549 human epithelial cells. Interestingly, although these cells produce MCP-1 in response to LPS, and this response could be antagonized by peptide; there was no production of MCP-1 by A549 cells in direct response to peptide, SEQ ID NO: 1. Peptide SEQ ID NO: 1 at high concentrations, did however induce production of IL-8, a neutrophil specific chemokine (Table 37). Thus, SEQ ID NO: 1 can induce a different spectrum of responses from different cell types and at different concentrations. A number of peptides from each of the formula groups were tested for their ability to induce IL-8 in A549 cells (Table 38). Many of these peptides at a low concentration, 10 pg/ml induced IL-8 above background levels. At high concentrations (100 ptg/ml) SEQ ID NO: 13 was also found to induce 152 WO 03/048383 PCT/CAO2/01830 IL-8 in whole human blood (Table 39). Peptide SEQ ID NO: 2 also significantly induced IL-8 in HBE cells (Table 40) and undifferentiated THP-1 cells (Table 41). [00127] BALB/c mice were given SEQ ID NO: 1 or endotoxin-free water by intratracheal instillation and the levels of MCP-1 and TNF-a examined in the bronchioalveolar lavage fluid after 3-4 hr. It was found that the mice treated with 50 tg/ml peptide, SEQ ID NO: 1 produced significantly increased levels of MCP-1 over mice given water or anesthetic alone (Table 42). This was not a pro-inflammatory response to peptide, SEQ ID NO: 1 since peptide did not significantly induce more TNF-a than mice given water or anesthetic alone. peptide, SEQ ID NO: 1 was also found not to significantly induce TNF-a production by RAW 264.7 cells and bone marrow-derived macrophages treated with peptide, SEQ ID NO: 1 (up to 100 pg/ml) (Table 43). Thus, peptide, SEQ ID NO: 1 selectively induces the production of chemokines without inducing the production of inflammatory mediators such as TNF a. This illustrates the dual role of peptide, SEQ ID NO: 1 as a factor that can block bacterial product-induced inflammation while helping to recruit phagocytes that can clear infections. [00128] Table 38: Induction of MCP-1 in RAW 264.7 cells and whole human blood. RAW 264.7 mouse macrophage cells or whole human blood were stimulated with increasing concentrations of LL-37 for 4 hr. The human blood samples were centrifuged and the serum was removed and tested for MCP-1 by ELISA along with the supernatants from the RAW 264.7 cells. The RAW cell data presented is the mean of three or more experiments ±+ standard error and the human blood data represents the mean ± standard error from three separate donors. Peptide, SEQ ID NO: 1 Monocyte chemoattractant protein (MCP)-1 (pg/ml) (pg/ml)* RAW cells Whole blood 0 135.3 + 16.3 112.7 + 43.3 10 165.7 + 18.2 239.3 + 113.3 153 WO 03/048383 PCT/CAO2/01830 Peptide, SEQ ID NO: 1 Monocyte chemoattractant protein (MCP)-1 (jig/ml) (pg/ml)* RAW cells Whole blood 50 367+11.5 371+105 100 571 + 17.4 596 + 248.1 [00129] Table 39: Induction of IL-8 in A549 cells and whole human blood. A549 cells or whole human blood were stimulated with increasing concentrations of peptide for 24 and 4 hr respectively. The human blood samples were centrifuged and the serum was removed and tested for IL-8 by ELISA along with the supernatants from the A549 cells. The A549 cell data presented is the mean of three or more experiments + standard error and the human blood data represents the mean ± standard error from three separate donors. Peptide, SEQ ID NO: 1 IL-8 (pg/ml) (plg/ml) A549 cells Whole blood 0 172 + 29.1 660.7 + 126.6 1 206.7 + 46.1 10 283.3 + 28.4 945.3 + 279.9 20 392 + 31.7 50 542.3 + 66.2 1160.3 + 192.4 100 1175.3 + 188.3 [00130] Table 40: Induction of IL-8 in A549 cells by Cationic peptides. A549 human epithelial cells were stimulated with 10 pg of peptide for 24 hr. The supernatant was removed and tested for IL-8 by ELISA. Peptide (10 ug/ml) IL-8 (ng/ml) No peptide 0.164 154 WO 03/048383 PCT/CAO2/01830 Peptide (10 ug/ml) IL-8 (ng/ml) LPS, no peptide 0.26 SEQ ID NO: 1 0.278 SEQ ID NO: 6 0.181 SEQ ID NO: 7 0.161 SEQ ID NO: 9 0.21 SEQ ID NO: 10 0.297 SEQ ID NO: 13 0.293 SEQ ID NO: 14 0.148 SEQ ID NO: 16 0.236 SEQ ID NO: 17 0.15 SEQ ID NO: 19 0.161 SEQ ID NO: 20 0.151 SEQ ID NO: 21 0.275 SEQ ID NO: 22 0.314 SEQ ID NO: 23 0.284 SEQ ID NO: 24 0.139 SEQ ID NO: 26 0.201 SEQ ID NO: 27 0.346 SEQ ID NO: 28 0.192 SEQ ID NO: 29 0.188 SEQ ID NO: 30 0.284 SEQ ID NO: 31 0.168 SEQ ID NO: 33 0.328 SEQ ID NO: 34 0.315 SEQ ID NO: 35 0.301 SEQ ID NO: 36 0.166 SEQ ID NO: 37 0.269 SEQ ID NO: 38 0.171 SEQ ID NO: 40 0.478 SEQ ID NO: 41 0.371 155 WO 03/048383 PCT/CA02/01830 Peptide (10 ug/ml) IL-8 (ng/ml) SEQ ID NO: 42 0.422 SEQ ID NO: 43 0.552 SEQ ID NO: 44 0.265 SEQ ID NO: 45 0.266 SEQ ID NO: 47 0.383 SEQ ID NO: 48 0.262 SEQ ID NO: 49 0.301 SEQ ID NO: 50 0.141 SEQ ID NO: 51 0.255 SEQ ID NO: 52 0.207 SEQ ID NO: 53 0.377 SEQ ID NO: 54 0.133 [00131] Table 41: Induction by Peptide of IL-8 in human blood. Whole human blood was stimulated with increasing concentrations of peptide for 4 hr. The human blood samples were centrifuged and the serum was removed and tested for IL-8 by ELISA. The data shown is the average 2 donors. SEQ ID NO: 3 (pg/ml) IL-8 (pg/ml) 0 85 10 70 100 323 [00132] Table 42: Induction of IL-8 in HBE cells. Increasing concentrations of the peptide were incubated with HBE cells for 8 h, the supernantant removed and tested for IL-8. The data is presented as the mean of three or more experiments + standard error. 156 WO 03/048383 PCT/CA02/01830 SEQ ID NO: 2 IL-8 (pg/ml) (pg/ml) 0 552+90 0.1 670+ 155 1 712+205 10 941+15 50 1490+715 [00133] Table 43: Induction of IL-8 in undifferentiated THP-1 cells. The human monocyte THP-1 cells were incubated with indicated concentrations of peptide for 8 hr. The supernatant was removed and tested for IL-8 by ELISA. SEQ ID NO: 3 IL-8 (pg/ml) ([tg/ml) 0 10.6 10 17.2 50 123.7 [00134] Table 44: Induction of MCP-1 by Peptide, SEQ ID NO: 1 in mouse airway. BALB/c mice were anaesthetised with avertin and given intratracheal instillation of peptide or water or no instillation (no treatment). The mice were monitored for 4 hours, anaesthetised and the BAL fluid was isolated and analyzed for MCP-1 and TNF-a concentrations by ELISA. The data shown is the mean of 4 or 5 mice for each condition + standard error. Condition MCP-1 (pg/ml) TNF-a (pg/ml) Water 16.5 + 5 664 + 107 peptide 111 +30 734 + 210 Avertin 6.5 + 0.5 393 + 129 157 WO 03/048383 PCT/CA02/01830 [00135] Table 45: Lack of Significant TNF-a induction by the Cationic Peptides. RAW 264.7 macrophage cells were incubated with indicated peptides (40 pg/ml) for 6 hours. The supernatant was collected and tested for levels of TNF-x by ELISA. The data is presented as the mean of three or more experiments + standard error. Peptide Treatment TNF-a (pg/ml) Media background 56 ± 8 LPS treatment, No peptide 15207 ± 186 SEQ ID NO: 1 274 15 SEQIDNO:5 223 45 SEQ ID NO: 6 297 32 SEQ ID NO: 7 270 ± 42 SEQ ID NO: 8 166 ± 23 SEQIDNO:9 171 + 33 SEQ ID NO: 10 288 ± 30 SEQ ID NO: 12 299 ± 65 SEQ ID NO: 13 216 ± 42 SEQIDNO:14 226 ± 41 SEQ ID NO: 15 346 ± 41 SEQ ID NO: 16 341 ± 68 SEQ ID NO: 17 249 + 49 SEQ ID NO: 19 397 ± 86 SEQ ID NO: 20 285 56 SEQ ID NO: 21 263 8 SEQ ID NO: 22 195 42 SEQ ID NO: 23 254 58 SEQ ID NO: 24 231 32 SEQ ID NO: 26 281 34 SEQ ID NO: 27 203 42 158 WO 03/048383 PCT/CA02/01830 Peptide Treatment TNF-ac (pg/ml) SEQ ID NO: 28 192 ± 26 SEQ ID NO: 29 242 ± 40 SEQ ID NO: 31 307 ± 71 SEQ ID NO: 33 196 ± 42 SEQ ID NO: 34 204 ± 51 SEQ ID NO: 35 274 ± 76 SEQ ID NO: 37 323 ± 41 SEQ ID NO: 38 199 ± 38 SEQ ID NO: 43 947 + 197 SEQ ID NO: 44 441 ± 145 SEQ ID NO: 45 398 ± 90 SEQ ID NO: 48 253 ± 33 SEQ ID NO: 49 324 ± 38 SEQ ID NO: 50 311 144 SEQ ID NO: 53 263 40 SEQ ID NO: 54 346 86 EXAMPLE 6 CATIONIC PEPTIDES INCREASE SURFACE EXPRESSION OF CHEMOKINE RECEPTORS [00136] To analyze cell surface expression of IL-8RB, CXCR-4, CCR2, and LFA 1, RAW macrophage cells were stained with 10 pig/ml of the appropriate primary antibody (Santa Cruz Biotechnology) followed by FITC-conjugated goat anti-rabbit IgG [IL-8RB and CXCR-4 (Jackson ImmunoResearch Laboratories, West Grove, PA)] or FITC-conjugated donkey anti-goat IgG (Santa Cruz). The cells were analyzed using a FACscan, counting 10,000 events and gating on forward and side scatter to exclude cell debris. [00137] The polynucleotide array data suggested that some peptides up-regulate the expression of the chemokine receptors IL-8RB, CXCR-4 and CCR2 by 10, 4 and 1.4 fold above unstimulated cells respectively. To confirm the polynucleotide array data, 159 WO 03/048383 PCT/CA02/01830 the surface expression was examined by flow cytometry of these receptors on RAW cells stimulated with peptide for 4 hr. When 50 pg/ml of peptide was incubated with RAW cells for 4 hr, IL-8RB was upregulated an average of 2.4-fold above unstimulated cells, CXCR-4 was up-regulated an average of 1.6-fold above unstimulated cells and CCR2 was up-regulated 1.8-fold above unstimulated cells (Table 46). As a control CEMA was demonstrated to cause similar up-regulation. Bac2A was the only peptide to show significant up-regulation of LFA-1 (3.8 fold higher than control cells). [00138] Table 46: Increased surface expression of CXCR-4, IL-8RB and CCR2 in response to peptides. RAW macrophage cells were stimulated with peptide for 4 hr. The cells were washed and stained with the appropriate primary and FITC-labeled secondary antibodies. The data shown represents the average (fold change of RAW cells stimulated with peptide from media) + standard error. Concentration Fold Increase in Protein Expression Peptide (pg/ml) IL-8RB CXCR-4 CCR2 SEQ ID 10 1.0 1.0 1.0 NO: 1 SEQ ID 50 1.3 + 0.05 1.3 + 0.03 1.3 + 0.03 NO: 1 SEQ ID 100 2.4 + 0.6 1.6 + 0.23 1.8 + 0.15 NO:1 SEQ ID 100 2.0 + 0.6 Not Done 4.5 NO: 3 CEMA 50 1.6 + 0.1 1.5 + 0.2 1.5 + 0.15 100 3.6 + 0.8 Not Done 4.7 + 1.1 160 WO 03/048383 PCT/CA02/01830 EXAMPLE 7 PHOSPHORYLATION OF MAP KINASES BY CATIONIC PEPTIDES [00139] The cells were seeded at 2.5x10 s - 5 x 10 s cells/ml and left overnight. They were washed once in media, serum starved in the morning (serum free media - 4hrs). The media was removed and replaced with PBS, then sat at 37 0 C for 15 minutes and then brought to room temp for 15 minutes. Peptide was added (concentrations 0.1ug/ml - 50ug/ml) or H 2 0 and incubated 10 min. The PBS was very quickly removed and replaced with ice-cold radioimmunoprecipitation (RIPA) buffer with inhibitors (NaF, B-glycerophosphate, MOL, Vanadate, PMSF, Leupeptin Aprotinin). The plates were shaken on ice for 10-15 min or until the cells were lysed and the lysates collected. The procedure for THP-1 cells was slightly different; more cells (2x10 6 ) were used. They were serum starved overnight, and tQ stop the reaction Iml of ice-cold PBS was added then they sat on ice 5-10 min, were spun down then resuspended in RIPA. Protein concentrations were determined using a protein assay (Pierce, Rockford, IL.). Cell lysates (20 jig of protein) were separated by SDS-PAGE and transferred to nitrocellulose filters. The filters were blocked for 1 h with 10 mM Tris-HC1, pH 7.5, 150 mM NaCl (TBS)/5% skim milk powder and then incubated overnight in the cold with primary antibody in TBS/0.05% Tween 20. After washing for 30 min with TBS/0.05% Tween 20, the filters were incubated for 1 h at room temperature with 1 Vg/ml secondary antibody in TBS. The filters were washed for 30 min with TBS/0.05% Tween 20 and then incubated 1 h at room temperature with horseradish peroxidase-conjugated sheep anti-mouse IgG (1:10,000 in TBS/0.05% Tween 20). After washing the filters for 30 min with TBS/0.1% Tween 20, immunoreactive bands were visualized by enhanced chemiluminescence (ECL) detection. For experiments with peripheral blood mononuclear cells: The peripheral blood (50-100ml) was collected from all subjects. Mononuclear cells were isolated from the peripheral blood by density gradient centrifugation on Ficoll-Hypaque. Interphase cells (mononuclear cells) were recovered, washed and then resuspended in recommended primary medium for cell culture (RPMI-1640) with 10% fetal calf serum (FCS) and 1% L-glutamine. Cells were added to 6 well culture plates at 4x10 6 cells/well and were allowed to adhere at 370 C in 5% CO 2 atmosphere for 1 hour. The 161 WO 03/048383 PCT/CA02/01830 supernatant medium and non-adherent cells were washed off and the appropriate media with peptide was added. The freshly harvested cells were consistently >99% viable as assessed by their ability to exclude trypan blue. After stimulation with peptide, lysates were collected by lysing the cells in RIPA buffer in the presence of various phosphatase- and kinase-inhibitors. Protein content was analyzed and approximately 30 pg of each sample was loaded in a 12% SDS-PAGE gel. The gels were blotted onto nitrocellulose, blocked for 1 hour with 5% skim milk powder in Tris buffered saline (TBS) with 1% Triton X 100. Phosphorylation was detected with phosphorylation-specific antibodies. [00140] The results of peptide-induced phosphorylation are summarized in Table 46. SEQ ID NO: 2 was found to cause dose dependent phosphorylation of p38 and ERK1/2 in the mouse macrophage RAW cell line and the HBE cells. SEQ ID NO: 3 caused phosphorylation of MAP kinases in THP-1 human monocyte cell line and phosphorylation of ERK1/2 in the mouse RAW cell line. [00141] Table 47: Phosphorylation of MAP kinases in response to peptides. Cell Line Peptide MAP kinase phosphorylated p38 ERK1/2 RAW 264.7 SEQ ID NO: 3 - + SEQ 1D NO: 2 + + HBE SEQ ID NO: 3 + SEQ ID NO: 2 + + THP-1 SEQ ID NO: 3 + + SEQ ID NO: 2 162 WO 03/048383 PCT/CA02/01830 [00142] Table 48: Peptide Phosphorylation of MAP kinases in human blood monocytes. SEQ ID NO: I at 50 tg/ml) was used to promote phosphorylation. p 3 8 phosphorylation ERK1/2 phosphorylation 15 minutes 60 minutes 15 minutes 60 minutes + + + EXAMPLE 8 CATIONIC PEPTIDES PROTECT AGAINST BACTERIAL INFECTION BY ENHANCING THE IMMUNE RESPONSE [00143] BALB/c mice were given lx 10 5 Salmonella and cationic peptide (200 Vg) by intraperitoneal injection. The mice were monitored for 24 hours at which point they were euthanized, the spleen removed, homogenized and resuspended in PBS and plated on Luria Broth agar plates with Kanamycin (50 tg/ml). The plates were incubated overnight at 37C and counted for viable bacteria (Table 49 and 50). CD-1 mice were given 1 x 10 8 S. aureus in 5 % porcine mucin and cationic peptide (200 Vg) by intraperitoneal injection (Table 51). The mice were monitored for 3 days at which point they were euthanized, blood removed and plated for viable counts. CD-1 male mice were given 5.8 x 10 6 CFU EHEC bacteria and cationic peptide (200 Vg) by intraperitoneal (IP) injection and monitored for 3 days (Table 52). In each of these animal models a subset of the peptides demonstrated protection against infections. The most protective peptides in the Salmonella model demonstrated an ability to induce a common subset of genes in epithelial cells (Table 53) when comparing the protection assay results in Tables 50 and 51 to the gene expression results in Tables 31-37. This clearly indicates that there is a pattern of gene expression that is consistent with the ability of a peptide to demonstrate protection. Many of the cationic peptides were shown not to be directly antimicrobial as tested by the Minimum Inhibitory Concentration (MIC) assay (Table 54). This demonstrates that the ability of peptides to protect against infection relies on the ability of the peptide to stimulate host innate immunity rather than on direct antimicrobial activity. 163 WO 03/048383 PCT/CA02/01830 [00144] Table 49: Effect of Cationic Peptides on Salmonella Infection in BALB/c mice. The BALB/c mice were injected IP with Salmonella and Peptide, and 24 h later the animals were euthanized, the spleen removed, homogenized, diluted in PBS and plate counts were done to determine bacteria viability. Peptide Viable Bacteria in the Spleen Statistical Significance Treatment (CFU/ml) (p value) Control 2.70 ± 0.84 X 10" SEQ ID NO: 1 1.50 ± 0.26 X 10 0.12 SEQ ID NO: 6 2.57 ± 0.72 X 104 0.03 SEQ ID NO: 13 3.80 ± 0.97 X 10 4 0.04 SEQ ID NO: 17 4.79 ± 1.27 X 104 0.04 SEQ ID NO: 27 1.01 ± 0.26 X 10 0.06 [00145] Table 50: Effect of Cationic Peptides on Salmonella Infection in BALB/c mice. The BALB/c mice were injected intraperitoneally with Salmonella and Peptide, and 24 h later the animals were euthanized, the spleen removed, homogenized, diluted in PBS and plate counts were done to determine bacteria viability. Peptide Treatment Viable Bacteria in the Spleen (CFU/ml) Control 1.88 ± 0.16 X 104 SEQ ID NO: 48 1.98 ± 0.18 X 10 4 SEQ ID NO: 26 7.1 ± 1.37 X 104 SEQ ID NO: 30 5.79 ± 0.43 X 10 SEQ ID NO: 37 1.57 + 0.44 X 104 SEQ ID NO: 5 2.75 ± 0.59 X 104 SEQ ID NO: 7 5.4 0.28 X 10 164 WO 03/048383 PCT/CA02/01830 SEQ ID NO: 9 1.23 ± 0.87 X 104 SEQ ID NO: 14 2.11 ± 0.23 X 10' SEQ ID NO: 20 2.78 ± 0.22 X 104 SEQ ID NO: 23 6.16 ± 0.32 X 10 [00146] Table 51. Effect of Cationic Peptides in a Murine S. aureus infection model. CD-1 mice were given 1 x 108 bacteria in 5 % porcine mucin via intraperitoneal (IP) injection. Cationic peptide (200 gg) was given via a separate IP injection. The mice were monitored for 3 days at which point they were euthanized, blood removed and plated for viable counts. The following peptides were not effective in controlling S. aureus infection: SEQ ID NO: 48, SEQ ID NO: 26 Treatment CFU/ml (blood) # Mice Survived (3 days)/ Total mice in group No Peptide 7.61 ± 1.7 x 10' 6 / 8 SEQ ID NO: 1 0 4 / 4 SEQ ID NO: 27 2.25 0.1 X 10 3 / 4 SEQ ID NO: 30 1.29 ±+ 0.04 X 101 4 / 4 SEQ ID NO: 37 9.65 ± 0.41 X 10 4 / 4 SEQ ID NO: 5 3.28 ± 1.7 x 10' 4 / 4 SEQ ID NO: 6 1.98 0.05 X 10 3 / 4 SEQ ID NO: 7 3.8 0.24 x 103 4 / 4 SEQ ID NO: 9 2.97 0.25 X 10 4 / 4 SEQ ID NO: 13 4.83 0.92 x 10' 3/4 SEQ ID NO: 17 9.6 ± 0.41 X 102 4 / 4 SEQ ID NO: 20 3.41 ± 1.6 x 10 4 / 4 SEQ ID NO: 23 4.39 ± 2.0 x 103 4 / 4 [00147] Table 52 Effect of Peptide in a Murine EHEC infection model. CD-1 male mice (5 weeks old) were given 5.8 x 106 CFU EHEC bacteria via intraperitoneal 165 WO 03/048383 PCT/CA02/01830 (IP) injection. Cationic peptide (200 pg) was given via a separate IP injection. The mice were monitored for 3 days. Treatment Peptide Survival (%) control none 25 SEQ ID NO: 23 200jig 100 [00148] Table 53. Up-regulation of patterns of gene expression in A549 epithelial cells induced by peptides that are active in vivo. The peptides SEQ ID NO: 30, SEQ ID NO: 7 and SEQ ID NO: 13 at concentrations of 50 pg/ml were each shown to increase the expression of a pattern of genes after 4 h treatment. Peptide was incubated with the human A549 epithelial cells for 4 h and the RNA was isolated, converted into labelled cDNA probes and hybridised to Human Operon arrays (PRHU04). The intensity of polynucleotides in control, unstimulated cells are shown in the second columns for labelling of cDNA (average of Cy3 and CyS). The Fold Up regulation column refers to the intensity of polynucleotide expression in peptide simulated cells divided by the intensity of unstimulated cells. The SEQ ID NO: 37 peptide was included as a negative control that was not active in the murine infection models. Fold Up regulation of Gene Target (Accession Unstimulated Expression relative to Untreated number) Cell Intensity Cells SEQ ID SEQ ID SEQ ID SEQ ID NO: 30 NO: 7 NO: 13 NO: 37 Zinc finger protein (AF061261) 13 2.6 9.4 9.4 1.0 Cell cycle gene (S70622) 1.62 8.5 3.2 3.2 0.7 IL-10 Receptor (U00672) 0.2 2.6 9 4.3 0.5 166 WO 03/048383 PCT/CA02/01830 Transferase (AF038664) 0.09 12.3 9.7 9.7 0.1 Homeobox protein (AC004774) 0.38 3.2 2.5 2.5 1.7 Forkhead protein (AF042832) 0.17 14.1 3.5 3.5 0.9 Unknown (AL096803) 0.12 4.8 4.3 4.3 0.6 KIAA0284 Protein (AB006622) 0.47 3.4 2.1 2.1 1.3 Hypothetical Protein (AL022393) 0.12 4.4 4.0 4.0 0.4 Receptor (AF112461) 0.16 2.4 10.0 10.0 1.9 Hypothetical Protein (AK002104) 0.51 4.7 2.6 2.6 1.0 Protein (AL050261) 0.26 3.3 2.8 2.8 1.0 Polypeptide (AF105424) 0.26 2.5 5.3 5.3 1.0 SPR1 protein (AB031480) 0.73 3.0 2.7 2.7 1.3 Dehydrogenase (D17793) 4.38 2.3 2.2 2.2 0.9 Transferase (M63509) 0.55 2.7 2.1 2.1 1.0 Peroxisome factor (AB013818) 0.37 3.4 2.9 2.9 1.4 [00149] Table 54: Most cationic peptides studied here and especially the cationic peptides effective in infection models are not significantly antimicrobial. A dilution series of peptide was incubated with the indicated bacteria overnight in a 96-well plate. The lowest concentration of peptide that killed the bacteria was used as the MIC. The symbol > indicates the MIC is too large to measure. An MIC of 8 ptg/ml or less was considered clinically meaningful activity. Abbreviations: E.coli, Escherichia 167 WO 03/048383 PCT/CA02/01830 coli; S.aureus, Staphylococcus aureus; P.aerug, Pseudomonas aeruginosa; S. Typhim, Salmonella enteritidis ssp. typhimurium; C. rhod, Citobacter rhodensis; EHEC, Enterohaemorrhagic E. coli. MIC (p g/ml) Peptide E. coli S.aureus P. aerug. S.typhim. C. rhod. EHEC Polymyxin 0.25 16 0.25 0.5 0.25 0.5 Gentamicin 0.25 0.25 0.25 0.25 0.25 0.5 SEQ ID NO: 1 32 > 96 64 8 4 SEQ ID NO: 5 128 > > > 64 64 SEQ ID NO: 6 128 > > 128 64 64 SEQ ID NO: 7 > > > > > > SEQ ID NO: 8 > > > > > > SEQ ID NO: 9 > > > > > > SEQ ID NO: 10 > > > > > 64 SEQ ID NO: 12 > > > > > > SEQ ID NO: 13 > > > > > > SEQ ID NO: 14 > > > > > > SEQ ID NO: 15 128 > > > 128 64 SEQ ID NO: 16 > > > > > > SEQ ID NO: 17 > > > > > > SEQ ID NO: 19 8 16 16 64 4 4 SEQ ID NO: 2 4 16 32 16 64 SEQ ID NO: 20 8 8 8 8 16 8 SEQ ID NO: 21 64 64 96 64 32 32 SEQ ID NO: 22 8 12 24 8 4 4 SEQ ID NO: 23 4 8 8 16 4 4 SEQ ID NO: 24 16 16 4 16 16 4 SEQ ID NO: 26 0.5 32 64 2 2 0.5 SEQ ID NO: 27 8 64 64 16 2 4 SEQ ID NO: 28 > > > 64 64 128 168 WO 03/048383 PCT/CA02/01830 MIC (pg/mi) Peptide E. coli S.aureus P. aerug. S.typhim. C. rhod. EHEC SEQ ID NO: 29 2 > > 16 32 4 SEQ ID NO: 30 16 > 128 16 16 4 SEQ ID NO: 31 > > 128 > > 64 SEQ ID NO: 33 16 32 > 16 64 8 SEQ ID NO: 34 8 > > 32 64 8 SEQ ID NO: 35 4 128 64 8 8 4 SEQ ID NO: 36 32 > > 32 32 16 SEQ ID NO: 37 > > > > > > SEQ ID NO: 38 0.5 32 64 4 8 4 SEQ ID NO: 40 4 32 8 4 4 2 SEQ ID NO: 41 4 64 8 8 2 2 SEQ ID NO: 42 1.5 64 4 2 2 1 SEQ ID NO: 43 8 128 16 16 8 4 SEQ ID NO: 44 8 > 128 128 64 64 SEQ ID NO: 45 8 > 128 128 16 16 SEQ ID NO: 47 4 > 16 16 4 4 SEQ ID NO: 48 16 > 128 16 1 2 SEQ ID NO: 49 4 > 16 8 4 4 SEQ ID NO: 50 8 > 16 16 16 8 SEQ ID NO: 51 4 > 8 32 4 8 SEQ ID NO: 52 8 > 32 8 2 2 SEQ ID NO: 53 4 > 8 8 16 8 SEQ ID NO: 54 64 > 16 64 16 32 169 WO 03/048383 PCT/CA02/01830 EXAMPLE 9 USE OF POLYNUCLEOTIDES INDUCED BY BACTERIAL SIGNALLING MOLECULES IN DIAGNOSTIC/SCREENING [00150] S. typhimurium LPS and E. coli 0111:B4 LPS were purchased from Sigma Chemical Co. (St. Louis, MO). LTA (Sigma) from S. aureus, was resuspended in endotoxin free water (Sigma). The Limulus amoebocyte lysate assay (Sigma) was performed on LTA preparations to confirm that lots were not significantly contaminated by endotoxin (i.e. <1 ng/ml, a concentration that did not cause significant cytokine production in the RAW cell assay). The CpG oligodeoxynucleotides were synthesized with an Applied Biosystems Inc., Model 392 DNA/RNA Synthesizer, Mississauga, ON., then purified and resuspended in endotoxin-free water (Sigma). The following sequences were used CpG: 5' TCATGACGTTCCTGACGTT-3' (SEQ ID NO: 57) and nonCpG: 5' TTCAGGACTTTCCTCAGGTT-3' (SEQ ID NO: 58). The nonCpG oligo was tested for its ability to stimulate production of cytokines and was found to cause no significant production of TNF-a or IL-6 and therefore was considered as a negative control. RNA was isolated from RAW 264.7 cells that had been incubated for 4h with medium alone, 100 ng/ml S. typhimurium LPS, 1 tg/ml S. aureus LTA, or 1 ptM CpG (concentrations that led to optimal induction of tumor necrosis factor (TNF-a) in RAW cells). The RNA was used to polynucleotiderate cDNA probes that were hybridized to Clontech Atlas polynucleotide array filters, as described above. The hybridization of the cDNA probes to each immobilized DNA was visualized by autoradiography and quantified using a phosphorimager. Results from at least 2 to 3 independent experiments are summarized in Tables 55-59. It was found that LPS treatment of RAW 264.7 cells resulted in increased expression of more than 60 polynucleotides including polynucleotides encoding inflammatory proteins such as IL-1P, inducible nitric oxide synthase (iNOS), MIP-lc, MIP-13, MIP-2cL, CD40, and a variety of transcription factors. When the changes in polynucleotide expression induced by LPS, LTA, and CpG DNA were compared, it was found that all three of these bacterial products increased the expression of pro-inflammatory polynucleotides such as iNOS, MIP-lca, MIP-2ca, IL-113, IL-15, TNFR1 and NF-KB to a similar extent 170 WO 03/048383 PCT/CA02/01830 (Table 57). Table 57 describes 19 polynucleotides that were up-regulated by the bacterial products to similar extents in that their stimulation ratios differed by less than 1.5 fold between the three bacterial products. There were also several polynucleotides that were down-regulated by LPS, LTA and CpG to a similar extent. It was also found that there were a number of polynucleotides that were differentially regulated in response to the three bacterial products (Table 58), which includes many of these polynucleotides that differed in expression levels by more than 1.5 fold between one or more bacterial products). LTA treatment differentially influenced expression of the largest subset of polynucleotides compared to LPS or CpG, including hyperstimulation of expression of Jun-D, Jun-B, Elk-1 and cyclins G2 and Al. There were only a few polynucleotides whose expression was altered more by LPS or CpG treatment. Polynucleotides that had preferentially increased expression due to LPS treatment compared to LTA or CpG treatment included the cAMP response element DNA-binding protein 1 (CRE-BPI), interferon inducible protein 1 and CACCC Box-binding protein BKLF. Polynucleotides that had preferentially increased expression after CpG treatment compared to LPS or LTA treatment included leukemia inhibitory factor (LIF) and protease nexin 1 (PN-1). These results indicate that although LPS, LTA, and CpG DNA stimulate largely overlapping polynucleotide expression responses, they also exhibit differential abilities to regulate certain subsets of polynucleotides. [00151] The other polynucleotide arrays used are the Human Operon arrays (identification number for the genome is PRHU04-S1), which consist of about 14,000 human oligos spotted in duplicate. Probes were prepared from 5 pg of total RNA and labeled with Cy3 or Cy5 labeled dUTP. In these experiments, A549 epithelial cells were plated in 100 mm tissue culture dishes at 2.5 x 106 cells/dish, incubated overnight and then stimulated with 100 ng/ml E. coli 0111:B4 LPS for 4 h. Total RNA was isolated using RNAqueous (Ambion). DNA contamination was removed with DNA-free kit (Ambion). The probes prepared from total RNA were purified and hybridized to printed glass slides overnight at 42-C and washed. After washing, the image was captured using a Perkin Elmer array scanner. The image processing software (Imapolynucleotide 5.0, Marina Del Rey, CA) determines the spot mean intensity, median intensities, and background intensities. An "in house" program was 171 WO 03/048383 PCT/CA02/01830 used to remove background. The program calculates the bottom 10 % intensity for each subgrid and subtracts this for each grid. Analysis was performed with Polynucleotidespring software (Redwood City, CA). The intensities for each spot were normalized by taking the median spot intensity value from the population of spot values within a slide and comparing this value to the values of all slides in the experiment. The relative changes seen with cells treated with LPS compared to control cells can be found in the Tables below. A number of previously unreported changes that would be useful in diagnosing infection are described in Table 60. [00152] To confirm and assess the functional significance of these changes, the levels of selected mRNAs and proteins were assessed and quantified by densitometry. Northern blots using a CD14, vimentin, and tristetraprolin-specific probe confirmed similar expression after stimulation with all 3 bacterial products (Table 60). Similarly measurement of the enzymatic activity of nitric oxide synthetase, iNOS, using Griess reagent to assess levels of the inflammatory mediator NO, demonstrated comparable levels of NO produced after 24 h, consistent with the similar up-regulation of iNOS expression (Table 59). Western blot analysis confirmed the preferential stimulation of leukaemia inhibitory factor (LIF, a member of the IL-6 family of cytokines) by CpG (Table 59). Other confirmatory experiments demonstrated that LPS up-regulated the expression of TNF-c and IL-6 as assessed by ELISA, and the up-regulated expression of MIP-2a, and IL-1P mRNA and down-regulation of DP-1 and cyclin D mRNA as assessed by Northern blot analysis. The analysis was expanded to a more clinically relevant ex vivo system, by examining the ability of the bacterial elements to stimulate pro-inflammatory cytokine production in whole human blood. It was found that E. coli LPS, S. typhimurium LPS, and S. aureus LTA all stimulated similar amounts of serum TNF-c, and IL-1p. CpG also stimulated production of these cytokines, albeit to much lower levels, confirming in part the cell line data. [00153] Table 55: Polynucleotides Up-regulated byE. coli 0111 :B4 LPS in A549 Epithelial Cells. E. coli 0111:B4 LPS (100 ng/ml) increased the expression of many polynucleotides in A549 cells as studied by polynucleotide microarrays. LPS was incubated with the A549 cells for 4 h and the RNA was isolated. 5 Ig total RNA was used to make Cy3/Cy5 labelled cDNA probes and hybridised onto Human 172 WO 03/048383 PCT/CA02/01830 Operon arrays (PRHU04). The intensity of unstimulated cells is shown in the second column of Table 55. The "Ratio: LPS/control" column refers to the intensity of polynucleotide expression in LPS simulated cells divided by in the intensity of unstimulated cells. Accession Gene Control: Ratio: Number Media only LPS/control Intensity D87451 ring finger protein 10 715.8 183.7 AF061261 C3H-type zinc finger protein 565.9 36.7 aldo-keto reductase family 1, D17793 member C3 220.1 35.9 M14630 prothymosin, alpha 168.2 31.3 AL049975 Unknown 145.6 62.3 ADP-ribosylation factor L04510 domain protein 1, 64kD 139.9 213.6 U10991 G2 protein 101.7 170.3 eukaryotic translation U39067 initiation factor 3, subunit 2 61.0 15.9 X03342 ribosomal protein L32 52.6 10.5 Rho-associated, coiled-coil NM_004850 containing protein kinase 2 48.1 11.8 AK000942 Unknown 46.9 8.4 serine/threonine protein AB040057 kinase MASK 42.1 44.3 AB020719 KIAAO912 protein 41.8 9.4 FEM-1-like death receptor AB007856 binding protein 41.2 15.7 procollagen-proline, 2 J02783 oxoglutarate 4-dioxygenase 36.1 14.1 AL137376 Unknown 32.5 17.3 AL137730 Unknown 29.4 11.9 173 WO 03/048383 PCT/CA02/01830 Accession Gene Control: Ratio: Number Media only LPS/control Intensity D25328 phosphofructokinase, platelet 27.3 8.5 malate dehydrogenase 2, AF047470 NAD 25.2 8.2 stress-induced M86752 phosphoprotein 1 22.9 5.9 M90696 cathepsin S 19.6 6.8 AK001143 Unknown 19.1 6.4 AF038406 NADH dehydrogenase 17.7 71.5 hypothetical protein AK000315 FLJ20308 17.3 17.4 M54915 pim-1 oncogene 16.0 11.4 proteasome subunit, beta D29011 type, 5 15.3 41.1 membrane protein of AK000237 cholinergic synaptic vesicles 15.1 9.4 AL034348 Unknown 15.1 15.8 AL161991 Unknown 14.2 8.1 AL049250 Unknown 12.7 5.6 AL050361 PTD017 protein 12.6 13.0 U74324 RAB interacting factor 12.3 5.2 M22538 NADH dehydrogenase 12.3 7.6 D87076 KIAA0239 protein 11.6 6.5 translocase of inner mitochondrial membrane 23 NM_006327 (yeast) homolog 11.5 10.0 AK001083 Unknown 11.1 8.6 mucin 5, subtype B, AJ001403 tracheobronchial 10.8 53.4 174 WO 03/048383 PCT/CA02/01830 Accession Gene Control: Ratio: Number Media only LPS/control Intensity RAP1, GTPase activating M64788 protein 1 10.7 7.6 X06614 retinoic acid receptor, alpha 10.7 5.5 calcium and integring binding U85611 protein 10.3 8.1 U23942 cytochrome P450, 51 10.1 10.2 AL031983 Unknown 9.7 302.8 protein-O NM_007171 mannosyltransferase 1 9.5 6.5 hypothetical protein AK000403 FLJ20396 9.5 66.6 NM_002950 ribophorin I 9.3 35.7 cAMP response element L05515 binding protein CRE-BPa 8.9 6.2 phosphoinositide-3-kinase, X83368 catalytic, gamma polypeptide 8.7 27.1 M30269 nidogen (enactin) 8.7 5.5 chromosome 11 open reading M91083 frame 13 8.2 6.6 D29833 salivary proline-rich protein 7.7 5.8 immunoglobulin superfamily AB024536 containing leucine-rich repeat 7.6 8.0 chromosome 11 open reading U39400 frame 4 7.4 7.3 AF028789 unc119 (C.elegans) homolog 7.4 27.0 signal sequence receptor, alpha (translocon-associated NM_003144 protein alpha) 7.3 5.9 175 WO 03/048383 PCT/CA02/01830 Accession Gene Control: Ratio: Number Media only LPS/control Intensity arachidonate 5-lipoxygenase X52195 activating protein 7.3 13.1 human growth factor regulated tyrosine kinase U43895 substrate 6.9 6.9 cyclin-dependent kinase L25876 inhibitor 3 6.7 10.3 L04490 NADH dehydrogenase 6.6 11.1 Z18948 S100 calcium-binding protein 6.3 11.0 myristoylated alanine-rich D10522 protein kinase C substrate 6.1 5.8 sialic acid binding Ig-like NM 014442 lectin 8 6.1 7.6 U81375 solute carrier family 29 6.0 6.4 malignancy-associated AF041410 protein 5.9 5.3 killer cell immunoglobulin U24077 like receptor 5.8 14.4 AL137614 hypothetical protein 4.8 6.8 mannosyl (alpha-1,3-) glycoprotein beta-1,2-N NM_002406 acetylglucosaminyltransferase 4.7 5.3 AB002348 KIAAO350 protein 4.7 7.6 AF165217 tropomodulin 4 (muscle) 4.6 12.3 branched chain keto acid dehydrogenase El, alpha Z14093 polypeptide 4.6 5.4 U82671 caltractin 3.8 44.5 176 WO 03/048383 PCT/CA02/01830 Accession Gene Control: Ratio: Number Media only LPS/control Intensity AL050136 Unknown 3.6 5.0 NM_005135 solute carrier family 12 3.6 5.0 hypothetical protein AK001961 FLJ11099 3.6 5.9 AL034410 Unknown 3.2 21.3 S74728 antiquitin 1 3.1 9.2 ribosomal protein L34 AL049714 pseudogene 2 3.0 19.5 NM_014075 PRO0593 protein 2.9 11.5 AF189279 phospholipase A2, group IIE 2.8 37.8 J03925 integrin, alpha M 2.7 9.9 NM_012177 F-box protein Fbx5 2.6 26.2 potassium voltage-gated channel, KQT-like subfamily, NM 004519 member 3 2.6 21.1 M28825 CD1A antigen, a polypeptide 2.6 16.8 actin, gamma 2, smooth X16940 muscle, enteric 2.4 11.8 major histocompatibility X03066 complex, class II, DO beta 2.2 36.5 hypothetical protein AK001237 FLJ10375 2.1 18.4 AB028971 KIAA1048 protein 2.0 9.4 ALl 37665 Unknown 2.0 7.3 [00154] Table 56: Polynucleotides Down-regulated byE. coli O111:B4 LPS in A549 Epithelial Cells. E. coli 0111 :B4 LPS (100 ng/ml) decreased the expression of many polynucleotides in A549 cells as studied by polynucleotide microarrays. LPS 177 WO 03/048383 PCT/CA02/01830 was incubated with the A549 cells for 4 h and the RNA was isolated. 5 tg total RNA was used to make Cy3/Cy5 labeled cDNA probes and hybridized onto Human Operon arrays (PRHU04). The intensity of unstimulated cells is shown in the second column of the Table. The "Ratio: LPS/control" column refers to the intensity of polynucleotide expression in LPS simulated cells divided by in the intensity of unstimulated cells. Accession Gene Control: Ratio: Number Media only LPS/control Intensity NM_017433 myosin liIA 167.8 0.03 X60484 H4 histone family member E 36.2 0.04 X60483 H4 histone family member D 36.9 0.05 AF151079 hypothetical protein 602.8 0.05 inhibitor of DNA binding 2, dominant M96843 negative helix-loop-helix protein 30.7 0.05 S79854 deiodinase, iodothyronine, type III 39.4 0.06 AB018266 matrin 3 15.7 0.08 M33374 NADH dehydrogenase 107.8 0.09 Homo sapiens mRNA for NUP98 AF005220 HOXD13 fusion protein, partial cds 105.2 0.09 Z80783 H2B histone family, member L 20.5 0.10 Z46261 H3 histone family, member A 9.7 0.12 Z80780 H2B histone family, member H 35.3 0.12 erythrocyte membrane protein band 7.2 U33931 (stomatin) 18.9 0.13 M60750 H2B histone family, member A 35.8 0.14 Z83738 H2B histone family, member E 19.3 0.15 Y14690 collagen, type V, alpha 2 7.5 0.15 X-ray repair complementing defective M30938 repair in Chinese hamster cells 5 11.3 0.16 L36055 eukaryotic translation initiation factor 4E 182.5 0.16 178 WO 03/048383 PCT/CA02/01830 Accession Gene Control: Ratio: Number Media only LPS/control Intensity binding protein 1 Z80779 H2B histone family, member G 54.3 0.16 5(3)-deoxyribonucleotidase; RB AF226869 associated KRAB repressor 7.1 0.18 D50924 KIAA0134 gene product 91.0 0.18 AL133415 vimentin 78.1 0.19 AL050179 tropomyosin 1 (alpha) 41.6 0.19 AJ005579 RD element 5.4 0.19 M80899 AHNAK nucleoprotein 11.6 0.19 NM_004873 BCL2-associated athanogene 5 6.2 0.19 X57138 H2A histone family, member N 58.3 0.20 AF081281 lysophospholipase I 7.2 0.22 U96759 von Hippel-Lindau binding protein 1 6.6 0.22 Human ribosomal protein L12 U85977 pseudogene, partial cds 342.6 0.22 D13315 glyoxalase I 7.5 0.22 AC003007 Unknown 218.2 0.22 AB032980 RU2S 246.6 0.22 U40282 integrin-linked kinase 10.1 0.22 U81984 endothelial PAS domain protein 1 4.7 0.23 chloride channel, nucleotide-sensitive, X91788 1A 9.6 0.23 AF018081 collagen, type XVIII, alpha 1 6.9 0.24 nuclear factor I/X (CCAAT-binding L31881 transcription factor) 13.6 0.24 B-cell translocation gene 1, anti X61123 proliferative 5.3 0.24 L32976 mitogen-activated protein kinase kinase 6.3 0.24 179 WO 03/048383 PCT/CA02/01830 Accession Gene Control: Ratio: Number Media only LPS/control Intensity kinase 11 immunoglobulin lambda-like M27749 polypeptide 3 5.5 0.24 X57128 H3 histone family, member C 9.0 0.25 phosphoinositide-3-kinase, regulatory X80907 subunit, polypeptide 2 5.8 0.25 H.sapiens (MAR11) MUC5AC mRNA Z34282 for mucin (partial) 100.6 0.26 X00089 H2A histone family, member M 4.7 0.26 AL035252 CD39-like 2 4.6 0.26 PERB11 family member in MHC class I X95289 region 27.5 0.26 AJ001340 U3 snoRNP-associated 55-kDa protein 4.0 0.26 NM_014161 HSPCO71 protein 10.6 0.27 U60873 Unknown 6.4 0.27 X91247 thioredoxin reductase 1 84.4 0.27 AK001284 hypothetical protein FLJ10422 4.2 0.27 U90840 synovial sarcoma, X breakpoint 3 6.6 0.27 X53777 ribosomal protein L17 39.9 0.27 AL035067 Unknown 10.0 0.28 AL1 17665 DKFZP586M1824 protein 3.9 0.28 ATPase, Ca++ transporting, plasma L14561 membrane 1 5.3 0.28 L19779 H2A histone family, member O 30.6 0.28 AL049782 Unknown 285.3 0.28 X00734 tubulin, beta, 5 39.7 0.29 AK001761 retinoic acid induced 3 23.7 0.29 U72661 ninjurin 1 4.4 0.29 180 WO 03/048383 PCT/CA02/01830 Accession Gene Control: Ratio: Number Media only LPS/control Intensity S48220 deiodinase, iodothyronine, type I 1,296.1 0.29 AF025304 EphB2 4.5 0.30 S82198 chymotrypsin C 4.1 0.30 Z80782 H2B histone family, member K 31.9 0.30 X68194 synaptophysin-like protein 7.9 0.30 AB028869 Unknown 4.2 0.30 AK000761 Unknown 4.3 0.30 [00155] Table 57: Polynucleotides expressed to similar extents after stimulation by the bacterial products LPS, LTA, and CpG DNA. Bacterial products (100 ng/ml S. typhimurium LPS, 1pg/ml S. aureus LTA or 1 4M CpG) were shown to potently induce the expression of several polynucleotides. Peptide was incubated with the RAW cells for 4 h and the RNA was isolated, converted into labeled cDNA probes and hybridized to Atlas arrays. The intensity of control, unstimulated cells is shown in the second column. The "Ratio LPS/LTA/CpG: Control" column refers to the intensity of polynucleotide expression in bacterial product-simulated cells divided by the intensity of unstimulated cells. Accession Control Ratio Ratio Ratio Protein/polynucleotide number Unstim. LPS: LTA: CpG: Intensity Control Control Control M15131 20 82 80 55 IL-13 M57422 20 77 64 90 tristetraprolin X53798 20 73 77 78 MIP-2ct M35590 188 50 48 58 MIP-13 28095 20 49 57 50 ICE 181 WO 03/048383 PCT/CA02/01830 Accession Control Ratio Ratio Ratio Protein/polynucleotide number Unstim. LPS: LTA: CpG: Intensity Control Control Control M87039 20 37 38 45 iNOS X57413 20 34 40 28 TGF3 X15842 20 20 21 15 c-rel proto-oncopolynucleotide X12531 489 19 20 26 MIP-la U14332 20 14 15 12 IL-15 M59378 580 10 13 11 TNFR1 U37522 151 6 6 6 TRAIL M57999 172 3.8 3.5 3.4 NF-KB U36277 402 3.2 3.5 2.7 I-KB (alpha subunit) X76850 194 3 3.8 2.5 MAPKAP-2 U06924 858 2.4 3 3.2 Stat 1 X14951 592 2 2 2 CD18 X60671 543 1.9 2.4 2.8 NF-2 M34510 5970 1.6 2 1.4 CD14 X51438 2702 1.3 2.2 2.0 vimentin X68932 4455 0.5 0.7 0.5 c-Fms Z21848 352 0.5 0.6 0.6 DNA polymerase X70472 614 0.4 0.6 0.5 B-myb [00156] Table 58: Polynucleotides that were differentially regulated by the bacterial products LPS, LTA, and CpG DNA. Bacterial products (100 ng/ml S. typhimurium LPS, 1ptg/ml S. aureus LTA or 1 gM CpG) were shown to potently induce the expression of several polynucleotides. Peptide was incubated with the RAW cells for 4 h and the RNA was isolated, converted into labeled cDNA probes and hybridized to Atlas arrays. The intensity of control, unstimulated cells is shown in the second column. The "Ratio LPS/LTA/CpG: Control" column refers to the 182 WO 03/048383 PCT/CA02/01830 intensity of polynucleotide expression in bacterial product-simulated cells divided by the intensity of unstimulated cells. Accession Unstim. Ratio Ratio Ratio Protein/polynucleotide number Control LPS: LTA: CpG: Intensity Control Control Control X72307 20 1.0 23 1.0 hepatocyte growth factor L38847 20 1.0 21 1.0 hepatoma transmembrane kinase ligand L34169 393 0.3 3 0.5 thrombopoietin J04113 289 1 4 3 Nur77 Z50013 20 7 21 5 H-ras proto-oncopolynucleotide X84311 20 4 12 2 Cyclin Al U95826 20 5 14 2 Cyclin G2 X87257 123 2 4 1 Elk-1 105205 20 18 39 20 Jun-D 103236 20 11 19 14 Jun-B M83649 20 71 80 42 Fas 1 receptor M83312 20 69 91 57 CD40L receptor X52264 20 17 23 9 ICAM-1 M13945 573 2 3 2 Pim-1 U60530 193 2 3 3 Mad related protein D10329 570 2 3 2 CD7 X06381 20 55 59 102 Leukemia inhibitory factor (LIF) X70296 20 6.9 13 22 Protease nexin 1 (PN-1) U36340 20 38 7 7 CACCC Box- binding protein BKLF S76657 20 11 6 7 CRE-BPI U19119 272 10 4 4 interferon inducible protein 1 183 WO 03/048383 PCT/CA02/01830 [00157] Table 59: Confirmation of Table 57 and 58 Array Data. a) Total RNA was isolated from unstimulated RAW macrophage cells and cells treated for 4 hr with 100 ng/mlS. typhimurium LPS, 1 ptg/ml S. aureus LTA, 1 pM CpG DNA or media alone and Northern blots were performed the membrane was probed for GAPDH, CD14, vimentin, and tristetraprolin as described previously [Scott et al]. The hybridization intensities of the Northern blots were compared to GAPDH to look for inconsistencies in loading. These experiments were repeated at least three times and the data shown is the average relative levels of each condition compared to media (as measured by densitometry) + standard error. b) RAW 264.7 cells were stimulated with 100 ng/ml S. typhimurium LPS, 1 ptg/ml S. aureus LTA, 1 pM CpG DNA or media alone for 24 hours. Protein lysates were prepared, run on SDS PAGE gels and western blots were performed to detect LIF (R&D Systems). These experiments were repeated at least three times and the data shown is the relative levels of LIF compared to media (as measured by densitometry) + standard error. c) Supernatant was collected from RAW macrophage cells treated with 100 ng/ml S. typhimurium LPS, 1 Vtg/ml S. aureus LTA, 1 pM CpG DNA, or media alone for 24 hours and tested for the amount of NO formed in the supernatant as estimated from the accumulation of the stable NO metabolite nitrite with the Griess reagent as described previously [Scott, et al]. The data shown is the average of three experiments + standard error. Relative levels Product Untreated LPS LTA CpG CD14a 1.0 2.2 + 0.4 1.8 + 0.2 1.5 + 0.3 Vimentina 1.0 1.2 + 0.07 1.5 + 0.05 1.3 + 0.07 Tristetraprolina 1.0 5.5 +0.5 5.5+ 1.5 9.5+ 1.5 LIFb 1.0 2.8 + 1.2 2.7 + 0.6 5.1 + 1.6 NOc 8 + 1.5 47 + 2.5 20 + 3 21 + 1.5 184 WO 03/048383 PCT/CA02/01830 [00158] Table 60. Pattern of Gene expression in A549 Human Epithelial cells up-regulated by bacterial signalling molecules (LPS). E. coli 0111 :B4 LPS (100 ng/ml) increased the expression of many polynucleotides in A549 cells as studied by polynucleotide microarrays. LPS was incubated with the A549 cells for 4 h and the RNA was isolated. 5 Vg total RNA was used to make Cy3/Cy5 labelled cDNA probes and hybridised onto Human Operon arrays (PRHU04). The examples of polynucleotide expression changes in LPS simulated cells represent a greater than 2 fold intensity level change of LPS treated cells from untreated cells. Accession Number Gene AL050337 interferon gamma receptor 1 U05875 interferon gamma receptor 2 NM_002310 leukemia inhibitory factor receptor U92971 coagulation factor II (thrombin) receptor-like 2 Z29575 tumor necrosis factor receptor superfamily member 17 L31584 Chemokine receptor 7 J03925 cAMP response element-binding protein M64788 RAP1, GTPase activating protein NM 004850 Rho-associated kinase 2 D87451 ring finger protein 10 AL049975 Unknown U39067 eukaryotic translation initiation factor 3, subunit 2 AK000942 Unknown AB040057 serine/threonine protein kinase MASK AB020719 KIAAO912 protein AB007856 FEM-1-like death receptor binding protein AL137376 Unknown AL137730 Unknown M90696 cathepsin S 185 WO 03/048383 PCT/CA02/01830 AK001143 Unknown AF038406 NADH dehydrogenase AK000315 hypothetical protein FLJ20308 M54915 pim-1 oncogene D29011 proteasome subunit, beta type, 5 AL034348 Unknown D87076 KIAA0239 protein AJ001403 mucin 5, subtype B, tracheobronchial J03925 integrin, alpha M EXAMPLE 10 ALTERING SIGNALING TO PROTECT AGAINST BACTERIAL INFECTIONS [00159] The Salmonella Typhimurium strain SL1344 was obtained from the American Type Culture Collection (ATCC; Manassas, VA) and grown in Luria Bertani (LB) broth. For macrophage infections, 10 ml LB in a 125 mL flask was inoculated from a frozen glycerol stock and cultured overnight with shaking at 37oC to stationary phase. RAW 264.7 cells (1x10 5 cells/well) were seeded in 24 well plates. Bacteria were diluted in culture medium to give a nominal multiplicity of infection (MOI) of approximately 100, bacteria were centrifuged onto the monolayer at 1000 rpm for 10 minutes to synchronize infection, and the infection was allowed to proceed for 20 min in a 37 0 C, 5% CO 2 incubator. Cells were washed 3 times with PBS to remove extracellular bacteria and then incubated in DMEM + 10% FBS containing 100 ag/ml gentamicin (Sigma, St. Louis, MO) to kill any remaining extracellular bacteria and prevent re-infection. After 2 h, the gentamicin concentration was lowered to 10 pg/ml and maintained throughout the assay. Cells were pretreated with inhibitors for 30 min prior to infection at the following concentrations: 50 pM PD 98059 (Calbiochem), 50 pM U 0126 (Promega), 2 mM diphenyliodonium (DPI), 250 pM acetovanillone (apocynin, Aldrich), 1 mM ascorbic acid (Sigma), 30 mM N acetyl cysteine (Sigma), and 2 mM NG-L-monomethyl arginine (L-NMMA, 186 WO 03/048383 PCT/CA02/01830 Molecular Probes) or 2 mM NG-D-monomethyl arginine (D-NMMA, Molecular Probes). Fresh inhibitors were added immediately after infection, at 2 h, and 6-8 h post-infection to ensure potency. Control cells were treated with equivalent volumes of dimethylsulfoxide (DMSO) per mL of media. Intracellular survival/replication of S. Typhimurium SL1344 was determined using the gentamicin-resistance assay, as previously described. Briefly, cells were washed twice with PBS to remove gentamicin, lysed with 1% Triton X-100/0.1% SDS in PBS at 2 h and 24 h post infection, and numbers of intracellular bacteria calculated from colony counts on LB agar plates. Under these infection conditions, macrophages contained an average of 1 bacterium per cell as assessed by standard plate counts, which permitted analysis of macrophages at 24 h post-infection. Bacterial filiamentation is related to bacterial stress. NADPH oxidase and iNOS can be activated by MEK/ERK signaling. The results (Table 61) clearly demonstrate that the alteration of cell signaling is a method whereby intracellular Salmonella infections can be resolved. Thus since bacteria to up-regulate multiple genes in human cells, this strategy of blocking signaling represents a general method of therapy against infection. [00160] Table 61: Effect of the Signaling Molecule MEK on Intracellular Bacteria in IFN-y-primed RAW cells. Treatment Effect b 0 None MEK inhibitor U 0126 Decrease bacterial filamentation (bacterial stress)c Increase in the number of intracellular S. Typhimurium MEK inhibitor PD 98059 Decrease bacterial filamentation (bacterial stress) c Increase in the number of intracellular S. Typhimurium 187 WO 03/048383 PCT/CA02/01830 Treatmenta Effect b NADPH oxidase inhibitors Decrease bacterial filamentation (bacterial stress) Increase in the number of intracellular S. Typhimurium EXAMPLE 11 ANTI-VIRAL ACTIVITY [00161] SDF-1, a C-X-C chemokine is a natural ligand for HIV-1 coreceptor CXCR4. The chemokine receptors CXCR4 and CCR5 are considered to be potential targets for the inhibition of HIV-1 replication. The crystal structure of SDF-1 exhibits antiparallel 3-sheets and a positively charged surface, features that are critical in binding to the negatively charged extracellular loops of CXCR4. These findings suggest that chemokine derivatives, small-size CXCR4 antagonists, or agonists mimicking the structure or ionic property of chemokines may be useful agents for the treatment of X4 HIV-1 infection. It was found that the cationic peptides inhibited SDF-1 induced T-cell migration suggesting that the peptides may act as CXCR4 antagonists. The migration assays were performed as follows. Human Jurkat T cells were resuspended to 5 x 106 / ml in chemotaxis medium (RPMI 1640 / 10mM Hepes / 0.5 % BSA). Migration assays were performed in 24 well plates using 5 ptm polycarbonate Transwell inserts (Costar). Briefly, peptide or controls were diluted in chemotaxis medium and placed in the lower chamber while 0.1 ml cells (5 x 106 / ml) was added to the upper chamber. After 3 hr at 37 0 C, the number of cells that had migrated into the lower chamber was determined using flow cytometry. The medium from the lower chamber was passed through a FACscan for 30 seconds, gating on forward and side scatter to exclude cell debris. The number of live cells was compared to a "100 % migration control" in which 5 x 105 /ml cells had been pipetted directly into the lower chamber and then counted on the FACscan for 30 seconds. The results demonstrate that the addition of peptide results in an inhibition of the migration of Human Jurkat T-cells (Table 62) probably by influencing CXCR4 expression (Tables 63 and 64). 188 WO 03/048383 PCT/CA02/01830 [00162] Table 62: Peptide inhibits the migration of human Jurkat-T cells: Migration (%) Experiment Positive SDF-1 SDF-1 + Negative control (100 ng/ml) SEQ ID 1 control (50 pg/ml) 1 100% 32% 0% <0.01% 2 100% 40% 0% 0% [00163] Table 63: Corresponding polynucleotide array data to Table 56: Unstimulated Ratio Accession Polynucl Polynucleotide Intensity peptide: Number eotide / Function Unstimulated Protein CXCR-4 Chemokine receptor 36 4 D87747 [00164] Table 64: Corresponding FACs data to Tables 62 and 63: Concentration Fold Increase in Protein Peptide (pg/ml) Expression CXCR-4 SEQ ID NO: 1 10 No change SEQ ID NO:1 50 1.3 + 0.03 SEQ ID NO:1 100 1.6 + 0.23 SEQ ID NO: 3 100 1.5 + 0.2 189 WO 03/048383 PCT/CA02/01830 [00165] Although the invention has been described with reference to the presently preferred embodiment, it should be understood that various modifications can be made without departing from the spirit of the invention. Accordingly, the invention is limited only by the following claims. 190

Claims (59)

1. A method of identifying a polynucleotide or pattern of polynucleotides regulated by one or more sepsis or inflammatory inducing agents and inhibited by a cationic peptide comprising contacting the polynucleotide or polynucleotides with one or more sepsis or inflammatory inducing agents, contacting the polynucleotide or polynucleotides with a cationic peptide either simultaneously or immediately thereafter, and determining a change in expression, wherein a change is indicative of a polynucleotide or pattern of polynucleotides that is regulated by a sepsis or inflammatory inducing agent and reduced by a cationic peptide.
2. The method of claim 1, wherein the sepsis or inflammatory inducing agent is LPS, LTA or CpG DNA, bacterial components or whole cells, or related agents.
3. The method of claim 1, comprising determining the level of expression of the polynucleotide prior to and following contacting with the sepsis or inflammatory inducing agent.
4. A polynucleotide or polynucleotide pattern identified by the method of claim 1.
5. A polynucleotide of claim 3, wherein the polynucleotide encodes a polypeptide involved in an inflammatory or septic response.
6. A method of identifying an agent that blocks sepsis or inflammation comprising combining a polynucleotide of claim 5 with an agent, wherein expression of the polynucleotide in the presence of the agent is modulated as compared with expression in the absence of the agent and wherein the modulation in expression affects the inflammatory or septic response.
7. The method of claim 6, wherein the effect is inhibition of the inflammatory or septic response.
8. An agent identified by the method of claim 6. 191 WO 03/048383 PCT/CA02/01830
9. The agent of claim 8, wherein the agent is a peptide, peptidomimetic, chemical compound, nucleic acid molecule or a polypeptide.
10. The agent of claim 8, wherein the peptide is selected from SEQ ID NO:4-54.
11. A method of identifying a pattern of polynucleotide expression for inhibition of an inflammatory or septic response comprising: contacting cells with LPS, LTA, CpG DNA and/or intact bacteria or bacterial components in the presence or absence of a cationic peptide; detecting a pattern of polynucleotide expression for the cells in the presence and absence of the peptide, wherein the pattern in the presence of the peptide represents inhibition of an inflammatory or septic response.
12. The method of claim 11, further comprising contacting cells with one or more compounds suspected of inhibiting an inflammatory or septic response and identifying a compound that provides a pattern of polynucleotide expression similar to a pattern obtained with a cationic peptide that inhibits an inflammatory or septic response.
13. A compound identified by the method of claim 11.
14. A method of identifying an agent that enhances innate immunity comprising: contacting a polynucleotide or polynucleotides that encode a polypeptide involved in innate immunity, with an agent of interest, wherein expression of the polynucleotide in the presence of the agent is modulated as compared with expression . of the polynucleotide in the absence of the agent and wherein the modulated expression results in enhancement of innate immunity.
15. The method of claim 14, wherein the agent does not stimulate a septic reaction.
16. The method of claim 14, wherein the agent inhibits the inflammatory or septic response. 192 WO 03/048383 PCT/CA02/01830
17. The method of claim 14, wherein the agent blocks the inflammatory or septic response.
18. The method as in any of claims 16 or 17, wherein the agent increases the expression of an anti-inflammatory encoding polynucleotide.
19. The method of claim 18, wherein the anti-inflammatory gene is selected from a subset that includes IL-1 R antagonist homolog 1 (AI167887), IL-10 R beta (AA486393), IL-10 R alpha (U00672), TNF Receptor member 1B (AA150416), TNF receptor member 5 (H98636), TNF receptor member 1 b (AA194983), IK cytokine down-regulator of HLA II (R39227), TGFB inducible early growth response 2 (AI473938), CD2 (AA927710), glucocorticoid-related polynucleotides (AK000892), or IL-10 (M5762720.
20. The method of claim 19, wherein the agent inhibits the expression of TNF alpha.
21. The method of claim 19, wherein the agent inhibits the expression of interleukins.
22. The method of claim 23, wherein the interleukin is IL-8.
23. The method of claim 16, wherein the agent is a peptide.
24. The method of claim 23, wherein the peptide is selected from SEQ ID NO:4
54. 25. An agent identified by the method of claim 14. 26. An agent of claim 25, wherein the agent is a peptide, peptidomimetic, chemical compound, or a nucleic acid molecule. 27. A method of identifying a pattern of polynucleotide expression for identification of a compound that selectively enhances innate immunity comprising: 193 WO 03/048383 PCT/CA02/01830 detecting a pattern of polynucleotide expression for cells contacted in the presence and absence of a cationic peptide, wherein the pattern in the presence of the peptide represents stimulation of innate immunity; detecting a pattern of polynucleotide expression for cells contacted in the presence of a test compound, wherein a pattern with the test compound that is similar to the pattern observed in the presence of the cationic peptide, is indicative of a compound that enhances innate immunity. 28. A compound identified by the method of claim 27. 29. The method of claim 27, wherein the compound does not stimulate a septic reaction. 30. The method of claim 27, wherein the polynucleotide expression pattern includes expression of pro-inflammatory polynucleotides. 31. The method of claim 30, wherein the pro-inflammatory polynucleotides include ring finger protein 10 (D87451), serine/threonine protein kinase MASK (AB040057), KIAAO912 protein (AB020719), KIAA0239 protein (D87076), RAP1, GTPase activating protein 1 (M64788), FEM-1-like death receptor binding protein (AB007856), cathepsin S (M90696), hypothetical protein FLJ20308 (AK000315), pim-1 oncogene (M54915), proteasome subunit beta type 5 (D29011), KIAA0239 protein (D87076), mucin 5 subtype B tracheobronchial (AJ001403), cAMP response element-binding protein CREBPa, integrin alpha M (J03925), Rho-associated kinase 2 (NM_004850), PTD017 protein (AL050361) unknown genes (AK001143, AK034348, AL049250, AL16199, AL031983), retinoic acid receptor (X06614), G protein-coupled receptors (Z94155, X81892, U52219, U22491, AF015257, U66579) chemokine (C-C motif) receptor 7 (L31584), tumor necrosis factor receptor superfamily member 17 (Z29575), interferon gamma receptor 2 (U05875), cytokine receptor-like factor 1 (AF059293), class I cytokine receptor (AF053004), coagulation factor II (thrombin) receptor-like 2 (U92971), leukemia inhibitory factor receptor (NM_002310), interferon gamma receptor 1 (AL050337) or any combination thereof. 194 WO 03/048383 PCT/CA02/01830 32. The method of claim 27, wherein the expression pattern includes expression of polynucleotides encoding chemokines. 33. The method of claim 27, wherein the expression pattern includes expression of cell differentiation factors. 34. The method of claim 27, wherein the polynucleotide expression pattern includes expression of cell surface receptors. 35. The method of claim 34, wherein the cell surface receptors include chemokine receptors or integrin receptors. 36. A method of identifying an agent that is capable of selectively enhancing innate immunity comprising: contacting a cell containing a polynucleotide or polynucleotides that encode a polypeptide involved in innate immunity, with an agent of interest, wherein expression of the polynucleotide or polynucleotides in the presence of the agent is modulated as compared with expression in the absence of the agent and wherein the modulated expression results in enhancement of innate immunity. 37. The method of claim 26 in which the pattern of expression is utilized in screening for compounds that enhance innate immunity. 38. A compound of claim 28, wherein the compound stimulates chemokine or chemokine receptor expression. 39. A compound of claim 38, wherein the chemokine or chemokine receptor is CXCR4, CCR5, CCR2, CCR6, MIP-1 alpha, IL-8, MCP-1, MCP-2, MCP-3, MCP-4, or MCP-5. 40. A compound of claim 28, wherein the compound is a peptide, peptidomimetic, chemical compound, or a nucleic acid molecule. 195 WO 03/048383 PCT/CA02/01830 41. A method of identifying an agent that is capable of both suppressing or blocking septic or inflammatory responses and enhancing innate immunity comprising: contacting a cell containing i) a polynucleotide or polynucleotides that encode a polypeptide capable of suppressing inflammatory or septic responses and ii) a polynucleotide or polynucleotides that encode a polypeptide involved in innate immunity, with an agent of interest, wherein expression of in the presence of the agent is modulated as compared with expression of the polynucleotide or polynucleotides in the absence of the agent and wherein the modulated expression results in suppression of inflammatory or septic responses and enhancement of innate immunity. 42. A method for inferring a state of infection in a mammalian subject from a nucleic acid sample of the subject comprising identifying in the nucleic acid sample a polynucleotide expression pattern exemplified by an increase in polynucleotide expression of at least 2 polynucleotides in Table 55 as compared to a non-infected subject. 43. A method for inferring a state of infection in a mammalian subject from a nucleic acid sample of the subject comprising identifying in the nucleic acid sample a polynucleotide expression pattern exemplified by a decrease in polynucleotide expression of at least 2 polynucleotides in Table 56 as compared to a non-infected subject. 44. A method for inferring a state of infection in a mammalian subject from a nucleic acid sample of the subject comprising identifying in the nucleic acid sample a polynucleotide expression pattern exemplified by a polynucleotide expression of at least 2 polynucleotides in Table 57 as compared to a non-infected subject. 45. The method of any of claims 30, 31 or 32, wherein the state of infection is due to a bacteria, virus, fungus or parasitic agent. 46. The method of any of claims 30, 31 or 32, wherein the state of infection is due to a Gram positive or Gram negative bacteria. 196 WO 03/048383 PCT/CAO2/01830 47. A polynucleotide expression pattern of a subject having a state of infection identified by the method of claim 31. 48. A cationic peptide that is an antagonist of CXCR-4. 49. A method of identifying a cationic peptide that is an antagonist of CXCR-4 comprising contacting T cells with SDF-1 in the presence of absence of a test peptide and measuring chemotaxis, wherein a decrease in chemotaxis in the presence of the test peptide is indicative of a peptide that is an antagonist of CXCR-4. 50. An isolated cationic peptide comprising the general formula X 1 X 2 X 3 IX 4 PX 4 IPXsX 2 X 1 (SEQ ID NO: 4), wherein X 1 is one or two of R, L or K, X 2 is one of C, S or A, X 3 is one of R or P, X 4 is one of A or V and X 5 is one of V or W. 51. The cationic peptide of claim 38, wherein the peptide is selected from the group consisting of: LLCRIVPVIPWCK (SEQ ID NO: 5), LRCPIAPVIPVCKK (SEQ ID NO: 6), KSRIVPAIPVSLL (SEQ ID NO: 7), KKSPIAPAIPWSR (SEQ ID NO: 8), RRARIVPAIPVARR (SEQ ID NO: 9) and LSRIAPAIPWAKL (SEQ ID NO: 10). 52. The peptide of claim 38, wherein the peptide has anti-inflammatory activity. 53. The peptide of claim 38, wherein the peptide has anti-sepsis activity. 54. An isolated cationic peptide comprising the general formula XILX 2 X 3 KX 4 X 2 XsX 3 PX 3 XI (SEQ ID NO: 11), wherein X 1 is one or two of D, E, S, T or N, X2 is one or two of P, G or D, X 3 is one of G, A, V, L, I or Y, X 4 is one of R, K or H and X 5 is one of S, T, C, M or R.
55. The cationic peptide of claim 42, wherein the peptide is selected from the group consisting of: DLPAKRGSAPGST (SEQ ID NO: 12), SELPGLKHPCVPGS (SEQ ID NO: 13), TTLGPVKRDSIPGE (SEQ ID NO: 14), SLPIKHDRLPATS (SEQ ID NO: 15), ELPLKRGRVPVE (SEQ ID NO: 16) and NLPDLKKPRVPATS (SEQ ID NO: 17).
56. The peptide of claim 42, wherein the peptide has anti-inflammatory activity. 197 WO 03/048383 PCT/CA02/01830
57. The peptide of claim 42, wherein the peptide has anti-sepsis activity.
58. An isolated cationic peptide comprising the general formula XIX 2 X 3 X 4 WX 4 WX 4 X 5 K (SEQ ID NO: 18), wherein X, is one to four chosen from A, P or R, X 2 is one or two aromatic amino acids (F, Y and W), X 3 is one of P or K, X 4 is one, two or none chosen from A, P, Y or W and X 5 is one to three chosen from R or P.
59. The cationic peptide of claim 46, wherein the peptide is selected from the group consisting of: RPRYPWWPWWPYRPRK (SEQ ID NO: 19), RRAWWKAWWARRK (SEQ ID NO: 20), RAPYWPWAWARPRK (SEQ ID NO: 21), RPAWKYWWPWPWPRRK (SEQ ID NO: 22), RAAFKWAWAWWRRK (SEQ ID NO: 23) and RRRWKWAWPRRK (SEQ ID NO: 24).
60. The peptide of claim 46, wherein the peptide has anti-inflammatory activity.
61. The peptide of claim 46, wherein the peptide has anti-sepsis activity.
62. An isolated cationic peptide comprising the general formula X 1 X 2 X 3 X 4 X 1 VX 3 X 4 RGX 4 X 3 X 4 X 1 X 3 XI (SEQ ID NO: 25) wherein X, is one or two of R or K, X 2 is a polar or charged amino acid (S, T, M, N, Q, D, E, K, R and H), X 3 is C, S, M, D or A and X 4 is F, I, V, M or R.
63. The cationic peptide of claim 50, wherein the peptide is selected from the group consisting of: RRMCIKVCVRGVCRRKCRK (SEQ ID NO: 26), KRSCFKVSMRGVSRRRCK (SEQ ID NO: 27), KKDAIKKVDIRGMDMRRAR (SEQ ID NO: 28), RKMVKVDVRGIMIRKDRR (SEQ ID NO: 29), KQCVKVAMRGMALRRCK (SEQ ID NO: 30) and RREAIRRVAMRGRDMKRMRR (SEQ ID NO: 31).
64. The peptide of claim 50, wherein the peptide has anti-inflammatory activity.
65. The peptide of claim 50, wherein the peptide has anti-sepsis activity.
66. An isolated cationic peptide comprising the general formula X1X2X 3 X 4 XIVX 5 X 4 RGX 4 X 5 X 4 XIX 3 XI (SEQ ID NO: 32), wherein X 1 is one or two 198 WO 03/048383 PCT/CA02/01830 of R or K, X 2 is a polar or charged amino acid (S, T, M, N, Q, D, E, K, R and H), X 3 is one of C, S, M, D or A, X 4 is one of F, I, V, M or R and X 5 is one of A, 1, S, M, D or R.
67. The cationic peptide of claim 54, wherein the peptide is selected from the group consisting of: RTCVKRVAMRGIIRKRCR (SEQ ID NO: 33), KKQMMKRVDVRGISVKRKR (SEQ ID NO: 34), KESIKVIIRGMMVRMKK (SEQ ID NO: 35), RRDCRRVMVRGIDIKAK (SEQ ID NO: 36), KRTAIKKVSRRGMSVKARR (SEQ ID NO: 37) and RHCIRRVSMRGIIMRRCK (SEQ ID NO: 38).
68. The peptide of claim 54, wherein the peptide has anti-inflammatory activity.
69. The peptide of claim 54, wherein the peptide has anti-sepsis activity.
70. An isolated cationic peptide comprising the general formula KXIKX 2 FX 2 KMLMX 2 ALKKX 3 (SEQ ID NO: 39), wherein X 1 is a polar amino acid (C, S, T, M, N and Q); X 2 is one of A, L, S or K and X 3 is 1-17 amino acids chosen from G, A, V, L, I, P, F, S, T, K and H.
71. The cationic peptide of claim 58, wherein the peptide is selected from the group consisting of: KCKLFKKMLMLALKKVLTTGLPALKLTK (SEQ ID NO: 40), KSKSFLKMLMKALKKVLTTGLPALIS (SEQ ID NO: 41), KTKKFAKMLMMALKKVVSTAKPLAILS (SEQ ID NO: 42), KMKSFAKMLMLALKKVLKVLTTALTLKAGLPS (SEQ ID NO: 43), KNKAFAKMLMKALKKVTTAAKPLTG (SEQ ID NO: 44) and KQKLFAKMLMSALKKKTLVTTPLAGK (SEQ ID NO: 45).
72. The peptide of claim 58, wherein the peptide has anti-inflammatory activity.
73. The peptide of claim 58, wherein the peptide has anti-sepsis activity.
74. An isolated cationic peptide comprising the general formula KWKX 2 X 1 X 1 X 2 X 2 XIX 2 X 2 XlX 1 X 2 X 2 IFHTALKPISS (SEQ ID NO: 46), wherein X 1 is a hydrophobic amino acid and X 2 is a hydrophilic amino acid. 199 WO 03/048383 PCT/CAO2/01830
75. The cationic peptide of claim 62, wherein the peptide is selected from the group consisting of: KWKSFLRTFKSPVRTIFHTALKP1SS (SEQ ID NO: 47), KWKSYAHTIMSPVRLIFHTALKPISS (SEQ ID NO: 48), KWKRGAHRFMKFLSTIFHTALKPISS (SEQ ID NO: 49), KWKKWAHSPRKVLTRIFHTALKPISS (SEQ ID NO: 50), KWKSLVMMFKKPARRIFHTALKPISS (SEQ ID NO: 51) and KWKHALMKAHMLWHMIFHTALKPISS (SEQ ID NO: 52).
76. The peptide of claim 62, wherein the peptide has anti-inflammatory activity.
77. The peptide of claim 62, wherein the peptide has anti-sepsis activity.
78. An isolated cationic peptide comprising the sequence KWKSFLRTFKSPVRTVFHTALKPISS (SEQ ID NO: 53).
79. An isolated cationic peptide comprising the sequence KWKSYAHTIMSPVRLVFHTALKPISS (SEQ ID NO: 54).
80. The method of claim 28, wherein the agent is a Zinc finger protein (AF061261); Cell cycle gene (S70622); IL-10 Receptor U00672); Transferase (AF038664); Homeobox protein (AC004774); Forkhead protein (AF042832); Unknown (AL096803); KIAA0284 Protein (AB006622); Hypothetical Protein (AL022393); Receptor (AF112461); Hypothetical Protein (AK002104); Protein (AL050261); Polypeptide (AF105424); SPR1 protein (AB031480); Dehydrogenase (D17793); Transferase (M63509); and Peroxisome factor (AB013818).
81. The polynucleotide expression pattern of a subject having a state of infection identified by claim 56 wherein the genes upregulated are Accession number D87451 ring finger protein 10; Accession number AL049975, Unknown; Accession number U39067, eukaryotic translation initiation factor 3 subunit 2; Accession number AK000942, Unknown; Accession number AB040057, serine/threonine protein kinase MASK; Accession number AB020719, KIAAO912 protein; Accession number AB007856, FEM-1-like death receptor binding protein; Accession number AL137376, Unknown; Accession number AL137730, Unknown; Accession number M90696, cathepsin S; Accession number AK001143, Unknown; Accession number 200 WO 03/048383 PCT/CA02/01830 AF038406, NADH dehydrogenase; Accession number AK000315, hypothetical protein FLJ20308; Accession number M54915, pim-1 oncogene; Accession number D29011, proteasome subunit beta type 5; Accession number AL034348, Unknown; Accession number D87076, KIAA0239 protein; Accession number AJ001403, tracheobronchial mucin 5 subtype B; Accession number J03925, integrin alpha M, Rho-associated kinase 2 (NM_004850), PTD017 protein (AL050361) unknown genes (AK001143, AK034348, AL049250, AL16199, AL031983), retinoic acid receptor (X06614), G protein-coupled receptors (Z94155, X81892, U52219, U22491, AF015257, U66579) chemokine (C-C motif) receptor 7 (L31584), tumor necrosis factor receptor superfamily member 17 (Z29575), interferon gamma receptor 2 (U05875), cytokine receptor-like factor 1 (AF059293), class I cytokine receptor (AF053004), coagulation factor II (thrombin) receptor-like 2 (U92971), leukemia inhibitory factor receptor (NM_002310), interferon gamma receptor 1 (AL050337), or any combination thereof.
82. The method of claim 32, wherein the chemokines include CXCR4, CXCR1, CXCR2, CCR2, CCR4, CCR5, CCR6, MIP-1 alpha, MDC, MIP-3 alpha, MCP-1, MCP-2, MCP-3, MCP-4, MCP-5, and RANTES.
83. The method of claim 33, wherein the cell differentiation factors includeTGF3 inducible early growth response 2 (AI473938), zinc finger proteins (AF061261, U00115, X78924), and transcription factors (U31556, AL137681, X68560).
84. A compound of claim 38, wherein the compound modifies kinase activity.
85. A compound of claim 84, wherein the kinase is selected from MAP kinase kinase 3 (D87116), MAP kinase kinase 6 (H07920), MAP kinase kinase 5 (W69649), MAP kinase 7 (H39192), MAP kinase 12 (AI936909), MAP kinase-activated protein kinase 3 (W68281), or MAP kinase kinase 1 (L11284).
86. A compound of claim 21, wherein the compound decreases proteasome subunit expression. 201 WO 03/048383 PCT/CA02/01830
87. A compound of claim 86, wherein the proteasome subunit includes polynucleotides with accession numbers Dl11094, L02426, D00763, AB009398, AF054185, M34079, M34079, or AL031177.
88. An isolated cationic peptide that reduces polynucleotide expression of SDF-1 receptor. 202
AU2002365675A 2001-12-03 2002-12-02 Effectors of innate immunity Expired AU2002365675B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2007201885A AU2007201885A1 (en) 2001-12-03 2007-04-27 Effectors of innate immunity

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US33663201P 2001-12-03 2001-12-03
US60/336,632 2001-12-03
PCT/CA2002/001830 WO2003048383A2 (en) 2001-12-03 2002-12-02 Effectors of innate immunity

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2007201885A Division AU2007201885A1 (en) 2001-12-03 2007-04-27 Effectors of innate immunity

Publications (2)

Publication Number Publication Date
AU2002365675A1 true AU2002365675A1 (en) 2003-06-17
AU2002365675B2 AU2002365675B2 (en) 2007-04-05

Family

ID=23316965

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002365675A Expired AU2002365675B2 (en) 2001-12-03 2002-12-02 Effectors of innate immunity

Country Status (11)

Country Link
EP (1) EP1470249A2 (en)
JP (1) JP2005536985A (en)
KR (1) KR20040077669A (en)
CN (2) CN101215601A (en)
AU (1) AU2002365675B2 (en)
CA (1) CA2468907A1 (en)
IL (1) IL162300A0 (en)
NZ (2) NZ533721A (en)
SG (1) SG159382A1 (en)
WO (1) WO2003048383A2 (en)
ZA (1) ZA200404919B (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7507787B2 (en) * 2001-12-03 2009-03-24 The University Of British Columbia Effectors of innate immunity
US7687454B2 (en) 2001-12-03 2010-03-30 The University Of British Columbia Effectors of innate immunity determination
ZA200602754B (en) * 2003-09-12 2007-06-27 Univ British Columbia Effectors of innate immunity determination
US20060014136A1 (en) * 2004-07-14 2006-01-19 Inimex Pharmaceuticals, Inc. Method of screening for protection from microbial infection
WO2006137444A1 (en) * 2005-06-22 2006-12-28 Seikagaku Corporation Method of eliminating reactivity from lipoarabinomannan and application of the same
GB0517090D0 (en) 2005-08-19 2005-09-28 Tcp Innovations Ltd ApoE mimetic agents
US20080118525A1 (en) * 2006-10-04 2008-05-22 Oreola Donini Novel peptides for treating and preventing immune-related disorders, including treating and preventing infection by modulating innate immunity
PL2236608T3 (en) * 2005-10-04 2017-06-30 Soligenix, Inc. Novel peptides for treating and preventing immune-related disorders, including treating and preventing infection by modulating innate immunity
ES2497441T3 (en) 2006-08-21 2014-09-22 The University Of British Columbia Small cationic immunomodulatory peptides
WO2009057695A1 (en) * 2007-10-30 2009-05-07 Olympus Corporation Method for detection of adenoma or cancer by genetic analysis
WO2010026489A1 (en) * 2008-09-05 2010-03-11 The University Of British Columbia Innate immunity modulators
WO2010042534A1 (en) * 2008-10-06 2010-04-15 The Regents Of The University Of Colorado, A Body Corporate Peptides and methods of use
AR091069A1 (en) 2012-05-18 2014-12-30 Amgen Inc PROTEINS OF UNION TO ANTIGEN DIRECTED AGAINST THE ST2 RECEIVER
EP4259279A1 (en) 2020-12-14 2023-10-18 Regeneron Pharmaceuticals, Inc. Methods of treating metabolic disorders and cardiovascular disease with inhibin subunit beta e (inhbe) inhibitors
WO2023063994A1 (en) * 2021-10-13 2023-04-20 Phenomune, LLC Testing methods for determination of t2r phenotype and applications thereof
KR20250044488A (en) * 2023-09-21 2025-04-01 성균관대학교산학협력단 Composition for treating sepsis that controls odorant receptor Olfr164

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5877274A (en) * 1995-06-02 1999-03-02 University Of British Columbia Antimicrobial cationic peptides
DE19734161A1 (en) * 1997-08-07 1999-04-01 Jerini Biotools Gmbh Antagonists of stroma cell-derived factor-1, for diagnosis and treatment of human immune deficiency virus (HIV) infection
US6288212B1 (en) * 1998-08-28 2001-09-11 The University Of British Columbia Anti-endotoxic, antimicrobial cationic peptides and methods of use therefor

Also Published As

Publication number Publication date
NZ563261A (en) 2008-08-29
IL162300A0 (en) 2005-11-20
NZ533721A (en) 2007-12-21
JP2005536985A (en) 2005-12-08
CN1615368A (en) 2005-05-11
AU2002365675B2 (en) 2007-04-05
EP1470249A2 (en) 2004-10-27
ZA200404919B (en) 2006-05-31
SG159382A1 (en) 2010-03-30
CA2468907A1 (en) 2003-06-12
WO2003048383A3 (en) 2004-08-05
CN101215601A (en) 2008-07-09
CN100357324C (en) 2007-12-26
HK1075677A1 (en) 2005-12-23
KR20040077669A (en) 2004-09-06
WO2003048383A2 (en) 2003-06-12

Similar Documents

Publication Publication Date Title
US7507787B2 (en) Effectors of innate immunity
AU2002365675A1 (en) Effectors of innate immunity
Vaidya et al. Toll-like receptors and innate antiviral responses
Deng et al. Granulysin, a cytolytic molecule, is also a chemoattractant and proinflammatory activator
Hedges et al. γδ T cells respond directly to pathogen-associated molecular patterns
Zang et al. Aberrant T cell migration toward RANTES and MIP-1α in patients with multiple sclerosis: overexpression of chemokine receptor CCR5
Yang et al. Human dendritic cells express functional formyl peptide receptor-like-2 (FPRL2) throughout maturation
Hedges et al. Differential mRNA expression in circulating γδ T lymphocyte subsets defines unique tissue-specific functions
Schlottmann et al. Prolonged classical NF‐κB activation prevents autophagy upon E. coli stimulation in vitro: a potential resolving mechanism of inflammation
US6187557B1 (en) c-IAP1 and c-IAP2: inhibitors of apoptosis
US20070134261A1 (en) Effectors of innate immunity
US7687454B2 (en) Effectors of innate immunity determination
Jiang et al. Differential gene expression patterns by oligonucleotide microarray of basal versus lipopolysaccharide-activated monocytes from cord blood versus adult peripheral blood
US12351610B2 (en) Interferon regulatory factor 5 inhibitors and uses thereof
Nagi-Miura et al. CAWS administration increases the expression of interferon γ and complement factors that lead to severe vasculitis in DBA/2 mice
US20070190533A1 (en) Effectors of innate immunity
KR20070033314A (en) Methods of Stimulating Innate Immunity Using Cationic Peptides
AU2007201885A1 (en) Effectors of innate immunity
HK1121196A (en) Effectors of innate immunity
HK1075677B (en) Effectors of innate immunity
JPWO2003070947A1 (en) Apoptosis-promoting substance and inhibitory substance interacting with CGI-94 and screening method thereof
HK1098969A (en) Methods of stimulating innate immunity using cationic peptides
Conti CLR16. 2: The identification, characterization, and functional analysis of a novel regualtor of T cell activation
JP2009500314A (en) Gene regulation
Choi et al. Differential gene expression analysis in k562 human leukemia cell line treated with benzene

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE APPLICANT/PATENTEE FROM UNIVERSITY OF BRITISH COLUMBIA TO THE UNIVERSITY OF BRITISH COLUMBIA

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired